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Abstract
Clinically, the renal proximal tubule (PT) seems to be vulnerable to mitochondrial
dysfunction (MD), which can affect normal transport processes (including
reabsorption of low molecular weight proteins [LMWPs]), resulting in the renal
Fanconi syndrome. I wanted to explore why the PT is vulnerable to MD, and how
this leads to impaired LMWP transport:
(1) Using the OK cell line, to model uptake of LMWPs in the PT, I found respiratory
chain (RC) inhibitors had minimal effect on the uptake of fluorescent-labelled
albumin, and also had a relatively small impact on [ATP], which was maintained
largely by glycolysis. Uptake of albumin was inhibited to a much greater extent by
blockade of glycolysis, implying an important role for ATP. The RC inhibitor
rotenone had a profound toxic effect on the structure of OK cells, due to extra-
mitochondrial inhibition of microtubule polymerisation.
(2) Multi-photon imaging of live rat kidney slices showed that mitochondrial
membrane potential was lower in the PT relative to distal tubule, and was better
maintained in the latter following RC inhibition. The basal rate of ROS production
(per cell) and glutathione levels were both higher in the PT, and RC substrates were
in a more oxidised state in this segment.
(3) Urinary screening of adult patients with either (a) mitochondrial cytopathy, or (b)
HIV and taking anti-retroviral therapy (ART) toxic to mitochondria, revealed high
rates of tubular proteinuria (including LMWPs) in both groups. Patients taking ART
had higher excretion of tubular proteins than those who were treatment naïve.
In conclusion, inhibition of ATP generation impaired protein uptake in a model of
the PT, and this was mirrored by increased tubular proteinuria in patients with either
genetic or toxic MD. Furthermore, differences in mitochondrial function were
demonstrated along the rodent nephron, which may render the PT vulnerable to MD.4
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Chapter 1 - General introduction
1.1 The renal proximal tubule
1.1.1 Structure of the proximal tubule
Every day the kidneys within a human being filter approximately 180 litres of fluid
from the blood stream, across the glomerular filtration barrier and into the renal
tubules. Only about 1% of this filtered load is excreted as urine; hence,
approximately 178 litres have to be reabsorbed by the renal tubule. The bulk of this
reabsorption (60-70%) is performed in the proximal tubule (PT). A concise
description of the structure of the PT is given below (for a more detailed account see
Shirley and Unwin (Shirley DG & Unwin RJ, 2005)). The PT extends from the
glomerulus to the thin descending loop of Henle, and is sub-divided into three
sections, denoted S1, S2 and S3 (Figure 1.1). The S1 section is predominantly
concerned with reabsorbing solutes via mechanisms that are coupled to sodium
transport. These solutes include amino acids, glucose, phosphate (HPO4
2-) and
bicarbonate. Whilst further solute reabsorption does occur in the S2 and S3
segments, these regions are also thought to be responsible for the secretion of organic
acids and bases; an important mechanism for excreting xenobiotics from the body.
The first part of the PT (S1 and partly S2) is convoluted, increasing surface area
(proximal convoluted tubule – PCT). The second part, including the remainder of S2
and all of S3, is straight (proximal straight tubule – PST [also known as the pars
recta]) and descends in the medullary rays through the inner cortex and outer
medulla, before becoming the thin descending limb of the loop of Henle. The PST is
joined in the medullary ray regions by thick ascending limbs of the loop of Henle and
collecting ducts.
1.1.2 Function of the proximal tubule – solute transport
The PT is a highly specialised epithelium, designed to transport large quantities of
water and solutes. The luminal surface is coated with a folded brush border that
dramatically increases the surface area available for absorption. A number of
transporters and channels are located in the luminal membrane to facilitate1516
trans-cellular transport, whilst the gap junctions between cells are relatively leaky,
allowing some paracellular transport to also occur. Water transport occurs via both
the paracellular and transcellular routes, the latter is facilitated by water channels
(aquaporin-1 – AQP-1 (Knepper et al., 1996)) inserted into the cell membrane. In
addition to reabsorbing a number of inorganic solutes (mainly coupled to sodium),
the PT is also responsible for the uptake of low molecular proteins (LMWPs)
(Christensen & Gburek, 2004), such as retinol binding protein (RBP), parathyroid
hormone and insulin, which are mostly freely filtered by the glomerulus and have to
be reclaimed to prevent urinary loss (‘tubular proteinuria’) and exposure of the distal
tubule to bioactive peptides (Figure 1.2). These LMWPs are thought to be scavenged
from the luminal fluid by a low-affinity high-capacity uptake system consisting of
two large receptors situated in the apical membrane called megalin and cubulin
(Verroust et al., 2002). Megalin is a 600kDa transmembrane protein belonging to the
low-density lipoprotein receptor family (Raychowdhury et al., 1989), whilst cubulin
is a 460kDa peripheral membrane protein identical to the intrinsic factor – vitamin
B12 receptor in the small intestine (Kozyraki et al., 1998). As cubulin is not a
transmemebrane protein, it cannot directly interact with clathryn and other mediators
of the endocytotic process; instead, it is thought to bind to megalin in order to
internalise ligands into the cell (Moestrup et al., 1998). In addition to interacting with
each other, megalin and cubulin share a number of ligands, including albumin (Zhai
et al., 2000). Upon binding, the receptor-ligand complexes are internalised via
receptor-mediated endocytosis into endosomes. These are then acidified in an ATP
dependent process, in order to promote dissociation of the proteins from the receptors
(Gekle et al., 1995); the latter are then recycled to the luminal membrane.
1.1.3 Metabolism in the proximal tubule is coupled to transport
Much of the transport in the PT is sodium coupled (e.g. HPO4
2-, glucose, amino
acids), and is driven by a low sodium concentration and relative electro-negativity
within the PT cells (as compared to the lumen of the tubule). The sodium
concentration within the cells of the PT is kept low by the activity of the electrogenic
Na
+/K
+-ATPase pumps located in the baso-lateral membrane. The large amounts of
transport that occur in the PT therefore clearly require vast amounts of energy in the17
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Figure 1.2. Solute transport in the proximal tubule. Substances
(X), such as glucose, amino acids and phosphate, are co-transported at the
luminal (apical) cell membrane with sodium. The gradient for sodium entry is
maintained by the baso-lateral sodium pump (Na+/K+-ATPase), with recycling of
potassium across the baso-lateral cell membrane, via a potassium channel. Low
molecular weight proteins (LMWPs) (<70kDa) are bound by two large non-
selective receptors (megalin and an associated protein cubilin) at the luminal
membrane (1). They bind LWMPs and the complex is internalized – via receptor-
mediated endocytosis – and packaged into early endosomes (2). Acidification of
the endosomes then dissociates the receptor-ligand complex and the protein
cargo is either transferred to lysosomes, where it is degraded, or transported to
the baso-lateral membrane and into the blood (3). The megalin receptor is
recycled to the luminal membrane (4). Mitochondria (depicted in green) are
located predominantly in the baso-lateral part of the cell.
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form of ATP. The bulk of this ATP requirement is thought to be met via
mitochondrial oxidative phosphorylation, which generates more ATP molecules per
substrate molecule than anaerobic glycolysis (Rich, 2003). The PT contains a high
density of mitochondria that are located in a baso-lateral distribution (Kaissling &
Kriz, 1979). The reason for this location is not known, however, this arrangement
does mean that the mitochondria are situated in close proximity to both the Na
+/K
+-
ATPase pumps (the major consumers of ATP) and the blood vessels running in
between tubules (the main oxygen supply). Metabolic activity and ionic transport are
thought be tightly coupled in the kidney, in order to match ATP supply with demand
(for review see (Soltoff, 1986)).
The PT is clinically vulnerable to disturbances of normal metabolism, due to
mitochondrial dysfunction (MD), from insults such as genetic mitochondrial
cytopathy (Niaudet & Rotig, 1996) or toxic xenobiotics (e.g., anti-retroviral therapy -
ART (Izzedine et al., 2005b; Izzedine et al., 2005c)). The reasons for this are not
properly understood; in vivo, the PT is thought to depend mainly on aerobic
metabolism for its energy supply, with very little anaerobic capacity compared with
distal tubule (DT) segments (Bagnasco et al., 1985). In fact, it has been shown that a
metabolic gradient exists in the tubules of the mammalian kidney, with aerobic
metabolism predominant in the cortex, near the kidney surface, whilst anaerobic
glycolysis predominates in the papilla; tubular cells in the outer medulla can use both
forms of metabolism more or less equally (Lee & Peter, 1969). This may explain
why, following significant ischaemia-reperfusion, PT cells tend to undergo necrosis,
whereas apoptosis is more common in DT cells (Oberbauer et al., 1999) . However,
there may be other aspects of mitochondrial function or its regulation that vary along
the nephron, which could underlie these clinical observations.
1.2 The renal Fanconi syndrome
1.2.1 Background
The renal Fanconi syndrome (FS) (also known as Lignac-de Toni-Debré-Fanconi
syndrome, and not to be confused with Fanconi’s anaemia) refers to a set of clinical
features resulting from a generalized failure of normal transport in the PT. FS was19
originally described in the 1930s by the Swiss paediatrician Guido Fanconi. It is
characterised by aminoaciduria, tubular proteinuria, phosphaturia, bicarbonate
wasting and glycosuria (in the absence of diabetes and hyperglycaemia) (Brodehl,
1992). The clinical features of FS are therefore explained by deficiency of solutes
normally reabsorbed in the PT, and include osteomalacia (due to
hypophosphataemia) and metabolic acidosis. Tubular proteinuria is a common and
early feature of FS. Tubular proteins consist of LMWPs (e.g. RBP) that are normally
reabsorbed by the PT, and enzymes (e.g. N-acetyl-beta-D-glucosaminidase – NAG)
that are released from damaged PT cells. RBP is relatively freely filtered by the
glomerulus and almost completely reabsorbed along the PT; its presence in the urine
in increased amounts usually indicates defective PT uptake and/or transport (Bernard
et al., 1982). NAG, which is not delivered, but is derived from PT cells, is an index
of PT damage when elevated in urine (Price, 1992). The presence of excess tubular
proteinuria is a sensitive and specific test for PT dysfunction (Norden et al., 2000).
Hypercalciuria can also occur, although the reasons for this are less clear.
1.2.2 Aetiology
FS was historically considered a rare disease, especially in adults. However, with the
advent of more sensitive screening tests for tubular proteinuria, it is increasingly
recognised that subclinical PT dysfunction is more common than was previously
appreciated (e.g. in conditions such as diabetes (Kalansooriya et al., 2007) and
hypertension (Schrader et al., 2006)). FS has a wide variety of causes, which include
toxins (especially heavy metals like cadmium (Barbier et al., 2005)), drugs (e.g.
aminoglycoside antibiotics (Ghiculescu & Kubler, 2006), some anti-retroviral drugs
[see later] (Izzedine et al., 2003) and ifosfamide (Skinner, 2003)), myeloma (Headley
et al., 1972) and some auto-immune diseases (e.g. Sjögren’s syndrome (Delplace,
1983)). Inherited forms of FS (which typically present in childhood) include
autosomal recessive diseases like cystinosis (Schulman & Schneider, 1976),
tyrosinaemia (Russo & O'Regan, 1990), fructose intolerance (Morris, Jr., 1968) and
glycogen storage disease type I (Reitsma-Bierens, 1993). There is also an autosomal
dominant idiopathic form of FS (Friedman et al., 1978), and X-linked forms such as
Dent’s disease (Wrong et al., 1994) and Lowe syndrome (Bockenhauer et al., 2008).
FS is the typical renal presentation of children with mitochondrial cytopathy20
(Niaudet & Rotig, 1997) (see later – ‘Renal involvement in children with
mitochondrial cytopathy’).
Some forms of FS are ‘incomplete’, that is they do not have all of the expected
clinical features of PT dysfunction. For example, patients with Dent’s disease or
Lowe syndrome present with most of the features of FS, but glycosuria can be
absent. The prevalence of FS is unknown and difficult to estimate as there is such a
wide variety of causes, many of which are relatively rare diseases. Cystinosis is
thought to be the most common cause in childhood, whereas drug toxicity and
myeloma are more prevalent in adulthood.
1.2.3 Pathogenesis
The underlying pathogenic mechanisms that unite these disparate causes of FS into
similar identifiable clinical entities are not well understood. FS clearly involves a
global breakdown of PT transport, which is quite dissimilar to monogenic transport
disorders such as Bartter or Gitelman syndrome. It is, therefore, likely that the
defects are occurring ‘downstream’ of the individual receptors in the transport
pathways.
Tubular proteinuria is an early and sensitive sign of PT dysfunction. The importance
of the megalin/cubulin system in the normal uptake of proteins by the PT has been
demonstrated in animal models. Genetically modified mice lacking megalin develop
significant tubular proteinuria (Leheste et al., 1999), whilst inbred dogs that fail to
insert cubulin into their apical PT membrane also have proteinuria, consisting of
cubulin ligands (Kozyraki et al., 2001; Birn et al., 2000). However, a lack of cubulin
does not seem to cause as severe proteinuria as megalin deficiency; perhaps because
cubulin mediated uptake of ligands is also megalin dependent, but megalin is thought
to be able to function in the absence of cubulin. Patients with mutations in cubulin,
who have juvenile megaloblastic anaemia due to vitamin B12 malabsorption, can
also develop pronounced proteinuria (Wahlstedt-Froberg et al., 2003).
Dent’s disease is an X-linked hereditary form of FS, characterised by tubular
proteinuria, hypercalcuria, nephrolithiasis and renal failure. It is divided into Dent 121
and Dent 2 depending on the underlying genetic mutation. Dent 1 is caused by
mutations in the CLCN5 gene (Thakker, 2000), which encodes a chloride channel
required for acidification of endosomes. This promotes dissociation of megalin and
cubulin receptors from their ligands, in order to allow recycling of the receptors to
the apical membrane. In mouse models of Dent 1, where CLCN5 has been knocked
out, the animals develop tubular proteinuria due to impaired endosomal acidification
and decreased expression of megalin and cubulin at the PT apical membrane
(Christensen et al., 2003; Marshansky et al., 2002; Piwon et al., 2000; Wang et al.,
2000). The animals also show decreased urinary excretion of megalin, which has
been described in humans with Dent’s disease, but not in another hereditary form of
FS associated with tubular proteinuria (Norden et al., 2002), perhaps implying that
the megalin pathway is not the only mechanism of PT protein uptake that can be
disturbed in FS. Dent 2 is caused by mutations in the OCRL gene (Hoopes, Jr. et al.,
2005; Utsch et al., 2006), abnormalities in which can also lead to Lowe syndrome, an
X-linked disease characterised by the triad of congenital cataracts, mental retardation
and FS (Schurman & Scheinman, 2009). OCRL encodes a phosphatidylinositol 4,5-
bisphosphate (PIP(2)) 5-phosphatase; the fact that mutations in either CLCN5 or
OCRL can both cause a similar phenotype (Dent’s disease), implies overlap in the
involvement of the respective gene products in endocytotic pathway in the PT. Some
patients with phenotypic Dent’s disease do not have identified mutations in either
CLCN5 or ORCL; discovery of the underlying genetic abnormalities in these patients
may provide new insights into PT protein uptake mechanisms.
A defect in metabolism is an attractive hypothesis that might explain a sub-lethal
functional defect in cellular transport. However, whilst there is considerable evidence
implicating mitochondria in the pathogenesis of FS (see below – ‘Evidence for
mitochondrial dysfunction as a cause of Fanconi syndrome’), the exact mechanism
by which dysfunction of these complex organelles could cause a problem with solute
transport remains speculative and poorly understood. Other suggested mechanisms of
a global breakdown in PT transport include back-leak of solutes and water across
abnormal tight junctions between cells (Van't Hoff, 2005), an abnormality in the
normal physical properties of the apical membrane (Hsu et al., 1994), or a change in
the membrane voltage that drives normal sodium dependent transport (Cetinkaya et22
al., 2002). Whilst some evidence exists for all of these hypotheses, none has been
conclusively proven to date, and FS remains a poorly understood condition.
1.2.4 Clinical Features
As explained above, the clinical features of FS are due to wasting of substances in
the urine (HPO4
2-, bicarbonate, glucose etc) that are normally retrieved from the
filtrate in the PT. The typical presenting feature in adults is bone pain secondary to
osteomalacia, due to hypophosphataemia. In addition, young children may
experience problems due to fluid loss, causing polyuria, polydipsia and failure to
thrive. This is probably due to a reduced capacity in the immature distal nephron
segments to compensate for fluid losses from the PT. If large amounts of sodium are
presented to the DT they may be exchanged there for potassium, under the influence
of aldosterone, leading to hypokalaemia and metabolic alkalosis. Some patients may
be detected via routine clinical screening (e.g. urine dipstick or serum creatinine)
performed for other reasons. Patients can present with other symptoms or signs of the
underlying disease; for example, renal stones or unexplained renal impairment in
Dent’s disease, or cardiac and neurological complications in mitochondrial disorders.
A thorough family history is therefore important in all cases, especially in those
without an obvious cause. A complete drug and occupational history is also crucial,
particularly focusing on any exposure to heavy metals or industrial solvents, or
herbal remedies obtained from unknown or unapproved sources.
1.2.5 Diagnosis of Fanconi syndrome
The diagnosis of FS is clinical and relies on identifying the cardinal features
discussed above. Frequently FS will be preceded by diagnostic features of the
underlying causative disease. Incomplete forms of FS can lead to clinical features
that be may be more difficult to immediately attribute to a problem with PT function,
and may require distinction from other non-renal diseases. For example, isolated
hypophosphataemia may be due to a partial FS, but equally may be caused by
malnutrition or a gastro-intestinal disease. The presence of excess tubular proteinuria
is a highly sensitive marker of PT dysfunction.23
Diagnosis of FS is usually achieved with the following investigations:
 Serum creatinine. This may be raised (and hence eGFR reduced), either
because of impaired PT secretion of creatinine, or because of concomitant
glomerular disease with reduced filtration.
 Serum HPO4
2-. It needs to be ascertained that hypophosphataemia (if present)
is due to renal wasting. Renal handling of HPO4
2- can be assessed by
calculating the capacity of the PT to reabsorb phosphate: TmHPO4
2- / GFR =
Plasma HPO4
2- - (Urine HPO4
2- x [Plasma Creatinine / Urine Creatinine])
(Walton & Bijvoet, 1975). An alternative is to calculate the fractional
excretion of phosphate ([Urine HPO4
2- x Plasma Creatinine] / [Urine
Creatinine x Plasma HPO4
2-] x 100).
 Serum bicarbonate. Renal tubular acidosis (RTA) type II (proximal) can
occur due to bicarbonate wasting, and can be distinguished from distal (type
1) RTA, because patients with proximal RTA can acidify their urine to pH <
5.5 following an acid load (e.g. with NH4Cl or combined fludrocortisone and
frusemide (Walsh et al., 2007)), whereas patients with distal RTA cannot.
 Serum potassium. Hypokalaemia is a feature of more severe cases of FS.
 Tubular proteinuria. Typically screened for by assaying for RBP (or other
LMWPs like α1- or β2-microglobulin) and PT enzymes such as NAG.
 Aminoaciduria is frequently screened for in children.
1.2.6 Screening for subclinical proximal tubular disease
The classical clinical features of FS represent the severe end of the spectrum of PT
disease (analogous to stages IV-V of CKD). It is likely that many more patients have
undiagnosed subclinical PT dysfunction, which can be screened for by testing for
tubular proteins, such as RBP and NAG. These can be compared with urinary
albumin to identify co-incident glomerular proteinuria. The glomerular filtration
barrier is relatively impermeable to albumin; hence, its appearance in the urine in
elevated amounts is widely accepted as a marker of glomerular disease (Norden et
al., 2000). Values of urinary proteins are usually expressed as a ratio to urine
creatinine (i.e. URBP/C, UNAG/C and UA/C, respectively), in order to account for
differences in urine concentration between samples.24
Urine protein:creatinine (UP/C) is a test for total urinary protein excretion; it is a
standard clinical screening tool for the presence of kidney disease and correlates well
to the 24-hour urinary protein excretion (Ginsberg et al., 1983). However, its
sensitivity for detecting renal tubular disease is unclear. Recently, The National
Institute for Clinical Excellence (NICE) in the UK
(www.nice.org.uk/Guidance/CG73) has advocated UA/C as a screening tool for
chronic kidney disease (CKD), as it is relatively cheap and results appear to be
consistent between different reporting laboratories. However, again it is unclear to
what extent UA/C is an effective screen for tubular disease. Although albuminuria is
thought to predominantly reflect glomerular pathology, some albumin uptake is
believed to occur in the PT (Thakkar et al., 1998); hence, small rises in UA/C might
be expected in patients with tubular disease.
1.2.7 Treatment
In cases of FS due to a multi-system disease (e.g. cystinosis), addressing the
underlying cause is clearly of paramount importance. General treatment approaches
for all forms of FS involves replacing solutes lost in the urine to prevent deficiencies:
 Vitamin D (calcitriol) and HPO4
2- supplements for hypophosphataemia.
 Oral bicarbonate supplements for metabolic acidosis.
 Oral potassium for hypokalaemia.
 Fluid replacement therapy may be required in children. If chronic excess fluid
losses are occurring, indomethacin can be given to pharmacologically reduce
GFR.
In cases of FS that subsequently develop chronic kidney disease, general measures to
slow progression are important, including blood pressure control, anti-proteinuric
therapy if there is significant proteinuria, and treatment of any cardiovascular risk
factors that are present (e.g. use of statins).25
1.3 Functions of mitochondria
1.3.1 Origins of mitochondria
Mitochondria are intracellular organelles present in almost all eukaryotic cells. They
probably evolved from a primitive aerobic prokaryotic structure that fused with a
larger anaerobic cell to form a new organism with a significant metabolic advantage
(Dyall et al., 2004). Over time, a complex symbiotic relationship has developed
between the mitochondrion and its host cell, going much further than the simple
provision of ATP. Mitochondria play a central role in the regulation of a range of
important cellular functions, including the generation of reactive oxygen species
(ROS), intracellular Ca
2+ homeostasis, biosynthesis and apoptosis (Duchen, 2004).
Thus, MD can be deleterious to the host cell in a variety of ways. Diseases associated
with MD include diabetes (Wiederkehr & Wollheim, 2006), septic shock (Singer et
al., 2004) and neuro-degenerative conditions such as Parkinson’s disease
(Mandemakers et al., 2007).
1.3.2 Mitochondrial ATP production
A major function of mitochondria is to provide chemical energy for the host cell in
the form of ATP, which is generated from ADP and HPO4
2- via oxidative
phosphorylation (Figure 1.3). ATP is the universal energy ‘currency’ of life;
significant amounts of energy are released when ATP is converted to ADP and
HPO4
2-.
In living cells the ATP/ADP ratio is maintained at a high level in the cytosol;
creating in effect an energy store, which can be rapidly mobilised (via ATP
breakdown to ADP) and coupled to the work done in normal cellular function; for
example, in powering cell membrane pumps like the Na
+/K
+-ATPase.
The process of oxidative phosphorylation essentially converts the chemical energy
stored in the bonds of carbon and hydrogen based organic fuels (such as glucose,
fatty acids and amino acids) to chemical energy stored in the bonds of ATP. This is
achieved by oxidising these fuel molecules and transferring the electrons along the
respiratory chain (RC) complexes, ultimately to oxygen molecules to form water.2627
The energy released by this process is then used to form ATP and is thus stored for
future usage.
The first step of oxidative phosphorylation is the breakdown of fuel molecules to
acetyl CoA. This molecule then enters the Krebs cycle within the mitochondria.
Here, it is converted to a variety of intermediates. Along the way, the substrates for
the mitochondrial RC are reduced; NAD
+ to NADH and FAD
2+ to FADH2. These
substrates are then, in turn, oxidised by complexes I and II of the RC, respectively.
Having entered the RC, electrons are passed along the complexes until they reach
complex IV (cytochrome c oxidase – COX), at which point they reduce oxygen to
form (along with protons) water. The complexes of the RC are large clusters of
proteins that are situated in close proximity in the inner mitochondrial membrane
(IMM). Electrons are shuttled from complexes I and II to complex III by the cofactor
ubiquinone (coenzyme Q10). From here they are passed onto complex IV by another
cofactor called cytochrome c. As the electrons pass through the RC complexes
energy is released, which is harnessed by complexes I, III and IV to pump protons
out of the mitochondrial matrix, across the IMM and into the inter-membrane space.
This then creates an electrochemical proton gradient across the IMM, sometimes
called the proton motive force (PMF), which is expressed in part as a potential
difference (ΔΨm - typically ~150mV (Duchen et al., 2003)), and in part as a pH
gradient (ΔpH). Protons then pass down this electro-chemical gradient through the
ATP synthase, and this movement is used to drive the energetically unfavourable
formation of ATP from ADP and PO4
2-. The usage of PMF as an intermediate to
harness the energy released by the oxidisation of organic fuel molecules, and convert
and store it as ATP molecules, is termed ‘chemiosmotic coupling’, and was first
proposed by the Nobel prize winner for Chemistry Peter Mitchell (Mitchell, 1961).
The degree to which the PMF is coupled to ATP synthesis depends on the amount of
proton leak back through the IMM that does not pass through the ATP synthase. This
can occur physiologically, for example to generate heat in brown fat (mainly found
in neonates), due to the actions of specialised uncoupling proteins (UCPs). More
recently, a number of related proteins have been identified which have been labelled
as belonging to a family of UCPs. The UCP of Brown fat is now known as UCP1
(Nicholls & Rial, 1999), but there are a number of related proteins, of which UCP228
and UCP3 have been most studied (for reviews see (Krauss et al., 2005; Nicholls,
2006)). There seems to be an emerging consensus that these ‘uncoupling proteins’
may be activated by ROS, and that they could serve to reduce ROS generation by
lowering PMF (Affourtit & Brand, 2008); this remains highly controversial and is
still very much a developing field. Certain pharmacological agents can also act as
uncouplers (e.g. aspirin (Petrescu & Tarba, 1997)).
In order to continually produce ATP, mitochondria require a steady supply of ADP,
which enters the organelles via an adenine nucleoside translocase (ANT) that
exchanges ATP for ADP (Winkler et al., 1968). ΔΨm is also important for
mitochondrial functions other than ATP production, such as Ca
2+ uptake into the
mitochondria from the cytosol (see later – ‘Calcium signalling’) and protein import.
1.3.3 Reactive oxygen species production
ROS are unstable molecules with an excess of electrons that have wide-ranging roles
in renal physiology and patho-physiology (Sachse & Wolf, 2007). Sources of
intracellular ROS include the RC, NADPH oxidase and xanthine oxidase. Within the
mitochondria, ROS are thought to be produced predominantly at RC complexes I and
III, and the rate of production of ROS from the RC is dependent on electron flux,
redox state and oxygen availability (for review see (Murphy, 2009)). The major ROS
molecule generated by the RC is superoxide (O2
-). This is then normally rapidly
converted to the less toxic species hydrogen peroxide (H2O2) by the enzyme
superoxide dismutase (SOD), of which an isoform is situated within mitochondria.
The total rate of ROS production within mitochondria will therefore reflect a balance
between generation by the RC and scavenging by protective enzymes.
The rate of production of ROS at complex I is favoured by the complex being in a
reduced state (Kushnareva et al., 2002); in other words by an excess of electrons
being present to form O2
-. This scenario typically occurs when the flux of electrons
along the RC is slow or completely halted. For this reason, agents that block electron
flow at complex I (such as rotenone) typically increase the production of ROS at this
site (Reinecke et al., 2006). When the activity of the ATP synthase is low, the
potential will tend to increase and electron flow will also be slower; hence, increased29
ROS production is often associated  with an increased ΔΨm. Conversely, a lower
ΔΨm, which tends to promote faster electron flow, is thought to decrease ROS
production by the RC; a paradigm that has fuelled interest in UCPs that can
potentially lower ΔΨm.
Another major source of O2
- in the kidney is the NADPH oxidase, and regional
differences in expression levels of the enzyme have been reported in the tubule (Gill
& Wilcox, 2006). Furthermore, there is evidence that the NADPH oxidase is
activated by angiotensin II, providing a putative link between systemic hypertension
and oxidative stress in the kidney (Wilcox, 2002), which may be important in the
pathogenesis of chronic kidney disease.
ROS are believed to have a number of toxic effects, including damage of DNA, lipid
peroxidation and involvement in cell death pathways (Trachootham et al., 2008).
Unsurprisingly, therefore, they have been implicated in the pathogenesis of a variety
of common disease processes (e.g. neurodegeneration (Fatokun et al., 2008)) and are
also suggested to be responsible for the ageing process (Gruber et al., 2008)
(although this remains controversial). Anti-oxidants have generally proved to be of
limited therapeutic value, although this may be due to difficulties in targeting them to
the mitochondria. As ROS species, like O2
-, are unstable they generally react with
structures in the near vicinity; a particular concern is therefore ROS induced mtDNA
damage. This has been suggested as a possible mechanism of progression of disease
in patients with mitochondrial cytopathy (Jacobson et al., 2005) (see later - ‘Patho-
physiology of mitochondrial cytopathy’). The hypothesis is that mutations in
mtDNA, which encode for proteins and RNA involved in the structure and
maintenance of the RC, will lead to abnormal RC function, leading to increased ROS
production. This in turn will damage the mtDNA further, leading to replication errors
and increasing the mutation rate, thus creating a positive feedback loop that over
time will cause increasing MD, which may explain the slow progression of many
mitochondrial diseases (and indeed perhaps the ‘normal’ process of ageing).
Although yet to be conclusively proven, this theory could explain why anti-oxidants
may only be efficacious in clinical disease if adequately targeted to mitochondria.30
1.3.4 Glutathione
Due to the potentially toxic actions of ROS, cells have acquired a range of anti-
oxidant defences, including enzymes such as SOD (as mentioned above) and catalase
(which catalyses the decomposition of H2O2 to H2O and O2 (Chelikani et al., 2004)).
Another important intracellular anti-oxidant is glutathione (GSH), which also has
other key roles in the kidney, including acting as a substrate or cofactor for drug
metabolism reactions (Lash, 2005). Conjugation reactions involving GSH are
catalysed by the enzyme glutathione-s-transferase (GST). GSH can donate reducing
equivalents to unstable molecules (i.e. ROS) and enter an oxidised state (glutathione
disulphide – GSSG); it can then be converted back to the reduced form by
glutathione reductase. The GSH/GSSG ratio is kept high in most cells (i.e. the GSH
pool is predominantly in a reduced state), in order to provide an effective anti-
oxidant system. A lowering of the GSH/GSSG ratio is, therefore, often taken as a
sign of oxidant stress within a cell.
Whilst the liver is the main source of circulating GSH, the kidney is responsible for
the uptake and clearance of GSH from the plasma (Griffith & Meister, 1979). Uptake
of GSH by the kidney occurs predominantly in the PT, via both the apical and baso-
lateral membranes, and utilises both sodium dependent and independent mechanisms
(Lash, 2005). In addition, the PT is also capable of synthesising GSH from precursor
amino acids. Experimentally, uptake of exogenous GSH by the PT appears to be
protective against oxidative stress (Lash et al., 1986).
1.3.5 Calcium signalling
Ca
2+ is an important intracellular second messenger, with multiple roles in cell
signalling, affecting diverse functions such as muscle contraction, neurotransmitter
secretion, gene transcription and egg fertilisation (for reviews see (Bootman et al.,
2001; Petersen et al., 2005)). Ca
2+ signals are compartmentalised within the cell and
are frequency and amplitude coded, which allows them to convey a diverse range of
information. An increase in intracellular [Ca
2+], in response to an extracellular
signalling stimulus, usually occurs either due to influx of Ca
2+ from the extracellular
fluid (via transient opening of either voltage or ligand gated cation channels), or from
release of Ca
2+ from intracellular stores. The majority of Ca
2+ within the cell is stored31
in the endoplasmic reticulum (ER), and can be released in response to activation of
1,4,5-trisphosphate (IP3) (Spat et al., 1986) or ryanodine (Franzini-Armstrong &
Protasi, 1997) receptors in the ER membrane. IP3 itself is an important second
messenger, generated following the action of neurotransmitters or hormones acting
on receptors in the cell membrane (Streb et al., 1983), while ryanodine receptors are
activated by ADP ribose (Bastide et al., 2002). Nicotinic acid adenine dinucleotide
phosphate (NAADP) is a more recently discovered second messenger that is thought
to cause intracellular Ca
2+ release from acidic organelles (such as lysosomes)
(Calcraft et al., 2009).
Following an increase in intracellular [Ca
2+], rapid uptake of Ca
2+ then usually
occurs, partly back into the ER, but also into the mitochondria, which act as a major
reservoir for Ca
2+ uptake. This movement of Ca
2+ into mitochondria is driven by the
electrochemical potential for Ca
2+ across the mitochondrial membrane – a low
intramitochondrial [Ca
2+] and a negative membrane potential, and is carried through
a Ca
2+ uniporter (Kirichok et al., 2004). Depending on their intracellular localisation,
mitochondria can therefore act as a ‘firewall’ against Ca
2+ signals propagating across
the cell, and this can be extremely important in spatially localising a Ca
2+ signal
within a polarised cell (Camello-Almaraz et al., 2002). Ca
2+ taken up by
mitochondria can be extruded via a Na
+/ Ca
2+ exchanger, in order to restore the
resting state. Intracellular [Ca
2+] is kept relatively low under quiescent conditions by
the activity of plasma membrane (PMCA) and sarco/endoplasmic reticulum
(SERCA) Ca
2+ ATPase pumps.
Ca
2+ signals in the PT have been observed in response to the physiological agonist
ATP, and these signals might have a role in regulating solute transport (Lee et al.,
2005) and cell proliferation (Lee & Han, 2006). Furthermore, elevations in
intracellular [Ca
2+] have been implicated in the pathogenesis of ischaemic renal
failure (Edelstein et al., 1997). It therefore follows that a disturbance in normal
mitochondrial function is likely to cause alterations in normal Ca
2+ signalling within
the PT, which may in turn have a functional effect on solute transport.32
1.3.6 Regulation of mitochondrial function
As discussed above, much has been learnt about mitochondrial function. In contrast,
relatively little is known to date about regulation of function, particularly in vivo. In
the kidney, metabolism is thought to be tightly coupled to membrane transport
(Soltoff, 1986). For example, an increase in solute transport will be reflected in an
increase in Na
+/K
+-ATPase activity, which will decrease cytosolic [ATP]. This, in
turn, will increase the ADP/ATP ratio in the mitochondria and favour the generation
of ATP by the mitochondrial ATP synthase. Conversely, a decrease in transport
activity, and increase in cytosolic [ATP], can lead to a lowering of ΔΨm and ATP
production, via an inhibitory feedback mechanism on the RC (Kadenbach & Arnold,
1999).
Ca
2+ is recognized to have an important regulatory role with regards to mitochondrial
function; an increase in mitochondrial Ca
2+ can increase the activity of key enzymes
involved in the supply of substrates to the RC (McCormack et al., 1990), and is also
thought to directly increase the activity of the ATP synthase (Territo et al., 2000).
Mitochondrial mass can be altered in muscle in response to challenges such as
exercise, cold and starvation. This process is thought to be mediated, at least in part,
by changes in the activity of AMP-activated protein kinase (AMPK); an
evolutionarily conserved fuel sensor, which is activated by decreases in intracellular
ATP/AMP ratio (Zong et al., 2002). Activated AMPK is believed to lead to an
increase in mitochondrial biogenesis via the effects of the transcription factor PGC-
1α (Jager et al., 2007). Interestingly, the drug metformin (a widely used treatment for
type II diabetes in patients with the ‘metabolic syndrome’) has been shown to
activate AMPK (Zhou et al., 2001).
At the level of an individual mitochondrion, ATP production is dependent on F1F0-
ATP synthase activity, which in turn is determined by both Δψm and the ADP/ATP
ratio. Δψm is dependent on substrate supply and RC complex activity, the degree of
proton leak across the inner mitochondrial membrane and the activity of the ATP
synthase. The nuclear-encoded mitochondrial protein IF1 has recently been shown
to have effects on ATP synthase activity and Δψm in cultured cells (Campanella et
al., 2008), and also on mitochondrial mass and structure (Campanella et al., 2009). In33
terms of overall ATP production in a given mitochondrion, the total number of RC
complexes and ATPase pumps is also clearly important. Therefore, it is apparent that
a number of different factors can affect mitochondrial ATP production, with the final
common pathway being the ATP synthase.
1.4 Mitochondrial cytopathy
1.4.1 Background
Mitochondria contain their own DNA (mtDNA) about 16.6 Kb long, which is
primarily maternally inherited and encodes for 13 proteins involved in the RC and
two rRNA subunits and 22 tRNA molecules necessary for protein synthesis
(Taanman, 1999). The majority of a mitochondrion’s approximately 1000 proteins
are encoded by nuclear (nDNA), rather than mtDNA. Unlike nDNA, mtDNA exists
as many copies in each cell and is thought to have a mutation rate as much as ten
times higher than nDNA (Brown et al., 1979). This is thought to be secondary to the
combination of a higher replication rate, closer proximity to the ROS-producing RC
and a lack of the protection that is afforded to nDNA by histones. This may cause
variation between cells in their mutant load, a phenomenon known as heteroplasmy;
cells in which all copies of mtDNA are affected are said to be homoplasmic. It
therefore follows that in order for clinical disease to develop, a threshold level of
mutant load has to occur within the cells of a particular issue. This threshold may
itself in turn depend on the relevant dependence of a particular tissue on aerobic or
anaerobic metabolism.
Mutations in mtDNA can take the form of deletions or point substitutions. Multiple
mtDNA deletions can be due to a defect in nDNA, causing a secondary abnormality
in mtDNA replication or repair. Diseases that are thought to be primarily due to a
defect in mitochondrial function are referred to as mitochondrial cytopathy, in order
to distinguish them from conditions in which mitochondrial involvement is a
secondary phenomenon, e.g., in cell death following ischaemia-reperfusion injury
(Plotnikov et al., 2007). Clearly, organs with a high rate of aerobic metabolism (e.g.,
the heart, skeletal muscle, brain and kidney) are more susceptible to mitochondrial
disease than cells or tissues with a higher anaerobic glycolytic capacity. Even within34
a tissue, variations exist among cell types in their relative dependence on aerobic
metabolism. Cells that are terminally differentiated (like podocytes) are especially
prone to the effects of mtDNA mutations, as rapidly dividing cells may segregate
mutant mtDNA unevenly, leading to daughter cells with differing mutant load. Over
time, due to a selective survival advantage, the daughter cells with a lower mutant
load may predominate, explaining why mutant loads are often lower in rapidly
dividing cells (such as leukocytes) than in other tissues in the body.
1.4.2 Phenotypic heterogeneity in mitochondrial cytopathy
Although certain patterns of disease are observed in mitochondrial cytopathy (Table
1.1), generally affecting the major aerobic organs, there is much phenotypic
heterogeneity.
Syndrome Features
Kearns-Sayre Cardiac conduction defects, ophthalmoplegia, retinitis
pigmentosa, deafness, cerebellar ataxia
Leber’s optic
atrophy
Blindness (predominantly in males)
Leigh Seizures, dementia, brain stem dysfunction
MELAS Encephalo-myopathy, lactic acidaemia and stroke like episodes
MERRF Myoclonic seizures, myopathy, short stature
MIDD Maternally inherited diabetes and deafness
NARP Neuropathy, ataxia, retinitis pigmentosa, and ptosis
Pearson Anaemia, pancreatic dysfunction
PEO Progressive external ophthalmoplegia
SANDO Sensory ataxic neuropathy, dysarthria and ophthalmoplegia
Table 1.1. Typical phenotypic patterns observed in mitochondrial cytopathy.
The same point mutation can produce a range of very different phenotypes; for
example, the A3243G mtDNA point mutation in the TL1 gene is associated with
MELAS (mitochondrial encephalo-myopathy lactic acidosis and stroke like
episodes) (Sproule & Kaufmann, 2008), renal glomerular disease (focal segmental35
glomerulosclerosis – FSGS) (Guery et al., 2003) and MIDD (maternally inherited
deafness and diabetes) (Guillausseau et al., 2001). Conversely, identical phenotypes
can be produced by different mutations. The reasons for this heterogeneity in
phenotype are not well understood. Possible explanations include interaction
between nDNA and mtDNA encoded proteins, unrecognised nDNA mutations and
the effects of environmental toxins.
The importance of the interaction between nuclear and mitochondrial genomes
cannot be overstated. MtDNA only encodes for a small proportion of mitochondrial
proteins and replication; transcription and translation are dependent on nuclear
encoded proteins that must be imported into mitochondria. It is thought that many of
the nuclear-encoded mitochondrial genes currently residing in the nucleus were
originally located in the mitochondrial genome, and have moved over time to the
nucleus for greater protection and a reduced mutation rate. It may be that in patients
with an identified pathogenic mtDNA mutation another, as yet unidentified, mutation
in nDNA is necessary to co-exist or develop for disease to occur. Environmental
toxins acting on a background of mutations in nuclear or mtDNA genes encoding
mitochondrial proteins could affect the timing, severity and organ specificity of
mitochondrial disease. For example, several toxins have been identified that may
cause diseases such as renal FS by disturbing mitochondrial function:
aminoglycosides (Simmons, Jr. et al., 1980), ifosfamide (DiCataldo A. et al., 1999),
and heavy metals (such as cadmium (Takebayashi et al., 2003)) are all examples.
The PT is particularly vulnerable to mitochondrial toxins, perhaps because it is a
major site for the excretion of xenobiotics.
1.4.3 Patho-physiology of mitochondrial cytopathy
How exactly a single point mutation in mtDNA can lead to clinical disease is not
well understood. Some insights into the cellular consequences of mtDNA mutation
have been gained from studies of transmitochondrial cybrids. These are immortalized
human cells depleted of mtDNA by exposure to a nucleoside analogue such as
2’,3’dideoxycytidine (ddC) (Nelson et al., 1997), which inhibits mtDNA replication.
Donor mitochondria are then introduced by fusion with platelets or enucleated skin36
fibroblasts, derived from patients with a known mtDNA mutation. This model has
the advantage that the effects of mtDNA mutations on cell metabolism can be
investigated without the confounding effects of unknown variations in nuclear genes
encoding mitochondrial proteins.
In cybrids derived from patients with MELAS due to the A3243G mutation,
significant reductions in mitochondrial translation products and impaired RC
function occur (Chomyn et al., 1992). The A3243G mutation has also been
associated with a number of cellular biochemical defects in addition to reduced RC
function, including increased oxidative stress (Rusanen et al., 2000), impaired Ca
2+
homeostasis (Moudy et al., 1995), lower Δψm (James et al., 1996), abnormal post-
transcriptional tRNA modification (Helm et al., 1999), and increased sensitivity to
signals for apoptosis (Mirabella et al., 2000). Yet significant protection was
conferred by only a 6% level of wildtype mtDNA in A3243G cybrids, indicating that
a mutant load of ~95% is required to produce abnormalities in cultured cells, and
perhaps also in disease. In patients with MELAS the mutant load varies widely
among different cell types and individuals, and clinical disease can occur with much
less than a 95% mutant load, which suggests that other factors are necessary in vivo
for disease to manifest itself, and/or that cybrid cells are relatively resistant to the
effects of mtDNA mutation, perhaps due to significant anaerobic metabolic capacity.
Some information has been obtained from studies in animal models with regards to
the mechanism(s) via which MD may cause disease in the kidneys. Puromycin
aminonucleoside nephrosis (PAN) is a rat model of human FSGS (Hagiwara et al.,
2006). In this model injections of puromycin aminonucleoside produced an early
nephrotic phase (analogous to minimal change disease in humans), followed by the
histological changes seen in FSGS. The development of FSGS was associated with a
reduction in whole kidney mtDNA and in mtDNA-encoded proteins in glomeruli.
Abnormalities in mitochondrial morphology in podocytes were also noted on
microscopy. How PAN causes these changes in mtDNA is unknown. In this model,
nitric oxide (NO) levels rose and fell in phase with the changes in mtDNA, which
might be important as NO can affect mitochondrial biogenesis though the generation
of cGMP (Nisoli et al., 2004).37
In the ‘mito-mouse’ (a mouse model of mitochondrial cytopathy), although multi-
organ disease did occur, the cause of death was renal failure at about 6 months of age
(Nakada et al., 2001). Histology of the kidneys showed dilated proximal and distal
tubules, as well as glomerular segmental sclerosis. RC function tests from affected
kidneys indicated that COX activity was reduced to ~28% of normal. This model
provides direct evidence for a link between mutation of mtDNA, a reduction in RC
function in the kidney and renal failure. Interestingly, the authors reported that the
tubular disease was largely cortical, perhaps reflecting the gradient in anaerobic
glycolytic capacity that exists in the kidney, increasing from cortex to medulla (Lee
& Peter, 1969). In general, producing useful animal models of mitochondrial
cytopathy has proved difficult for a variety of reasons, including the lack of a simple
method to transfer mtDNA alone, phenotypic variability observed with the same
mtDNA mutation and the fact that apparently pathogenic mutations in humans can be
neutral polymorphisms in other species (for review see (Khan et al., 2006)). The
‘mito-mouse’ was generated by injecting mitochondria containing a 4696 base-pair
mtDNA deletion into mouse embryos. Other approaches have involved altering
nuclear genes to affect mtDNA replication and induce mutations (e.g. mutated pol-γ
(Trifunovic et al., 2004; Kujoth et al., 2005)), or expression of restriction enzymes
targeted to mitochondria to induce mutations of mtDNA (Bayona-Bafaluy et al.,
2005). Although these techniques can produce animals with organ dysfunction and
shortened life-spans, the phenotypes vary due to the random nature of mtDNA
mutations that are induced. Substantial improvements, especially with regards to
mtDNA transfer techniques, will be required in order to model human mitochondrial
cytopathy more accurately, and in particular the effects of common pathogenic single
mtDNA mutations.
In spite of a major research effort, how mitochondrial cytopathy can lead to disease
at a cellular level is still unclear. As previously mentioned (see earlier – ‘Reactive
oxygen species production’), one attractive theory is that mtDNA mutations may
increase oxidative stress, which in turn causes oxidative damage to the RC, acting as
a positive feedback mechanism that amplifies mitochondrial dysfunction (Jacobson
et al., 2005). Such a process could account for the slow progression of disease in
many patients, despite the expression of the mutation from birth, but this is
speculative.38
It is well recognised that patients with end stage renal failure, even if on
haemodialysis, can develop a uraemic myopathy. This may be related to a range of
factors, including alterations in vitamin D metabolism and erythropoietin deficiency.
However, there is some evidence for abnormal mitochondrial function in skeletal
muscle in these patients too, suggesting that they may have any acquired form of
mitochondrial cytopathy, and that the relationship between renal disease and
mitochondrial dysfunction may be a two-way process. Skeletal muscle biopsies from
haemodialysis patients have shown abnormalities in mitochondrial morphology on
electron microscopy (Diesel et al., 1993; Shah et al., 1983) and revealed limited
aerobic capacity (Moore et al., 1993); however, others have reported preserved
mitochondrial function (Miro et al., 2002; Barany et al., 1991). Excess lactate
production during exercise has been described in haemodialysis patients (Parrish,
1981; Lundin et al., 1987), but this may be related to abnormalities in oxygen
delivery rather than intrinsic mitochondrial defects (Sala et al., 2001). Finally,
carnitinine deficiency has been implicated in uraemic myopathy. Carnitine is located
on the inner side of the mitochondrial membrane, and plays a key role in transporting
fatty acids from the cytosol into the mitochondria so they may be broken down, via
beta-oxidation, to be used as substrates for oxidative phosphorylation. Haemodialysis
patients can become carnitine deficient due to losses across the dialytic membranes
(Guarnieri et al., 2001), which might explain the development of myopathy.
However, some studies have disputed that dialysis patients are actually carnitine
deficient in muscle (Mingardi et al., 1980; Wanner & Horl, 1988), and carnitine
supplementation has not been conclusively proven to objectively improve uraemic
myopathy (Davenport, 2004; Vaux et al., 2004).
1.4.4 Renal involvement in children with mitochondrial cytopathy
Much of the current literature on mitochondrial cytopathy and renal disease comes
from paediatrics and has been presented in several published reviews (Niaudet &
Rotig, 1997; Niaudet, 1998; Rotig, 2003). The commonest renal manifestation seems
to be FS (Martin-Hernandez et al., 2005; Neiberger et al., 2002); although the
nephrotic syndrome, tubulo-interstitial disease, a Bartter’s-like syndrome and renal
tubular acidosis have all been described (Niaudet & Rotig, 1996). So far, no clear39
pattern has emerged linking particular gene mutations with specific RC defects or a
particular renal phenotype. However, it has been noted that most of the children
described present at an early age (generally under 2 years old) and renal dysfunction
was diagnosed after developing a severe and generalized multi-system disorder. A
range of underlying gene defects has been described, including point mutations and
deletions of mtDNA. Children with FS often have mtDNA deletions and have
syndromes known to be caused by mtDNA deletion, such as Pearson (refractory
sideroblastic anaemia, diabetes and lactic acidosis) or Kearns-Sayre (external
ophthalmoplegia, retinopathy, myopathy and ataxia).
A variety of mutations in nuclear genes encoding mitochondrial proteins have been
reported in the last few years that cause renal disease in children. Both tubulopathy
(Rahman et al., 2001) and nephrotic syndrome (Salviati et al., 2005; Rotig et al.,
2000) have been associated with co-enzyme Q10 (ubiquinone) deficiency, and, more
recently, mutations in two nuclear genes (COQ2 (Quinzii et al., 2006) and PDSS2
(Lopez et al., 2006)) encoding components of the co-enzyme Q10 biosynthetic
pathway have been described in patients with renal disease. Mutation of BCS1L can
lead to impaired complex III assembly (Lonlay et al., 2001), while mutation of
COX10 can lead to impaired complex IV activity (Valnot et al., 2000); both have
been described in patients with PT disease. Recently, a mtDNA depletion syndrome
causing tubular disease (due to a defect in the nuclear gene RRM2B (Bourdon et al.,
2007)) has been described.
A screening study in children with mitochondrial cytopathy showed that almost half
had either FS or sub-clinical proximal tubulopathy (Martin-Hernandez et al., 2005),
suggesting that the burden of PT disease in these patients is significantly
underestimated, whatever the underlying mutation. Measuring serum lactate has
often been used as a screening test for mitochondrial cytopathy, though in the
presence of renal disease (FS) it may be normal owing to increased urinary loss of
lactate, which is normally reabsorbed by the PT (Thirumurugan et al., 2004). In
children with multi-system mitochondrial cytopathy the prognosis is often poor; the
reason for the high prevalence of PT disease in children is not known.40
1.4.5 Renal involvement in adults with mitochondrial cytopathy
The situation to date in the literature concerning adults with mitochondrial cytopathy
seems to be somewhat different from children. Although a range of renal pathologies
have been reported, including tubulo-interstitial disease and multi-cystic disease, the
most common histological finding has been glomerular sclerosis (FSGS) (Guery et
al., 2003; Li et al., 2007; Lowik et al., 2005). For reasons that are not yet clear, there
appears to be a female preponderance in the literature, which has not been observed
in children, and there is wide variation in age at presentation. FSGS has been
described in children with mitochondrial cytopathy (Gucer et al., 2005; Scaglia et al.,
2003), but does not appear to be as frequent as tubular disease. Involvement of other
organs is common, but the severe multi-system disease seen in children is rare.
Hearing loss seems to be particularly common and has led to some confusion with
Alport’s disease (which can be differentiated by the presence of haematuria and non-
progressive hearing loss). Diabetes is also common and can be aggravated by
steroids given to treat FSGS, although renal histology suggests that diabetes is not
responsible for the nephropathy (Guery et al., 2003).
In contrast to mitochondrial cytopathy-related renal involvement in children, a
significant number of adult patients seem to present with renal disease before a
mitochondrial diagnosis. Various clues can suggest the underlying diagnosis,
including the presence of subclinical disease in other tissues, a positive family
history (though not necessarily of renal disease) with maternal inheritance, a lack of
response to conventional therapy, and the presence of abnormal looking
mitochondria on electron microscopy (EM) of renal biopsy tissue.
In contrast to the heterogeneity of underlying mtDNA mutations in paediatric
patients, only a single point mutation (A3243G) appears to predominate in adult
patients with renal disease. In addition to causing a variety of renal disorders, this
mutation is associated with >80% of cases of MELAS syndrome (Schmiedel et al.,
2003) and MIDD (Reardon et al., 1992). It is also been associated with
cardiomyopathy (Nan et al., 2002) and external ophthalmoplegia (Hansrote et al.,
2002). In renal patients, the prevalence of this mutation might be far higher than
currently recognised: one study of diabetic patients on haemodialysis reported a41
prevalence of 5.9% (Iwasaki et al., 2001), compared with an estimated prevalence of
0.24% in the general population (Manwaring et al., 2007). Moreover, in a screening
study of patients with MIDD, 28% were found to have renal involvement ranging
from asymptomatic proteinuria to end stage renal disease (Guillausseau et al., 2001).
The A3243G mutation is thought to account for ~0.06% of cases of diabetes mellitus
in the UK (Gerbitz et al., 1995). Mutations of mtDNA, including A3243G
(Sangkhathat et al., 2005), have also been described in patients with kidney tumours
(Hervouet & Godinot, 2006; Wada et al., 2006).
1.4.6 Differences between adults and children
Interesting differences between paediatric and adult patients with mitochondrial
cytopathy-related renal disease exist in the literature to date. Children seem to
present with a proximal tubulopathy at an early age, as part of an established and
severe multi-organ disease due to mtDNA deletions (and/or nuclear mutations), and
to have a poor prognosis. The mutations are generally sporadic and they are not
usually passed on because of the early onset and severity of disease, and because
survival into adulthood is rare (although in general humans don’t seem to pass on
mtDNA deletions to their offspring for reasons that are still unclear).
To some extent the pattern of genetic mutations described causing mitochondrial
cytopathy and renal disease in children and adults reflects the general situation in
mitochondrial cytopathy; whereby nuclear mutations are more likely to present in
childhood, whereas mtDNA mutations tend to present later in life (for a review of
mitochondrial disease in childhood see (Moslemi & Darin, 2007)). Most nuclear
mutations are expressed in all tissues and would be expected to cause severe multi-
system disease. However, the clinical pattern of disease does not always follow the
levels of expression of mutant genes in different tissues (Papadopoulou et al., 1999).
The reasons for this are still unclear; although a possible explanation is that
expression levels may vary during embryonic development, resulting in particular
patterns of disease in the newborn (Rotig & Munnich, 2003), but this is unproven.
Within the kidney, differential expression of affected proteins in different regions of
the nephron (e.g., glomerulus vs. tubule) provides an attractive, though speculative,
explanation for the spectrum of phenotypes seen in mitochondrial cytopathy. In42
adults with point mtDNA mutations, heteroplasmy of mutant load among different
tissues is an obvious explanation for the wide variation in phenotype, including
severity and organ specificity.
Unlike children, adults tend to present with a milder phenotype and sometimes with
only renal disease. Furthermore, renal pathology is more usually glomerular; in all
cases the underlying defect is due to a single point mutation in mtDNA that can be
maternally inherited. The reason why a particular pathology (FSGS) should occur in
these cases is unknown. Any terminally differentiated cells with a heteroplasmic
mtDNA pool will be vulnerable to mitochondrial cytopathy, since cell division
provides an opportunity to segregate mutant mtDNA unevenly between daughter
cells, which can result in a clone of cells with a lower mutant load and a metabolic
(and selective) advantage. Daughter cells with a higher mutant load may be
recognised as damaged and are deleted by apoptosis. Podocytes are terminally
differentiated and unable to undergo regenerative proliferation in response to cell
loss (Pavenstadt et al., 2003), which might explain the relatively high prevalence of
glomerular disease in adults with mitochondrial cytopathy.
Recently, interest has grown in the capacity of the renal tubule to regenerate itself
following an acute toxic insult. The origin of the cells that repopulate the tubule is
currently uncertain; possibilities include proliferation of existing tubular cells or
migration of stem cells into the damaged kidney from the blood stream (Imai &
Iwatani, 2007). If the former hypothesis is true, and the renal tubule has an inherent
capacity to regenerate itself via division of epithelial cells, this would provide a
potential mechanism via which mtDNA mutant load could be reduced over time.
This might explain why terminally differentiated cells that cannot be regenerated,
such as podocytes, might be more vulnerable to the chronic effects of mtDNA
mutations.
It is surprising that one mtDNA mutation appears to predominate in adult
nephrology, given the high rate of mtDNA mutation, and that >200 mtDNA
mutations that have been described in other medical specialities (see MITOMAP: A
Human Mitochondrial Genome Database [http://www.mitomap.org]). It could reflect43
a lack of awareness of mitochondrial cytopathy as a cause of renal disease;
eventually other unexplained cases of chronic renal disease may be linked to other
mtDNA mutations. Because it seems to be a common mutation, A3243G is included
in mtDNA screening by most clinical genetics laboratories and this may bias towards
a high reported prevalence.
To date, the literature on renal disease in adults with mitochondrial cytopathy is
small, and apparent differences between children and adults should therefore be
interpreted with caution, especially as systematic screening studies of nephropathy in
adults with mitochondrial disease (using sensitive renal tubular markers) have not
been performed previously. In theory, given the vulnerability of the PT to MD, high
rates of renal tubular disease would also be expected in adults with mitochondrial
cytopathy. As more and more patients are recognised to have mitochondrial disease
(due to improvements in diagnostic techniques), and increasing numbers survive to
adulthood, understanding the effects of MD on the adult kidney is becoming
increasingly important.
1.5 HIV, anti-retroviral therapy and the proximal tubule
1.5.1 Mitochondrial toxicity of HIV and its therapy
As survival from HIV improves, due to the development of more clinically effective
anti-retroviral therapy (ART), the balance of nephropathy attributed to HIV is
changing from direct pathological effects of the virus (traditional HIV associated
nephropathy – ‘HIVAN’) to ART-related renal toxicity (Wyatt & Klotman, 2006;
Roling et al., 2006). It is therefore important that the burden and nature of ART-
related kidney disease is investigated and understood.
Both HIV and some forms of ART are thought to be toxic to mitochondria. In
treatment naïve patients, depletion of mtDNA has been reported in peripheral blood
mononuclear cells, consistent with a toxic effect of the virus (Maagaard et al., 2006),
which is also thought to induce oxidative stress in some cell types (Mollace et al.,
2001). Nucleoside analogue reverse transcriptase inhibitors (NRTIs) are a commonly
used form of ART. They are incorporated into the replicating virus by the reverse44
transcriptase enzyme that recognises them as appropriate substrates. However, once
incorporated they cause a cessation of transcription. They are highly effective,
especially when used in combination with other forms of ART (highly active ART –
HAART), and have revolutionised the expected survival from the disease. However,
they are not without significant side effects, including mitochondrial toxicity. The
basis of this toxicity is that NRTIs inhibit the mtDNA polymerase gamma (pol-γ) 
(Lewis & Dalakas, 1995), the enzyme responsible for mtDNA replication. Unlike
nDNA, mtDNA does not utilise other polymerases and is therefore specifically
affected, leading to a gradual decrease in mtDNA levels (often expressed as the
mtDNA/nDNA ratio). Patients taking ART may develop hyperlipidaemia, central
obesity and insulin resistance; features of the ‘metabolic syndrome’, in which
mitochondrial toxicity is thought to play a central role in the pathogenesis (Villarroya
et al., 2007).
In vitro tests in cell lines derived from various different organs appear to show a
consistent ‘pecking order’ of NRTI related mitochondrial toxicity as follows (in
descending order of toxicity): didanosine (ddI), stavudine, zidovudine (AZT), and
finally tenofovir (TDF - which is thought to have little or no in vitro mitochondrial
toxicity at all) (Birkus et al., 2002). However, in vivo, the situation is somewhat
different, with certain agents appearing to cause toxicity in particular organs (e.g.
AZT and the heart, ddI and the pancreas, TDF and the kidney (Hoschele, 2006)). The
reasons for this are not clear, but potentially confounding factors include pol-γ -
independent mechanisms of mitochondrial toxicity, the toxic effects of the virus
itself, previously undiagnosed underlying mtDNA mutations and drug interactions.
Perhaps unsurprisingly, ART thought to be toxic to mitochondria has been reported
to cause FS (Miller et al., 2003; Izzedine et al., 2003).
1.5.2 Nephrotoxicity of Tenofovir
TDF is a widely used and effective nucleotide reverse transcriptase inhibitor that,
unlike other NRTIs, is thought to have little or no mitochondrial toxicity in vitro
(Biesecker et al., 2003; Birkus et al., 2002; Vidal et al., 2006). Furthermore,
randomised control studies have not shown an association between treatment with
TDF and clinically significant renal toxicity (Jones et al., 2004; Izzedine et al.,45
2005a; Schooley et al., 2002). Subsequently, however, numerous case reports of
renal tubular toxicity in patients taking TDF have emerged in the literature (de la
Prada et al., 2006; Malik et al., 2005; Peyriere et al., 2004; Quimby & Brito, 2005;
Rifkin & Perazella, 2004). In many of these cases, patients developed FS. Most of
the original TDF studies that screened for renal dysfunction focused on measuring
serum creatinine (and eGFR) and urine dipstick proteinuria (mainly albuminuria);
both of which are predominantly markers of glomerular disease, and will not
necessarily detect tubular disease, especially in milder cases.
The mechanism of TDF toxicity is not well understood. As previously mentioned, in
vitro tests suggest that TDF is not toxic to mitochondria, however, some evidence
has emerged in the literature to suggest that TDF may potentiate the mitochondrial
toxicity of other forms of ART used concurrently. For example, the combination of
TDF and ddI has been associated with mtDNA depletion in human kidney biopsies
(Cote et al., 2006) and peripheral blood mononuclear cells (Saumoy et al., 2004).
Recently, another study, using a mouse model of HIV (hemizygous HIV-1 TG mice
(Dickie et al., 1991)), has re-examined the mitochondrial toxicity of TDF (Kohler et
al., 2009). Although the authors of this study found that TDF caused an increase in
the overall mtDNA/nDNA ratio in the whole mouse kidney, in isolated PTs of
animals exposed to TDF there was a significant reduction in the mtDNA/nDNA
ratio. This implies that TDF is specifically toxic to mitochondria in the PT, perhaps
because of the fact that active secretion by this nephron segment into the urine is a
significant excretion pathway for the drug (Barditch-Crovo et al., 2001). Drug
interactions that interfere with the excretion pathway of TDF may therefore play an
important role in the development of tubular toxicity; in many of the reported cases
of TDF induced FS patients have also been taking ritonovir boosted PIs and/or ddI as
part of their HAART. TDF and ddI are both renally excreted via the PT and compete
for the same baso-lateral organic anion transporter (Cihlar et al., 2001). TDF exits
the PT cells via luminal multi-drug resistance-associated protein-4 (MRP4)
transporters (Imaoka et al., 2007); Ritonovir is a substrate for MRP2 transporters
(Huisman et al., 2002), and it has been suggested that an interaction at MRP4
transporters between TDF and ritonovir might account for an increase in cellular
TDF levels to toxic levels, although this remains to be proven.46
1.6 Mitochondrial dysfunction as a cause of Fanconi syndrome
1.6.1 Evidence for mitochondrial dysfunction as a cause of Fanconi syndrome
As discussed previously, the pathogenesis of FS is poorly understood. A sub-lethal
defect in PT cell metabolism has been suggested as an attractive (if speculative)
unifying mechanism, which might lead to a breakdown of PT cell transport in the
absence of cell death. Various strands of evidence exist to implicate mitochondrial
dysfunction in the patho-physiology and support this hypothesis. Firstly, as stated
earlier, the typical renal presentation of children with mitochondrial cytopathy is FS.
Secondly, various drugs known to be toxic to mitochondria have been found to cause
reversible FS (including ART) (Izzedine et al., 2003). Thirdly, abnormalities in
mitochondrial appearance have been reported in experimental and clinical types of
FS, including myeloma (Morel-Maroger Striker et al., 1994). Moreover, FS has been
reported in primary biliary cirrhosis, a condition characterised by the presence of
anti-mitochondrial antibodies (Lino et al., 2005). Fourthly, several inborn errors of
metabolism can cause FS, and the excess metabolites that accumulate in these
disorders (such as cystinosis (Foreman et al., 1995) and tyrosinaemia (Roth et al.,
1991)) have been found to be toxic to mitochondria. Lastly, directly applying
inhibitors of the mitochondrial respiratory chain can lead to inhibition of sodium and
PO4
2- transport in PT cells in vitro (Gullans et al., 1982).
1.6.2 Possible mechanisms via which mitochondrial dysfunction might impair solute
transport in the proximal tubule
Although there is a wealth of clinical evidence implicating mitochondrial
dysfunction in the pathogenesis of FS, the exact mechanism that links the two
remains unknown. As discussed already, much remains to be learnt in general about
the cellular mechanisms by which mitochondrial cytopathy causes disease in any
organ.
Clearly, a reduction in cytosolic ATP, due to abnormal RC function, is one
possibility. In an in vitro model of cystinosis-induced FS in isolated PTs, depletion of
intracellular ATP and defective transport were both attenuated by incubation with
exogenous ATP (Coor et al., 1991). PT cells are thought to have very little anaerobic47
capacity for generating ATP (Bagnasco et al., 1985), so a reduction in RC activity is
likely to have a significant effect on cytosolic ATP levels in this nephron segment.
As endocytosis is an active process, alterations in local ATP concentration might be
expected to have an inhibitory effect. However, given the varied and important
cellular roles of mitochondria beyond ATP synthesis, it is quite possible that MD
could affect endocytosis by other non-ATP mediated mechanisms, such as altered
Ca
2+ signalling or increased ROS production. Mitochondria have a crucial role in
regulating intracellular Ca
2+ signalling, including the spatial localisation of Ca
2+
signals in polarised epithelia such as pancreatic acinar cells (Camello-Almaraz et al.,
2002). However, nothing is known to date about the effect of mitochondria on the
spatial localisation of Ca
2+ signals in the PT. Changes in Ca
2+ concentration have
been implicated as a control mechanism for endocytosis in neurons (Wu, 2004), and
increasing the concentration of Ca
2+ in a renal cell line with ionomycin was reported
to affect endocytosis of the LMWP insulin (Carvou et al., 2007). ROS generated
from mitochondria have been reported to affect endocytosis in alveolar epithelial
cells (Dada et al., 2003).
1.7 Fluorescence live-cell imaging
1.7.1 Single-photon excitation confocal imaging
Fluorescence microscopy utilizes the fact that electrons orbiting certain molecules
(called fluorophores) can be excited to a higher state by absorbing a photon of light
at a wavelength particular to the fluorophore. After a period of time, the electrons
will return to the ground state, and in doing so will emit light at lower energy, and
hence at a longer wavelength. Standard confocal fluorescence microscopy involves
illuminating a region of interest in a specimen with a laser at a wavelength known to
excite the fluorophore being studied (Wright et al., 1993). Emitted light from the
fluorophore is then passed through a series of filters to remove both any reflected
excitation light and also light emitted from any other fluorophores that may be
partially excited. A pinhole is used to collect light only that is confocal to the plane
of focus desired in the specimen, in order to produce a sharply focused image (Figure
1.4). Photonmultiplier tubes (PMTs) are then used as detectors in order to convert the
light signal into a digital image that can be used for analysis with appropriate4849
imaging software. PMTs work on the principle that incoming photons are converted
to electrons by a photocathode; this electron signal is then amplified by a series of
electrodes (called dynodes) in order to produce an electrical signal. The fluorescent
properties of some fluorophores may be altered by certain conditions, e.g. binding of
other molecules, such as Ca
2+ or ROS. This phenomenon has been exploited
extensively in biological research as a means of observing physiological processes at
a molecular level in real time within living cells, which would otherwise not be
visible using standard light microscopy.
1.7.2 Multi-photon excitation fluorescence imaging
Whilst an appropriate and powerful technique for investigating physiological
processes in isolated or monolayers of cells, standard single-photon excitation
confocal microscopy has limitations with regards to imaging whole sections of tissue
(such as tissue slices or whole organs). The main drawbacks are, firstly, that light in
the ultraviolet to visible range (typically used for single-photon excitation of many
dyes) does not penetrate solid tissue nearly as well, and undergoes more scattering,
compared to longer wavelength (infrared) light. Secondly, confocal imaging results
in a double cone section of tissue being illuminated, with the consequence of
potential bleaching and phototoxicity outside of the plane of focus.
These disadvantages of single-photon excitation imaging led to the development of
multi-photon imaging. The principles of multi-photon imaging were first described
by Maria Göppert-Mayer in a PhD thesis in 1931. The technique has since been
developed by Denk (Denk & Svoboda, 1997) and others, and is now more widely
used in biological imaging. Essentially, multi-photon imaging relies on the principle
that electrons in fluorophores can be excited not only by a single photon at the
appropriate wavelength, but also, alternatively, by 2 photons arriving simultaneously,
each at approximately half the wavelength (and hence half the energy), or even 3
arriving, each at approximately a third of the wavelength (Figure 1.5). In practice
most multi-photon microscopy relies on two-photon excitation, hence the terms
multi-photon and two-photon microscopy are often used inter-changeably.5051
The fact that excitation will only occur if 2 or more photons arrive at a fluorophore
simultaneously has two major implications for multi-photon microscopy. First, in
order to increase the likelihood of simultaneous arrival, without having to increase
laser power to toxic levels, the excitation laser needs to be pulsed at high frequency.
Second, because excitation is only likely to occur in an environment of high photon
density, the probability of excitation drops off steeply (as a fourth power function)
anywhere in the tissue other than the narrow plane of focus. Hence, surrounding
tissue is far less exposed to photo-toxicity than in standard single-photon confocal
microscopy. This can be particularly advantageous when imaging a specimen
repeatedly, for example during a timed series experiment. Furthermore, the image is
intrinsically confocal, and a pinhole is not required.
Multi-photon microscopy is, therefore, an ideal technique for studying cellular
physiology in intact tissue sections. It is an exciting tool in biological imaging with
significant potential. Its use in the renal field has been relatively limited so far,
although some groups have utilised it to make some interesting and novel
observations of renal function in vivo (Molitoris & Sandoval, 2005; Sipos et al.,
2007); some of which have questioned our understanding of basic renal physiology
(Russo et al., 2007; Russo et al., 2009). However, multi-photon microscopy has not
been used previously to make measures of mitochondrial function in the kidney.
1.8 Experimental models of the proximal tubule
1.8.1 Immortalised cell cultures derived from the proximal tubule epithelium
Experimental models of the PT range from isolated cultured cells derived from the
PT (either primary or immortalised), to more intact in vitro tissue preparations (such
as isolated tubules or kidney slices), right up to fully intact kidneys either in vivo or
perfused in vitro. All have various advantages and disadvantages.
A number of immortalised cell models of the PT exist in research, which are derived
from different organisms. These include the llcpk (pig) (Ishibashi, 2006), HKC
(human) (Niculescu-Duvaz et al., 2007) and WKPT (rat) (Carvou et al., 2007). They
have the advantage of being relatively easy and cheap to grow, and provide an almost52
limitless supply of tissue for experiments, without the need for further animal
sacrifice. However, although widely used and capable of forming transporting
monolayers in culture, all of these models suffer from several drawbacks. Firstly,
following removal from the in vivo situation, PT epithelial cells tend to rapidly lose
their phenotype, and this has been the major limiting factor in the usage of primary
PT cultures in in vitro studies. Secondly, as part of the general loss of phenotype,
cultured PT cells have considerably less transport capacity, with a much less well
developed luminal brush border, than in vivo. Lastly, in common with most
immortalised cultured cell lines, the metabolism of PT cells tends to change with
time and passage number, with a gradual switch to a greater usage of anaerobic ATP
generation, rather than aerobic oxidative phosphorylation (Gstraunthaler et al.,
1999). In contrast, in vivo the cells of the PT are thought to have very limited
anaerobic capacity.
1.8.2 The Opossum Kidney (OK) cell line
OK cells are an immortalised PT cell line derived from the American opossum
(Didelphys virginiana). They are a much used model of PT epithelium and take up
LMWPs via receptor mediated endocytosis (Sidaway et al., 2004); the rate of uptake
is generally thought to be greater than that of other PT-derived cell lines. They form
a polarised monolayer with both tight junctions and a brush border (Rabkin et al.,
1989). The existence of megalin and cubulin (two crucial components of the PT
endocytotic apparatus) has been demonstrated in OK cells (Zhai et al., 2000).
Furthermore, OK cells have also been used in studies of uptake of dextrans via fluid
phase endocytosis (pinocytosis) (Gekle et al., 1995). Notwithstanding the general
drawbacks of immortalised cells in culture, they are considered to provide a suitable
model in which to investigate the effect of potential inhibitors on LMWP uptake.
1.8.3 The renal slice model
Although a useful model, cell lines are always limited by the relevance of any
findings to the situation in vivo. This is due to the fact that, when removed from their
native environment, cells can undergo significant phenotypic changes. Native tissue
is therefore preferable, not only because it is more ‘physiological’, and findings are53
more likely to reflect the true in vivo state, but also because it allows comparison
between adjacent cells of different tissue types. This sort of comparative approach
can be very revealing in understanding the topographical patterns of disease observed
within organs.
Clearly, the most physiological approach to studying the kidney is to use a whole
intact functioning organ, ideally in vivo. The isolated perfused kidney has been used
previously for pharmacological (Taft, 2004) and transport experiments (McTigue et
al., 1983), but not generally for imaging studies. In vivo imaging of the intact kidney
with a standard confocal microscope has been described, however, this approach was
limited by the fact that laser penetration into the tissue is very limited (50-100µm),
allowing only the very superficial structures in the organ to be studied. Nevertheless,
this approach did allow the visualisation of physiological processes, such as insulin
endocytosis, in real time in a live rodent (Simeoni et al., 2004).
The renal imaging field has subsequently been significantly enhanced by the
development of multi-photon imaging, which allows visualisation of structures up to
~200µm below the surface of the organ. This has permitted the studying, in real time,
of a range of physiological processes, including glomerular filtration, LMWP
endocytosis, and both capillary and tubular flow rates (Molitoris & Sandoval, 2005;
Sipos et al., 2007). However, imaging a whole organ still presents significant
practical difficulties, in spite of the advances in imaging technology. These include
the challenge of keeping the organ (and the animal if imaging in vivo) in good health,
throughout the period of experimentation. Furthermore, in spite of increased laser
penetration, it is still only possible to visualise structures such as the glomeruli in
certain species of rat (e.g. Munich Wistar (Hackbarth et al., 1983)), and large
sections of the kidney (such as the medulla) remain beyond the reach of the laser.
However, the main limiting factor at present, at least in terms of imaging cellular
processes, is the difficulty of achieving adequate loading into cells of standard
fluorophores. When loading these dyes into isolated cells in culture, they are often
incubated for some time (usually over half an hour) and may require other agents
(such as pluronic, which disperses micelles of the lipophilic dye) to enhance uptake
into cells. Clearly, these sorts of incubation times are not feasible in the intact organ,
where dyes have to be perfused through the vasculature, and individual cells within54
the organ are likely to come into contact with relatively small amounts of the dye for
short periods of time. In the intact animal, where dyes are usually injected via the
femoral vein, the dye will be diluted in the entire body water volume. Large volumes
of dye may therefore be required, which is a problem due to the high cost of many of
the dyes. Furthermore, in the case of AM-ester dyes, extracellular esterases can break
down the dyes before they even reach the target organ (Jobsis et al., 2007). In the
particular case of the kidney, the vast array of efflux pumps that exist in the cell
membrane, which are capable of extruding foreign molecules (like dyes) from the
tubular cells (Launay-Vacher et al., 2006), provide yet another challenge for in vivo
imaging.
A compromise solution that allows both visualisation of all nephron segments and
incubation with dyes for prolonged periods is the renal slice model. Here, slices of
kidney are made with a tissue slicer at a typical thickness of 200µm. This approach
preserves to some extent the architecture of the organ and thus allows comparisons to
be made between different tubule types side-by-side. Interactions between adjacent
cells that may be vital for normal signalling and metabolism may still occur. By
slicing at the appropriate level, either the cortex or medulla can be visualised. Tissue
slices have been used for a range of kidney studies (Bacic et al., 2003; Hong et al.,
1983; Parrish et al., 1995; Plotnikov et al., 2007; Rosenberg et al., 1961; Vickers et
al., 2004; Weinberger et al., 1975), and important insights have been made with
regards to renal metabolism using this approach (Balaban et al., 1980; Lee & Peter,
1969). However, this model does have some drawbacks too. For a start, the slicing
process is inherently traumatic, and results in the obliteration of natural osmotic and
solute gradients that normally occur across polarised cells in the kidney, and drive
transport processes. Therefore it is unclear to what extent transport will still occur in
ex vivo kidney slices. Given that metabolism is thought to be coupled to ATP
demand for transport in the cells of the nephron, it is therefore possible that the in
vivo situation may not be accurately modelled in the slice preparation. Furthermore,
the inner parts of the slice may be poorly accessible to dyes and reagents, and also to
oxygen, which may lead to hypoxia and altered metabolism (Balaban et al., 1980).
In spite of these drawbacks, the reality is that the tissue slice is a much used and
useful model that provides a balance between the benefits of in vivo intact organ55
work and in vitro cell culture. For example, multi-photon imaging of brain slices has
provided important insights into physiological processes in the central nervous
system, such as neurotransmitter release (Axmacher et al., 2004) and Ca
2+ signalling
(Ladewig et al., 2003). However, the technology has not, as yet, been applied to
kidney slices.
1.9 Imaging of mitochondrial function
1.9.1 Mitochondrial membrane potential (Δψm)
Various aspects of mitochondrial function can in turn be measured using suitable
fluorescent probes, and imaged in real-time using confocal single or multi-photon
excitation confocal microscopy. Δψm is central to mitochondrial function, affecting
processes such as ATP and ROS production, and Ca
2+ and protein import. It can be
measured using positively charged lipophilic fluorescent dyes, such as tetramethyl
rhodamine methyl ester (TMRM), which accumulate into the mitochondrial matrix
due to the relative negativity within the organelle, compared with the cytosol
(Duchen et al., 2003). The degree of accumulation is proportional to Δψm, when the
dyes are used in the ‘linear range’. That is, at a sufficiently low concentration that
they will not self-quench emitted light, due to a high concentration of dye in a
relatively small area and resulting high probability of collisional quenching. To test
which mode these dyes are behaving in, a RC uncoupling agent (e.g.
carbonylcyanide p-trifluoromethoxyphenylhydrazone [FCCP]) can be applied that
will depolarise Δψm, and cause the dye to redistribute into the cytosol and
surrounding extracellular fluid; if the dye is operating in the linear range (typically
nM concentrations), this will cause a decrease in the mitochondrial fluorescence
signal. However, the reverse will happen if the dye is in the quench/de-quench range
(typically µM concentrations), as a movement of dye out of the mitochondria will
reduce the level of auto-quenching, and lead to an increase in mitochondrial
fluorescence signal.
Δψm is dependent on a number of factors; including RC activity, the rate of ATP
synthesis and the degree of proton leak. A change in Δψm may therefore reflect a
change in one or more of these factors. Very little is known about variations in Δψm56
between different tissue types in vivo. However, it has been postulated that a
relatively low membrane potential may potentially be advantageous in aerobic
tissues as ROS production increases with increasing potential; hence, maintaining a
low potential might reduce harmful ROS production in the long-term (Kadenbach,
2003).
1.9.2 Reactive oxygen species production
Fluorescent probes such as dichlorodihydrofluorescein (DCF) (LeBel et al., 1992)
and dihydroethidium (also called hydroethidine - HEt) (Bindokas et al., 1996) can be
used in intact cells to measure the rate of ROS production. HEt is normally
fluorescent in the blue range, but upon oxidation by O2
- it becomes fluorescent in the
red range. Over time, the red fluorescence signal in a cell loaded with HEt will
increase, and the rate of increase in signal is taken to be proportional to the rate of
ROS production. Ethidium is freely diffusible within cells and binds DNA avidly;
therefore, signal change is normally predominantly observed in the nucleus of the
cell. HEt has been used previously to investigate rates of ROS production in isolated
segments of the nephron (Li et al., 2002; Zou et al., 2001). Mitosox is a fluorescent
ROS-sensitive dye that is tagged with a triphenylphosphonium (TPP
+) cation to
specifically target it to mitochondria (Robinson et al., 2006) (in a potential dependent
manner); changes in mitosox fluorescence signal are therefore thought to reflect
changes in mitochondrial O2
- production (Abramov et al., 2007).
1.9.3 Glutathione
Because of the potentially damaging effects of ROS, living cells require protective
anti-oxidant systems. One of the major intracellular anti-oxidants is GSH.
Intracellular levels of GSH can be measured via biochemical methods (Brehe et al.,
1976). Alternatively, for live cell imaging the dye monochlorobimane (MCB) can be
used as it forms a fluorescent adduct with GSH in a reaction catalyzed by GST
(Keelan et al., 2001), and emits a signal in the blue range when excited with
ultraviolet light.57
1.9.4 NADH and FAD
2+ autofluorescence and redox state
The reduced forms of NAD
+ (NADH) and flavoprotein (FADH2) are the substrates
for complexes I and II of the RC, respectively. It has been known since the 1950s
that NADH (and not NAD
+) is fluorescent in the blue range when excited with
ultraviolet light (for review see (Mayevsky & Chance, 2007)). Conversely, oxidised
flavoproteins (FAD
2+), but not the reduced form (FADH2), are fluorescent in the
green range when excited at about 450nm. Therefore, with appropriate excitation and
optics, by measuring the relative intensity of the fluorescence signals arising from
NADH and FAD
2+, it has been suggested that a ratiometric readout is available of the
relative redox states of the two substrate pools (Duchen et al., 2003).
The signals per se do not give any information about the total size of the substrate
pools, simply the amounts that are in either a reduced (NADH) or oxidised (FAD
2+)
state. Because of this, protocols have been developed to allow calibration of the full
dynamic range (complete reduction to complete oxidisation), in order to make sense
of them. This calibration can be performed by manipulating RC activity. For
example, RC inhibition (e.g. with cyanide [CN]) will push the substrate pools into a
fully reduced state, as oxidisation of the substrates at RC complexes will cease to
occur, but reduction of the substrates by intermediates in the Kreb’s cycle will
continue, until a maximally reduced state is achieved. Under these circumstances, the
NADH signal will be maximal, whilst the FAD
2+ signal will be minimal. The
advantage of using CN as a RC blocking agent is that its effects are readily reversible
and it can be washed off. After a suitable period of recovery, a RC uncoupling agent,
such as FCCP, can be applied that will lead to maximal RC activity (as it is no longer
constrained by the rate-limiting ATP synthase). Under these conditions, substrates at
RC complexes I and II will be maximally oxidised in order to support RC activity to
as greater extent as is possible. The NADH signal will therefore be at its lowest,
whilst the FAD
2+ signal will be at its highest. By normalising the baseline NADH
and FAD
2+ signals to these two extreme states (typically by denoting them as a value
from 1 to 0), the resting signals can be calibrated to the maximal available substrate
pools.58
These techniques have been used, for example, to learn more about the metabolism
of eggs (Dumollard et al., 2007), carotid body cells (Duchen & Biscoe, 1992) and
cardiac myocytes (O'Rourke et al., 1994). Once established, the resting redox state
can be used, in tandem with other measurements (such as Δψm) to gain insights into
RC activity within intact live cells. For example, the substrates in mitochondria in a
cell with a high ATP turnover rate would be expected to be in a relatively oxidised
state, whereas in a cell under ischaemic conditions (and RC compromise), the
substrates would be expected to be in a more reduced state. One caveat to the above
is that the redox state of RC substrates is not only determined by RC activity. As the
oxidised forms of the RC substrates are continuously reduced by intermediates in the
Kreb’s cycle, it follows that changes in Kreb’s cycle activity could also affect the
redox state of RC substrates. These sorts of changes could potentially occur if there
was any significant alteration in the supply of acetyl-CoA (the final common
pathway of carbohydrate, fatty acid and amino acid metabolism) to the Kreb’s cycle,
e.g. during starvation. However, in normal experimental conditions, the supply of
nutrients in the media used is held constant, under these conditions changes in
mitochondrial redox state will predominantly reflect changes in RC function.
1.9.5 Calcium signalling
A variety of Ca
2+-sensitive molecular probes are now available that can be loaded
into intact cells and respond to changes in intracellular [Ca
2+] with a change in their
fluorescent properties, which in turn can be measured using confocal or digital
imaging techniques (for review see (Takahashi et al., 1999)). Indicators vary
according to their properties, for example, some (e.g. Fluo-3 and Fluo-4) require
single wavelength excitation, whilst others are ratiometric (e.g. Fura-2). Some tend to
aggregate into organelles (e.g. Rhod-2 into mitochondria (Trollinger et al., 1997)),
which can be useful in resolving compartmentalised Ca
2+ signals, however, the
extent to which they do so can depend on the cell type and loading protocol used.
In order to permit adequate loading into intact cells, most Ca
2+-sensitive dyes are
prepared as an AM-ester, which masks charged groups and increases their lipid
solubility, and hence movement through the cell membrane. Once inside of the cell,
intracellular esterases de-esterify the conjugated dyes, and the remaining charged59
hydrophilic fluorescent indicator becomes trapped within the cell or organelle.
Changes in intracellular [Ca
2+], in response to a common extracellular agonist (such
as ATP or histamine) can then be detected as changes in the intensity of the
fluorescence signal emitted by the dye.60
Aims
1. To explore the underlying cellular mechanisms whereby mitochondrial
dysfunction can lead to impaired proximal tubular transport of low molecular
weight proteins, via receptor mediated endocytosis, using the OK cell line as
an in vitro model of the proximal tubule.
2. To investigate differences in mitochondrial function between the proximal
tubule and more distal parts of the nephron, both at rest and in response to
respiratory chain inhibition, in order to help to explain the clinical
vulnerability of the proximal tubule to mitochondrial dysfunction.
3. To establish a clinical link between changes in mitochondrial function and
proximal tubular transport, by determining the prevalence and nature of
tubular proteinuria (raised urinary levels of low molecular weight proteins
and proximal tubular enzymes) in patients with mitochondrial dysfunction;
either genetic, or acquired due to HIV and/or its treatment.61
Chapter 2 - Methods
2.1 Endocytosis of albumin and dextran by OK cells
2.1.1 Cell culture
OK cells were kindly provided by Dr Alex Pearson (South West Thames Institute for
Renal Research). They were grown in DMEM:F12, supplemented with 5% fetal
bovine serum, and passaged every 6 days. For experiments, cells were grown on
13mm sterile cover slips, coated with poly-L-lysine, in 24-well plates until confluent
(usually 5-6 days).
2.1.2 Cell death assay
To establish whether or not OK cells were alive after exposure to RC inhibitors for 2
hours, cells were loaded with Hoechst 33342 5µM (excited at 720nm) and Propidium
iodide 10µM (excited at 514nm). The former stains all cell nuclei, whilst the latter is
normally excluded by a viable cell membrane, and thus stains only the nuclei of
permeabilised, dead cells (Ciancio et al., 1988). Digitonin (20µM), which disrupts
the integrity of the cell membrane, was used as a positive control. When assessing
the specific toxicity of the glycolytic inhibitors iodoacetic acid (IAA) and 2-
deoxyglucose (2-DG), pyruvate 5mM was added to the solution as a substrate for
oxidative phosphorylation.
2.1.3 Endocytosis assay
FITC-labelled albumin (FA) was used as a ligand for endocytosis by OK cells in
order to model LMWP uptake in the PT. Cell models of the PT vary in the degree to
which they endocytose different proteins. OK cells are known to endocytose albumin
avidly (Gekle et al., 1995); hence, this protein was chosen as a ligand. FITC-insulin
has also been used previously as a ligand for in vitro studies of PT endocytosis
(Rabkin et al., 1989), however, preliminary experiments revealed very low uptake in
the OK cells. FITC-dextran (FD) was used to investigate fluid-phase endocytosis
(pinocytosis).62
For endocytosis experiments, OK cells were washed 4 times in a HEPES-buffered
solution (pH 7.4), containing (in mmol/l): NaCl 138, KCl 5.6, NaHCO3 4.2,
NaH2PO4 1.2, MgCl2 1.2, CaCl2 2.6, glucose 10 and HEPES 10. They were then
incubated in HEPES-buffered solution (pH 7.4) containing FA (50µg/ml) or FD
(5mg/ml) for 1 hour at 37°C. The cells were then washed with 0.2M acetic acid/0.5M
NaCl to remove any FA bound to the external cell membrane, and then subsequently
6 times with ice cold HEPES-buffered solution, to remove any FA or FD in solution
and prevent further endocytosis (which is temperature dependent). The cells were
fixed with 4% para-formaldehyde for 15 minutes, and were then mounted on slides
with Citifluor AF1 glycerol/phosphate buffered saline mountant (Citifluor Ltd,
London, UK), and imaged with a Zeiss LSM 510 inverted confocal microscope (Carl
Zeiss Ltd, Welwyn Garden City, Hertfordshire, UK). Random fields were selected,
using the bright field setting, with a x40 oil immersion objective, and a 10µm deep
image z-stack (with 1µm intervals) was imaged for each field at 488nm. The mean
fluorescence signal collected for each stack was calculated using Zeiss LSM
software, with identical threshold values used throughout.
The polarity of endocytosis in OK cells (i.e. apical versus baso-lateral uptake) was
established by growing cells to confluence on Transwell plates (Appleton Woods,
Birmingham, UK). FA was then applied to either the apical or baso-lateral membrane
of the insert, using the same protocol as above. Inserts were removed and mounted
using Mowiol (a mountant that sets solid - a kind gift from Dr N Carvou, UCL), and
imaged according to the same protocol as above.
To investigate the effects of mitochondrial RC inhibitors on the uptake of FA or FD
in OK cells, either rotenone 10µM, piericidin 10µM or CN 1mM (all supra-maximal
concentrations) were added to the HEPES-buffered solution at the start of the 1 hour
incubation, to inhibit either complex I (rotenone and piericidin) or IV (CN) of the
RC, respectively. 2-DG 5mM was used (in the presence of pyruvate 5mM) to
investigate the effect of blocking glycolysis.63
2.1.4 Dynamic measurement of intracellular ATP
Two different methods were employed to measure the effects of RC inhibition on
cytosolic [ATP]. The first involved the usage of the dyes Magnesium Green (Mg
Green, Molecular probes, Invitrogen, Paisley, UK) and TMRM, to provide a dual
readout of changes in ATP levels and Δψm (Leyssens et al., 1996). The principle of
this test is that cytosolic free [Mg
2+] changes inversely in response to changes in
[ATP], due to that fact that ATP has a higher affinity for Mg
2+ than ADP, and most
Mg
2+ in the cell is bound to ATP. Mg Green fluorescence signal intensity changes in
proportion to increases or decreases in [Mg
2+]; therefore, the fluorescence signal
changes inversely in response to alterations in [ATP]. Meanwhile, changes in TMRM
signal represent changes in Δψm.
Mg Green was loaded at a concentration of 5µM with 0.01% pluronic and 2.5mM
probenecid (to enhance loading) at 20°C for 20 minutes. It was then washed off and
the cells were incubated for a further 20 minutes with TMRM 50nM and verapamil
100µM (to enhance loading). TMRM 50nM is a suitably low concentration such that
the dye operates in the ‘linear range’; i.e. a reduction in Δψm leads to a decrease in
the mitochondrial TMRM fluorescence signal and a corresponding increase in the
cytosolic TMRM signal. The bulk of the extra-nuclear volume in OK cells is filled
with mitochondria; hence, in order to obtain a ‘cytosolic’ signal for recording
simultaneous changes in Mg Green and TMRM, regions of interest (ROIs) within the
nuclei of cells were used for the purposes of analysis.
The second method utilized for measuring changes in ATP levels was a luciferin-
luciferase assay, with changes in luminescence recorded using a custom built
luminometer (with assistance from Cairn Research, Faversham, Kent). OK cells were
tansfected with cytoplasmically targeted luciferase (Invitrogen, Paisley, UK),
according to the manufacturer’s protocol. Luciferin 50µM was then added and the
luminescence signal emitted measured. The RC inhibitor rotenone 10µM and the
glycolysis inhibitor IAA 1mM were sequentially added to the recording chamber, in
order to investigate the effects of each on the luminescence signal (and, therefore, on
cytosolic [ATP]).64
2.1.5 Measurement of ROS production
In order to measure mitochondrial ROS production, OK cells were loaded with the
O2
- sensitive dye mitosox 5µM (Molecular probes, Invitrogen, Paisley, UK), which
localizes to mitochondria. The cells were incubated with the dye for 10 minutes at
room temperature before imaging. Mitosox was excited at 543nm and light was
collected using a 560-615nm band-pass filter. NADH was simultaneously excited at
364 nm, and emitted signal was collected using a 435-485nm band-pass filter.
Images were acquired only every 2 minutes to minimise laser-induced photo-toxicity.
After a 10 minute control period, the RC inhibitors rotenone 10µM, piericidin 10µM
or CN 1mM were added. For the purposes of analysis, the NADH signal was used to
identify mitochondrial dense areas of the cell, around which ROIs were drawn. The
rate of increase in fluorescence signal was taken to be proportional to the rate of ROS
production.
2.1.6 Electron microscopy of OK cell structure
EM of OK cells was performed with the assistance of the Dr A Loesch, at The EM
Unit of The Royal Free and UCL Medical School. OK cells were grown on melinex
polyester film until a confluent monolayer had been formed (5-7 days). Cells were
then exposed to rotenone 10µM in a HEPES-buffered solution (see earlier –
‘Endocytosis assay’) for 1 hour at 37°C. At the end of the experiment the drug was
washed off and primary fixation was performed in 1% paraformaldehyde/1.5%
glutaraldehyde in phosphate buffered solution (PBS). Following a wash with PBS,
secondary fixation was performed using 1% osmium tetroxide/1.5% potassium
ferricyanide in PBS. The cells were then thoroughly washed with distilled water
followed by dehydration through graded ethanol (30%, 50%, 70%, 90% and 100%).
They were infiltrated with a 50:50 mixture of 100% ethanol/Epoxy resin and finally
an overnight infiltration was performed with 100% resin.
Pieces of the melinex were then flat embedded with the cells face up in the liquid
resin. These were then polymerised at 70ºC overnight. The melinex was then stripped
away from the cells leaving them embedded in the resin. The resin blocks were
trimmed down and a secondary embedding was carried out with the cells face up.
Using a Reichert Ultracut E ultramicrotome, semi-thin sections were cut with glass65
knives and stained with toluidine blue. Ultra-thin sections were cut with diamond
knife picked up on copper grids and stained with uranyl acetate and Reynold's lead
citrate. The grids were viewed with a Philips CM120 electron microscope and digital
images collected with an AMT digital camera.
2.1.7 Statistical analysis
The results are calculated as means ± SEM. One-way analysis of variance (ANOVA)
was used to investigate statistical differences among the study groups. Where
differences were found, individual groups were then compared with each other by an
unpaired t-test. A p value of <0.05 was taken as significant.
2.2 Multi-photon imaging of mitochondrial function in live kidney
slices
2.2.1 Formation of live kidney slices
In the second part of the laboratory study, live slices of rat kidney were used to
investigate differences in mitochondrial function amongst different segments of the
nephron. To make the slices, kidneys were used from adult male Sprague Dawley
rats. All procedures were carried out in accordance with the Animals (Scientific
Procedures) Act 1986. Animals (weighing 250-400g) were anesthetized using intra-
peritoneal pentobarbitone (50-100mg/kg). After adequate anaesthesia, the left kidney
was removed via a midline incision and immediately placed in ice-cold HEPES-
buffered solution containing (in mM): NaCl 118, NaHCO3 10, KCl 4.7, MgSO4 1.44,
KH2PO4 1.2, CaCl2 1.8, Hepes 10, glucose 5 and pyruvate 5. One pole of the kidney
was sectioned from the rest of the organ and mounted on a stage using glue, in ice
cold oxygenated HEPES-buffered solution (pH 7.4) containing glucose and sodium
pyruvate (both 5mM). Slices were then made at 200µm using a Micron 650V tissue
slicer. The slices were incubated at room temperature until usage, in a chamber
containing HEPES-buffered solution (pH 7.4), further supplemented with sodium
butyrate (5mM), and gassed with carbogen (95% CO2, 5%O2).66
2.2.2 Identification of tubule types
Different tubule types in kidney slices are easily distinguishable by their size and
morphology (see Figure 2.1 and Results). In order to confirm the identity of tubule
types, immunostaining was performed using antibodies that bind to known nephron
segments. PT cells were labelled with a mouse antibody to aquaporin-1 (AQP-1)
(Sabolic et al., 1992), whilst DT cells were labelled with a sheep antibody to Tamm
Horsfall protein (THP) (Bachmann et al., 1985).
The protocol for staining of PT with anti-AQP-1 antibodies was as follows. Rat
kidney slices (200µm) were fixed overnight at 4C in 4% paraformaldehyde. They
were then washed for 10 minutes in PBST (0.1M phosphate buffer solution and 0.1%
triton), and incubated for 30 minutes with PBST and 10% donkey serum. A mouse
antibody to AQP-1 was diluted 1/200 in PBST and incubated overnight with the
slice. This was then washed 3 times in PBS. A secondary donkey anti-mouse
antibody (conjugated to FITC) was diluted 1/200 in PBS and applied for 2 hours. The
specimen was subsequently washed 3 times with PBS and mounted with Citifluor
AF1 glycerol/phosphate buffered saline mountant (Citifluor Ltd, London, UK). The
same protocol was used for staining of DT with anti-THP antibodies; however,
bovine serum albumin (rather than donkey serum) was used as the blocking agent,
the primary antibody was used at 1/500 and incubated for 3 hours, and streptavidin
red was used instead of FITC to identify staining.
2.2.3 Dye loading and imaging
A perfusion system was devised that allowed both dyes and reagents to be applied to
the slice (Figure 2.2). Gravity was used to feed solutions containing dyes into the
specially designed slice chamber (Harvard Apparatus, Edenbridge, Kent, UK). A
peristaltic suction pump was used to provide the outflow from the chamber. This set-
up allowed rapid changes to take place between different solutions. Dyes were
perfused and recirculated for at least 20 minutes before imaging to allow adequate
loading. Various markers of mitochondrial function were imaged in real time, in
different tubule types, using a Zeiss LSM 510 upright multi-photon NLO (non-linear
optics) (Carl Zeiss Ltd, Welwyn Garden City, Hertfordshire, UK), coupled with a
Coherent Chameleon tunable laser (Coherent UK Ltd, Ely, UK). Experiments were676869
performed at room temperature, as at 37°C the slices were extremely sensitive to
small fluctuations in temperature, and responded by swelling or contracting. This
inevitably changed the focal plane (which is relatively narrow in multi-photon
imaging), and made imaging over a period of time extremely difficult.
For single measurements of resting Δψm, regions of a slice were randomly selected
using the bright field setting, and the fluorescence signal at the plane of maximal
overall intensity was then recorded. ROIs were drawn around individual tubules to
obtain the mean fluorescence intensity per tubule. For experiments involving HEt,
regions of interest were drawn around the cell nuclei, where the bulk of the signal
change was observed (as the dye binds to DNA). All values given are the mean
signal, per image pixel, within the relevant region of interest. In timed series
experiments images were taken in serial z-stacks in order to account for movement in
the z axis over time. These z-stacks were then reconstructed as 2-D images using the
Zeiss LSM software. Image analysis was performed using Zeiss LSM and Image J
(http://rsbweb.nih.gov/ij/) software.
For all probes used the optimal excitation wavelength was established by generating
two-photon excitation spectra. Calcein-AM was used at a concentration of 2µM
(with 0.002% pluronic) and was excited at 800nm. TMRM was used at a
concentration of 50nM; verapamil 10µM was used to inhibit dye export from the
cells by the multi-drug resistance transporter (MDR). TMRM was optimally excited
at 860nm. Rhodamine 123 was used at a concentration of 100nM and excited at
800nm. HEt was loaded at a concentration of 5µM, while MCB was used at a
concentration of 50µM; both were excited at 720nm. Mitochondrial NADH
fluorescence was excited at 720nm; FAD
2+ was excited at 458nm (single-photon
excitation, as I found that the signal was masked by other sources of green
autofluorescence when imaging with two-photon excitation). Emitted light was
collected with the following filters: band-pass 435-485nm (NADH and MCB), long-
pass 515nm (calcein), band-pass 500-550nm (FAD
2+) and band-pass 575-640nm
(TMRM, Rhodamine 123 and HEt).70
2.2.4 Chemical inhibition of the respiratory chain
In order to investigate differences between mitochondria in the PT and other nephron
segments, in response to a toxic stimulus, chemical inhibition of the RC was used as
a model of ischaemia. For control experiments the slices were perfused with HEPES-
buffered solution (containing glucose and pyruvate as substrates), and gassed with
carbogen (95% CO2, 5%O2), at a speed of ~5ml/min. To model ischaemia, the
substrates were replaced with choline chloride (to maintain osmolarity), gassed with
nitrogen or argon, and the pH was reduced to 6.9. Because the slices were imaged in
an open chamber (designed for an upright microscope), oxygen could potentially
diffuse into the solution from the surrounding air, resulting in ‘hypoxia’ rather than
‘anoxia’ (the in vivo situation). A RC inhibitor (CN 1mM) was therefore included to
model anoxia, as per a method used for similar work involving ischaemia in brain
slices (Karadottir et al., 2005). Oxygen was still kept as low as possible, by gassing
with nitrogen or argon, to minimise the likelihood of artefactual ROS production.
2.2.5 Statistical analysis
The results are calculated as means ± SEM. The significance of differences between
groups was examined using the unpaired t-test. A p value <0.05 was taken as
significant.
2.3 Clinical study
2.3.1 Study groups
To further characterise the clinical effects of MD on the human kidney, I have
screened two well defined populations of patients for evidence of PT dysfunction.
The first consisted of adult patients (>18 years old [the effects of MD on the kidney
in children have been studied previously (Martin-Hernandez et al., 2005)]), with
known genetic or biochemical mitochondrial disease, who attend the clinics of Prof
MG Hanna, Dr S Rahman and Prof N Wood at The National Hospital for Neurology.
The majority have undergone detailed mtDNA screening with identification of
mutations, and some have also undergone RC function tests on muscle tissue.71
The second group consisted of HIV patients attending The Mortimer Market Centre,
Camden PCT, who may or may not be taking ART, some forms of which are thought
to be toxic to mitochondria. HIV itself is thought to be toxic to the renal tubule
(Conaldi et al., 1998); hence, I recruited treatment naïve patients, as well as those
taking ART. Those on ART were sub-divided into two groups, depending on
whether or not they had ever been exposed to TDF; in order to address the question
(given the recent concerns in the literature) about whether TDF is more toxic to the
PT than other forms of ART.
Data on demographics, drug and medical history and routine laboratory tests were
collected from review of clinic notes and clinic databases. The Modification of Diet
in Renal Disease (MDRD) method (4-variable, IDMS-traceable) was used to
calculate eGFR (Levey et al., 1999).
2.3.2 Exclusion criteria
Pre-existing renal disease, which was defined as a serum creatinine >130µmol/l
and/or dipstick positive proteinuria, was the main exclusion criteria. Clearly, in the
modern era of routine eGFR reporting by laboratories, a patient with a serum
creatinine <130µmol/l does not necessarily have a normal eGFR. However, in non-
renal clinics, this is the sort of arbitrary cut-off below which non-renal physicians
would probably be fairly reassured about renal function, and would be unlikely to
investigate further. Due to the relative rarity of mitochondrial cytopathy, no further
exclusion criteria were applied to these patients.
In the HIV study, patients who were co-infected with viral Hepatitis B or C, or had
diabetes, were excluded, due to their potentially confounding effects on renal
function. Furthermore, patients with any previous history of significant renal disease
(even if it had since resolved) were also excluded. Patients in both treatment groups
were stable on their current ART regimen for more than 6 months, and had an HIV
RNA level <50 copies/ml for at least 3 months prior to study entry (although not
necessarily <50 copies/ml at the actual time of recruitment).72
2.3.3 Ethical approval
The study was approved by the National Hospital for Neurology and Neurosurgery
Regional Ethics Committee. It was also formally approved by the Research and
Development Departments of University College London Hospitals NHS Trust and
North Central London Research Network. Patients were recruited by physicians
working in the relevant clinics. All patients provided written informed consent.
Copies of the patient information sheets and consent forms are included in the
appendix.
2.3.4 Sample processing
Urine samples were collected and frozen at -80°C within 4 hours. They were then
analysed by Dr M Lapsley (Chemical Pathology, St Helier Hospital) for RBP, NAG
and albumin. UP/C was measured by The Clinical Biochemistry Service at Univeristy
College London Hospitals NHS Trust.
Urinary RBP was measured using a sandwich micro-titre plate enzyme
immunoassay, with polyclonal antibodies from Dako Ltd (Denmark); the second
antibody was labelled with horseradish peroxidase. Reference ranges for the normal
adult population have been established previously (Lapsley et al., 1998). Urinary
NAG was measured with a kit from PPR Diagnostics Ltd (London, UK), using a
microtitre plate format direct assay of enzyme activity, and using 2-methoxy-4-(2-
nitrovinyl) phenyl- glucosaminide as substrate; the reference range used was that
given by the manufacturers. For the purposes of the study, the upper limits of normal
for URBP/C and UNAG/C were defined as 2 standard deviations above the mean value in
the reference populations (URBP/C < 18µg/mmol and UNAG/C < 28µmol/hour/mmol).
Urinary albumin was measured on a Siemens Advia 2400 Chemistry System
(Siemens Healthcare, Camberley, UK) by an immuno-turbidimetric (antibody
reaction) method, using reagents from Olympus Ltd (Watford, UK). Urinary
creatinine was also measured on a Siemens Advia 2400 using a modified Jaffe
reaction. Urinary protein was measured using a Roche Integra 800 analyzer (Roche
Diagnostics UK, Burgess Hill, UK).73
To investigate the effectiveness or either UP/C or UA/C as screening tools for detecting
renal tubular disorders, the proportions of patients in each study group with abnormal
values of UP/C and UA/C were compared to the proportions with evidence of tubular
disease (defined as elevated URBP/C and/or UNAG/C).
2.3.5 Statistical analysis
One-way analysis of variance (ANOVA - for parametric data) or the Kruskal-Wallis
test (for non-parametric data) was used to investigate statistical differences among
the study groups. Where differences were found, individual groups were then
compared with each other by an unpaired t-test (for parametric data) or an unpaired
Mann-Whitney test (for non-parametric data). The relationship between variables
was explored using the Spearman correlation coefficient (rs). A p value of < 0.05
was taken as significant. Agreement between different urinary tests in defining
abnormal proteinuria was measured by Kappa (κ) test (0, no agreement to 1, perfect 
agreement).74
Chapter 3 – Results: The effect of mitochondrial respiratory
chain inhibition on endocytosis of albumin and dextran in
OK cells
3.1 FITC-albumin uptake is greatest at the apical membrane in OK
cells and is partly megalin-mediated
OK cells form a confluent monolayer when grown in normal culture conditions; they
endocytose FITC-albumin (FA) when incubated at 37°C, which can be measured as a
progressive increase in fluorescence signal over 1 hour (Figure 3.1A). This
endocytosis is, at least in part, mediated via the megalin receptor, as it is inhibited by
receptor associated protein (RAP), an inhibitor of megalin mediated endocytosis in
OK cells (Zhai et al., 2000) (Figure 3.1B).
To assess the polarity of FA uptake, OK cells were grown on Transwell inserts until
confluent. Significantly greater uptake of FA was observed after 1 hour when FA
was applied to the apical membrane than when applied to the baso-lateral membrane
(Figure 3.2). This is consistent with the situation in the PT in vivo, where LMWP
endocytosis is thought to occur mainly at the apical membrane. From here on,
endocytosis experiments were performed with OK cells grown as monolayers on
coverslips, where the cell membrane exposed to ligands is predominantly apical.757677
3.2 Respiratory chain inhibition causes minimal cell death in OK
cells
To ensure that exposure of OK cells to inhibitors of the mitochondrial RC does not
result in rapid necrotic cell death, within the time period of the endocytosis assay, a
standard hoechst/propidium iodide assay was performed. After 2 hours (twice the
length of the endocytosis assay period), the proportion of dead cells observed
(compared to control [0.17% ± 0.17 per x40 objective field, n=5]) was not
significantly increased following incubation with rotenone 10µM (2.39% ± 0.73,
n=5, p>0.9), CN 1mM (0.20% ± 0.20, n=5, p>0.9) or 2-DG (1.62% ± 0.50, n=5,
p>0.9) (Figure 3.3A). A much higher rate of cell death was observed with IAA 1mM
(in the presence of pyruvate) (38.75% ± 3.72, n=5), which was significantly different
from all other groups (p<0.001). As IAA is an inhibitor of glycolysis, this result
could imply a relatively greater dependence on this metabolic pathway for survival in
these cells (although 2-DG did not have the same effect).
3.3 Blockade of glycolysis has a much greater effect on FITC-
albumin uptake than respiratory chain inhibition in OK cells.
The control fluorescence signal emitted by OK cells per x40 objective field (assigned
the value of 100%), after incubation for 1 hour at 37°C with FA, was reduced by a
small amount by incubation with the RC inhibitors rotenone 10µM (92.8% of control
signal ± 2.4, n=20), piericidin 10µM (89.5% ± 2.0, n=20) or CN 1 mM (93.7% ± 1.8,
n=20) (Figure 3.3B); although only the results obtained with piericidin achieved
statistical significance (p<0.05). This shows that inhibition of the RC in OK cells has
only a small effect on receptor-mediated endocytosis at the apical membrane.
However, incubation with 2-DG produced a much larger decrease in fluorescence
signal (51.6% of control signal ± 1.7, n=15, p<0.001); implying that blockade of
glycolysis has a greater inhibitory effect on endocytosis than RC inhibition in this
model.7879
3.4 Rotenone causes an altered pattern of FITC-albumin and FITC-
dextran uptake in OK cells
When imaging the uptake of FA in OK cells, it was noted that although there was
relatively little difference between the various RC inhibitors in the effect on total
uptake, there was a marked difference in the pattern of uptake that was unique to
rotenone. Neither piericidin nor CN appeared to change the control pattern of FA
uptake (Figure 3.4A,C-E); however, a striking difference was observed in the
presence of rotenone (Figure 3.4B and F). Instead of the normal predominance of
uptake at the apical brush border, the rotenone treated cells appeared flatter and
uptake was more lateral in the cells.
The uptake of FA in OK cells is thought to be predominantly via receptor-mediated
endocytosis; an efficient and relatively specific uptake system. However, cells are
thought to be able to import substances from their surrounding environment via fluid
phase endocytosis (pinocytosis), which occurs due to constant invagination and
pinching off of normal cell membranes. This is a much less efficient uptake system,
nevertheless it may play a role in the reabsorption of solutes in the PT. Dextran
molecules are known to be taken up by the PT in vivo (Molitoris & Sandoval, 2005),
and by OK cells in vitro via fluid phase endocytosis (Gekle et al., 1995).
I therefore investigated the effect of rotenone on fluid phase endocytosis in OK cells.
The control pattern of uptake of FD was similar to that of FA, with the majority of
FD appearing in the vicinity of the apical brush border (Figure 3.4G). Rotenone
10µM also markedly affected the pattern of uptake of FD, in a manner analogous to
its effects on FA uptake (Figure 3.4H). This suggests that the striking effects of
rotenone on FA uptake are more likely to be due widespread structural changes
within the cell, affecting generalized uptake machinery, rather than a specific
targeted effect on megalin/cubulin receptor-mediated endocytosis (see below –
‘Extra-mitochondrial effects of rotenone’).
The effects of rotenone on the pattern of FA uptake were unlikely to be due to an
impairment of substrate utilization at complex I, as piericidin did not have the same8081
effect. Accordingly, bypassing the inhibition of electron flow at complex I with the
addition of the complex II substrate methyl-succinate 5mM (which should restore
normal RC function and ATP production) did not affect the uptake pattern observed
with rotenone (Figure 3.5A).
I postulated that the effects of rotenone may have been due to excess ROS
production (see below – ‘Rotenone increases ROS production in OK cells’), as
rotenone causes inhibition of the RC at complex I, a potential site of ROS generation
in mitochondria. However, the anti-oxidant MnTBAP 50µM had no effect on the
pattern of FA uptake seen with rotenone, either alone (Figure 3.5B), or even in
combination with a cocktail of other anti-oxidant agents (catalase 250U/ml [a
catalyst for the decomposition of hydrogen peroxide], Trolox 750µM [an anti-
oxidant derivative of vitamin E] and ascorbate 1mM [vitamin C – another anti-
oxidant]) (Figure 3.5C).
3.5 Respiratory chain inhibition has relatively little effect on
cytosolic ATP levels in OK cells
Receptor mediated endocytosis is an active process, thought to be dependent on ATP
(Podbilewicz & Mellman, 1990). To measure the effect of RC inhibition on cytosolic
ATP levels, OK cells were loaded with the ATP-sensitive dye Mg green and excited
at 488nm. Mg green fluorescence signal changes inversely in response to changes in
cytosolic ATP levels. Cells were simultaneously loaded with TMRM 50nM, a
marker of mitochondrial membrane potential (Δψm), which was excited at 543nm.
Regions of interest (ROI) were drawn around nuclei in order to obtain a cytosolic
signal for the benefit of analysis.
Inhibition of the RC with rotenone 10µM caused no increase in the Mg green signal,
suggesting a minimal effect on the cytosolic ATP level (Figure 3.6). However,
rotenone did cause an increase in the cytosolic TMRM signal, consistent with
depolarization of Δψm and redistribution of the dye from the mitochondria into the
cytosol. This change provided a positive control and implied that the drug was
‘working’ as expected (i.e. inhibiting RC activity). In response to subsequent8283
inhibition of glycolysis with IAA (1mM), Mg green signal increased, consistent with
a fall in cytoplasmic ATP concentration. IAA also caused a further rise in the TMRM
signal, consistent with further depolarization of Δψm, which is dependent on reverse
activity of the F1F0-ATPase and ATP breakdown for maintenance of potential when
the RC is blocked.
The effect of RC inhibition on cytosolic ATP levels was further investigated using a
luciferin-luciferase assay and a custom built luminometer. Addition of luciferin to
OK cells, transfected with cytosolic luciferase, produced a large rise in
luminescence, reflecting high transfection efficiency. Addition of rotenone 10µM
caused only a small drop in luminescence signal (normalized luminescence value
0.735 ± 0.009 [where 1 = maximal signal post luciferin and 0 = zero counts]). A
much greater decrease was observed in response to the addition of IAA 1mM
(normalized luminescence value 0.185 ± 0.003, n=11 experiments, p<0.01); a
representative luminescence trace from one of these experiments is shown along with
the normalized pooled values (Figure 3.7).
Overall, these results suggest that the OK cells, like many immortalized cultured
cells, are predominantly dependent on anaerobic glycolysis for ATP production, and
RC inhibition has at most only a minimal effect on cytoplasmic ATP levels. This
could potentially explain the relatively small effect of RC inhibition on FA uptake in
my in vitro assay.
3.6 Rotenone increases ROS production in OK cells
Mitochondria have other important roles besides ATP production and are a major
source of ROS, which have wide-ranging physiological and patho-physiological
effects. I therefore investigated the effects of RC inhibition on mitochondrial ROS
production in OK cells by loading them with the ROS-sensitive dye mitosox, which
localizes to mitochondria and was excited at 543nm. For the purposes of analysis,
ROIs were drawn around mitochondrial-rich regions of each cell, which were
identified randomly using the mitochondrial NADH signal emitted when excited at
364nm. The fluorescence signal from cells loaded with mitosox increased848586
progressively with time, and the rate of increase was taken to be proportional to the
rate of ROS production.
Rotenone 10µM caused a significant increase in the rate of change of mitosox signal
(rate post-rotenone 282% ± 21 of the control rate, n=163 cells, p<0.001), but this
increase was obliterated in the presence of the anti-oxidant MnTBAP 50µM (rate
post rotenone and MnTBAP 103% ± 16 of the control rate, n=225 cells) (Figure 3.8).
This implies that MnTBAP is capable of nullifying the increase in ROS production
normally seen in response to rotenone, suggesting that a rise ROS was not likely to
be responsible for the profound structural effects of rotenone on the OK cells, as
these were not prevented by MnTBAP at the same dose.
The rate of change of mitosox signal was not significantly increased by piericidin
(99% ± 4 of the control rate, n=218 cells, p>0.9), another RC complex I inhibitor,
suggesting that the increase in ROS production observed with rotenone is specific to
that drug, rather than inhibition of complex I per se. The rate of change of mitosox
signal was significantly decreased by CN (57% ± 5 of control rate, n=140 cells,
p<0.001), showing that blockade of the RC at complex IV reduces the rate of ROS
production in OK cells.
3.7 Extra-mitochondrial effects of rotenone
Given that MnTBAP did not prevent the effects of rotenone on the pattern of FA
endocytosis (in spite of the fact that it clearly prevented the rise in ROS production
associated with rotenone), and that the RC inhibitors piericidin and CN did not
produce the same pattern, it was considered that the effect of rotenone on
endocytosis could have been extra-mitochondrial.
There is some literature suggesting that rotenone can depolymerise microtubules
(Brinkley et al., 1974; Marshall & Himes, 1978; Ren & Feng, 2007), in addition to
its effects on the RC, and an intact cytoskeleton is required for albumin endocytosis
in OK cells (Gekle et al., 1997). Colchicine is an established inhibitor of microtubule8788
polymerisation, and a pattern of FA uptake similar to that seen with rotenone was
observed in response to colchicine 10μM (Figure 3.5D). Furthermore, co-incubation
with Taxol (a microtubule stabilizing agent) and rotenone produced a pattern of FA
uptake similar to control (Figure 3.5E). These results suggest that the effects of
rotenone on the pattern of FA uptake in OK cells were due to inhibition of
microtubule polymerization.
The structural effects of rotenone on OK cells were further investigated using EM.
Control images demonstrated that OK cells form a confluent polarized monolayer in
culture with an apical brush border (Figure 3.9A-C). Addition of rotenone 10µM
caused widespread structural damage, including the loss of the brush border, and the
appearance of numerous large vacuoles and abnormally shaped swollen mitochondria
(Figure 3.9D-F).
3.8 Discussion
3.8.1 The relationship between cytosolic ATP and albumin endocytosis
Inhibition of the mitochondrial RC in vitro in OK cells produced only a small effect
on the uptake of FA, which was surprising given the apparent vulnerability of the PT
to MD in vivo. In patients with mitochondrial cytopathy, RC function may be
impaired (though not necessarily), but complete cessation of RC activity within cells
is unlikely. It was therefore also surprising that OK cells showed very little necrosis
after 2 hours of complete RC blockade, given that they are derived from the PT,
which has very little anaerobic ATP-generating capacity in vivo, and is the prominent
site of necrosis following experimental ischaemia-reperfusion injury (Shanley et al.,
1986c). However, in contrast to the native PT, I have demonstrated that OK cells do
indeed have significant capacity to generate ATP anaerobically, which probably
explains their resistance to RC blockade. This may well also explain why only a
small decrease in FA endocytosis was observed following RC inhibition; the
magnitude of decrease of endocytosis was of the same order as the reduction in
cytosolic [ATP] after RC inhibition. This is suggestive (though not conclusive) that
ATP may play an important role in endocytosis, as found in other studies (see later –
‘General discussion - The relationship between mitochondrial function and8990
endocytosis in the proximal tubule’). In support of this hypothesis, blockade of
glycolysis with 2-DG produced a much larger decrease in both cytosolic [ATP] and
FA uptake. IAA is another established inhibitor of glycolysis; however, this agent
proved to be highly toxic to the cells, leading to rapid necrosis, and therefore could
not be used in conjunction with the 1 hour FA uptake assay. Greater vulnerability to
IAA, compared to RC inhibition, again suggests that OK cells are predominantly
dependent on anaerobic metabolism. However, it is unclear why 2-DG, another
glycolytic inhibitor, was not as toxic as IAA; presumably the differences are due to
the fact that the two agents target different steps in the glycolytic pathway, but this
was not explored further in this project. Immortalised cells in culture tend to become
increasingly anaerobic with time (Gstraunthaler et al., 1999), due to The Warburg
effect (Kim & Dang, 2006). This weakens their value as a model system to study
metabolic phenomena in the PT, which has to be balanced against their many
advantages.
3.8.2 Rotenone is highly toxic to OK cells
Rotenone had marked structural effects on the OK cells, with widespread cellular
damage observed on EM, leading to an altered pattern of both FA and FD uptake.
This means that rotenone had an effect on both receptor mediated and fluid phase
endocytosis.
Exposure of rats to rotenone produces a phenotype similar to Parkinson’s disease,
with a characteristic loss of nigrostriatal dopaminergic neurons in the brain (Betarbet
et al., 2000); this has led to an epidemiological link between Parkinson’s disease in
humans and exposure to pesticides containing rotenone (Gorell et al., 1998).
Evidence has suggested that the toxicity of rotenone to neurons is mediated more via
oxidative stress, rather than a drop in cytosolic ATP (Sherer et al., 2003). The
mechanism of the toxic effect of rotenone on OK cells in my study was unlikely to
involve inhibition of complex I in the RC alone, as the effects were not mimicked by
piericidin (another complex I inhibitor). Furthermore, although rotenone did cause a
rise in ROS production (that was not observed with other RC inhibitors), this rise
was obliterated by MnTBAP, which had no protective effect on the pattern of FA
uptake.91
Another established (although generally less well known) effect of rotenone, other
than RC complex I inhibition, is toxicity to microtubules (Marshall & Himes, 1978).
The similarity between the effects of rotenone and colchicine on FA uptake in OK
cells suggests that the toxicity of the former may have been mediated via inhibition
of microtubule proliferation; this was further supported by the protective effects of
the microtubule stabilizing agent Taxol.
Inhibition of microtubule polymerization has been reported previously to reduce
albumin uptake by OK cells (Gekle et al., 1997). Microtubules are an important part
of the cell cytoskeleton, and in addition to their structural role, they are also involved
in key physiological processes, such as mitosis and transport of vesicles (via ATP
dependent motor proteins such as kinesin and dynein). This latter role is thought to
be important in trafficking ion transporters to the correct membrane in polarized
cells, such as those of the renal epithelium (Hamm-Alvarez & Sheetz, 1998). Indeed,
abnormal localization of megalin has been observed in the PT in rats exposed to the
microtubule polymerization inhibitor colchicine (Gutmann et al., 1989). Infusion of
colchicine into rats in another study led to the observation of significant structural
abnormalities in the PT on EM, which are likely to have inhibitory effects on normal
endocytosis (Elkjaer et al., 1995). Amongst the abnormalities reported were an
increase in the size and number of intracellular endocytotic vesicles, which mirrors
my findings in OK cells exposed to rotenone. The vesicles were reported to be in a
more baso-lateral location than under control conditions and, conversely,
mitochondria were found in sub-apical cytoplasm, rather than their usual baso-lateral
distribution; findings that together highlight the importance of microtubules in
determining normal cell polarity. Interestingly, structural abnormalities were not
reported in mitochondria following colchicine exposure, perhaps suggesting that the
abnormal appearance of mitochondria in OK cells exposed to rotenone in my study
may have been related more to effects on the RC, rather than on microtubules.
Immuno-fluorescence staining for AQP1 in rat kidney revealed that the normal apical
membrane localization of this channel was altered by colchicine exposure, leading to
a diffuse signal seen throughout the cytoplasm (Elkjaer et al., 1995); resulting in
images that were analogous to those of OK cells exposed to FA and rotenone in my
study.92
The toxic effect of rotenone on microtubule polymerisation is severe enough to arrest
mitosis in cultured cells and is thought to be mediated via binding to tubulin in a
manner analogous to colchicine (Brinkley et al., 1974). Indeed, some have argued
that it is actually the effect of rotenone on microtubules that explains its apparent
selective toxicity to dopaminergic neurons (Ren & Feng, 2007). A wide variety of
heavy metals have been implicated as environmental causes of renal tubular
dysfunction (Wedeen & DeBroe, 2005); however, unlike PD, no epidemiological
connection has been made to date between rotenone exposure and kidney disease in
humans (although colchicine is used extensively in clinical practice for treating
crystal arthropathies). Although my findings regarding the toxic effects of rotenone
may, therefore, not relate directly to human disease, from an experimental viewpoint
they raise an important issue related to the extra-mitochondrial effects of rotenone, as
it is a commonly used reagent in studies investigating the effects of mitochondrial
RC inhibition. They also reinforce the importance of microtubules in the function of
polarised transporting epithelia, such as the PT.
3.8.3 The effect of mitochondrial respiratory chain inhibition on ROS production
In order to investigate other possible mediators of the effects of RC inhibition on
endocytosis (aside from changes in ATP levels), I measured the effects of RC
inhibitors on mitochondrial ROS production in OK cells, by using the ROS-sensitive
dye mitosox, which localizes to mitochondria. I found that inhibiting the RC with
piericidin did not lead to a significant increase in ROS production, whilst CN
actually decreased the rate.
A previous investigation of the effects of CN on ROS production in another renal
cell line (LLC-MK2) reported an increase in ROS production and oxidative stress in
response to CN (Hariharakrishnan et al., 2009). However, the incubation period for
that study was much longer (4 hours), the dye used to measure ROS (DCF) does not
specifically measure mitochondrial ROS production and CN causes other potentially
confounding effects (such as inhibition of the anti-oxidant enzyme SOD (Loven et
al., 1982)). The authors reported that LLC-MK2 cells were one of a number of renal-
derived cell lines tested (they did not state which ones), and were found to be93
particularly sensitive to the toxic effects of CN. Interestingly, they also found a large
drop in cytosolic ATP levels in response to CN in these cells, implying a much
greater dependence on aerobic metabolism compared with OK cells, perhaps
explaining why the LLC-MK2 cells are so sensitive to CN. From a metabolic
viewpoint, LLC-MK2 cells may, therefore, provide a more realistic model of PT
cells in vivo; however, they lack the capacity for avid endocytosis of protein
observed in OK cells.
Rotenone is thought to cause an increase in ROS production at complex I via
inhibition of electron flow at the ubiquinone binding site, leading to an increased
NADH/NAD
+ ratio at the ‘upstream’ flavin binding site of complex I, which favours
increased O2
- formation (Hirst et al., 2008). In contrast, rotenone tends to block the
increase in ROS production observed during ‘reverse electron flow’ (e.g. during
excess utilization of succinate as a substrate by complex II), by preventing electrons
from reaching the flavin binding site (Hirst et al., 2008). Given the fact that rotenone
increased ROS production in the OK cells, it is therefore likely that electron flow is
in the ‘forward direction’ in these cells under resting conditions. Differences between
rotenone and piericidin in ROS generation at RC complex I have been reported
before (Ohnishi et al., 2005). Although both are thought to share a common binding
domain with overlapping sites (Okun et al., 1999), differences in the effects of the
two reagents may be due to different conformational changes induced in the complex
by binding of either reagent (Ino et al., 2003). However, much still remains to be
elucidated about the behaviour of complex I and the mechanisms of ROS generation
at this site, particularly in different tissue types.94
Chapter 4 – Results: Multi-photon imaging of
mitochondrial function in live slices of rat kidney
4.1 Viability and orientation
Tissue was used for up to 6 hours following removal of the kidney. Various
structures could be imaged by slicing at different levels (including cortical structures
such as glomeruli and proximal and distal tubules, and medullary structures such as
capillaries and the loops of Henle), and cell viability was confirmed by uptake and
retention of the dye calcein-AM (Figure 4.1A-C). This dye enters cells and is cleaved
to the fluorescent form by intracellular esterases, which are only active in live cells.
Hence, it is a widely used and reliable marker of cell viability (Bratosin et al., 2005).
Structures were identified by their characteristic morphology, location, and green
auto-fluorescence emission pattern at 800nm excitation (Figure 4.1D). PT cells
emitted considerably greater autofluorescence in the green range than DT cells. The
source(s) of this signal are unknown, although are likely to include oxidized
flavoproteins (see below – ‘Autofluorescence measurements reveal that mitochondria
in the proximal tubule are in a more oxidised state’). Autofluorescence in the green
range appeared to vary in different sections of the PT, which may represent
differences between different anatomical sections (S1, S2 and S3); however, this was
not explored further in this project, partly due to a lack of specific markers for these
segments.
Identification of tubules was confirmed in preliminary experiments by using fixed
slices stained with specific antibodies (Figure 4.1E-F). PT cells were labelled using
an antibody to aquaporin-1 (Sabolic et al., 1992). As depicted, PT cells occupied the
bulk of the volume of both the renal cortex and medullary rays. DT cells (thick
ascending limb of the loop of Henle) were labelled with an antibody to Tamm
Horsfall protein (Bachmann et al., 1985). The red fluorescent signal from the DT
antibodies can be contrasted with the green autofluorescence from the PT, which
demonstrates the clear difference in size and morphology between the two tubule
types (PT being much larger). Control specimens showed little or no signal. Given
that identification of tubule types based on morphology was straightforward (at least9596
PT versus DT, I was not able to resolve sub-sections on the PT), routine antibody
staining to confirm identity was not performed in further experiments (this would
also have required fixation of the live tissue).
4.2 Mitochondrial membrane potential is higher in distal tubules
Δψm lies at the heart of mitochondrial function, determining rates of ATP synthesis,
ROS production, Ca
2+ accumulation and protein import. The cationic lipophilic
indicator TMRM was used to explore the distribution of Δψm in the tubules. The dye
clearly concentrated in mitochondria, as expected, showing the characteristic
distribution described in the literature, with mitochondria aligned in rows at the baso-
lateral poles of the cells (Kaissling & Kriz, 1979) (Figure 4.2A). The signal intensity
at any given pixel is a function of dye concentration, which in turn is a function of
potential. The mitochondrial signal was isolated by applying threshold settings to
remove the background cytoplasmic signal, so that values of pixels outside the
mitochondria were excluded from measurements. The mean signal intensity in the
remaining pixels within mitochondria was therefore independent of mitochondrial
density in any given tubule. This is important as cell size and mitochondrial density
vary along the length of the nephron.
The signal was clearly heterogeneous across the slice and was considerably higher in
cells of the DT, giving a mean fluorescence intensity per x40 objective field of 1038
± 80 A.U., compared with a mean in convoluted PT of 566 ± 23 A.U. (p<0.001),
which in turn was significantly higher than straight PT, where the mean was 385 ± 3
A.U. (p<0.001; data are from 3 fields per slice, randomly selected using the bright
field setting, from a total of 3 slices) (Figure 4.2B-C and E) and with all microscope
settings kept constant. These observations suggest that mitochondria in the DT are
more polarized compared with the PT. A similar pattern of signal was also observed
using rhodamine 123 (Figure 4.2D), another cationic dye that functions in the same
way as TMRM, showing that this difference was not specific for TMRM.
It has been shown previously that PT cells in isolated tubules are vulnerable to
hypoxia, after which Δψm can be partially maintained by reversal of the F1Fo-ATPase9798
(Feldkamp et al., 2005a). Another possibility is that the lower potential reflects an
increase in ATP turnover in PT compared with DT, in which case oligomycin may
increase the potential in the PT more than in the DT. However, oligomycin (an
inhibitor of ATPase and ATP synthase activity) addition (5μg/ml) had no significant
effect on potential after 30 minutes and did not alter the differences in Δψm between
PT and DT (Figure 4.2E).
4.3 TMRM signal remains higher in the distal tubule in the presence
of efflux pump inhibitors
Both rhodamine 123 and TMRM are substrates for the MDR (Neyfakh, 1988).
Extrusion of the dyes from the cells via the MDR could therefore provide an
alternative explanation for differences in TMRM signal between tubule types.
Verapamil, an inhibitor of MDR, enhanced loading of TMRM in both the PT and
DT, with the fluorescence intensity rising in the PT from a mean value per x40
objective field of 357 ± 11 A.U. before verapamil, to 522 ± 65 A.U. after verapamil
(p<0.03); in the DT, rising from a mean of 613 ± 46 A.U. to 1054 ± 165 A.U. after
verapamil (p<0.03; in each case 3 randomly selected fields were imaged per slice,
from a total of 3 slices). However, verapamil did not affect the clear signal
differences between the PT and DT (Figure 4.3A). Cimetidine, an inhibitor of renal
organic cation transporters (Wright, 2005), did not have any significant effect on
TMRM loading (Figure 4.3B). Taken together, these results provide more evidence
to support the notion that differences in TMRM signal between tubule types
represent genuine differences in Δψm, rather than artefact.
4.4 Mitochondrial membrane potential is better maintained in the
distal tubule during anoxia
The PT is particularly vulnerable to ischaemia in vivo. By using an on-stage
perfusion system, the effects of chemical anoxia (a model of in vivo ischemia) on
mitochondrial function in renal tubules were imaged in real-time. Chemical anoxia
was induced using a buffer (gassed with nitrogen rather than oxygen) containing99100
sodium cyanide (CN) 1mM, which competes for oxygen at complex IV of the RC.
Δψm in PT mitochondria fell rapidly in response to inhibition of respiration (Figure
4.4A). However, in cells of the DT, Δψm fell very slowly and was then maintained at
a plateau for long periods. Even after 1 hour of chemical anoxia DT mitochondria
still maintained a significant potential, as shown by a further response to the
uncoupling  agent  FCCP  (which  causes  complete  depolarization  of  Δψm) (Figure
4.4B). Values were normalised from 1 (the starting fluorescence signal) to 0 (the
fluorescence signal post FCCP, taken as complete depolarization of Δψm, i.e. 0mV),
in order to make meaningful comparisons between PT and DT, as they have different
resting TMRM signal intensities.
These differences between PT and DT were abolished by inhibition of the ATPase
with oligomycin (5µg/ml), after which Δψm fell rapidly and completely depolarized
in DT cells in response to chemical anoxia. This suggests that the ATPase in
mitochondria of DT cells has a much greater capacity to pump protons - maintaining
the membrane potential when the RC is compromised - compared with PT
mitochondria.
4.5 ROS production is increased to a greater extent in proximal
tubules by complex I inhibition
Mitochondria are a major source of intracellular ROS, which may play an important
role in renal pathology. I measured rates of ROS generation in tubules using HEt,
which becomes fluorescent on oxidization by O2
-. Hence, in cells producing ROS,
HEt fluorescence signal increases with time and the rate of increase is proportional to
the rate of ROS production. Since the ROS-dependent oxidized product of HEt binds
to DNA, most of the signal change observed occurs in the nucleus; therefore, I
measured the mean rate of fluorescence intensity change in the nuclei of renal tubular
cells. Thus, the data acquired reflect the total rate of ROS production per cell and are
not normalized to intracellular mitochondrial mass (see later discussion – ‘Reactive
oxygen species production in renal tubules’). Unfortunately, I was not able to
achieve adequate loading with the dye mitosox in the slice model, so could not
directly measure mitochondrial ROS production.101102
Under resting conditions the basal rate of HEt oxidation was higher in the PT cells
(mean fluorescence intensity increase hour
-1 +70.9% ± 4.6; n=44 cells from 4
separate slices) than in the DT cells (mean increase hour
-1 +34.3% ± 4.3; n=35 cells
from 4 separate slices, p<0.01) (Figure 4.5A).
Within mitochondria, complexes I and III of the RC are thought to be the main
sources of ROS. Exposure to 10µM rotenone (an inhibitor of complex I of the RC)
increased the rate of signal change in both tubule segments (Figure 4.5A and C), and
the relative increase in the rate in the PT (mean rate post rotenone 501% ± 64 of the
control rate) was greater than that in the DT cells (mean rate post rotenone 162% ±
45 of the control rate, p<0.001); consistent with a much bigger relative increase in
ROS production in response to rotenone in the PT than in the DT. This observation
could be explained by differences in either the amount or resting redox state of
complex I in the two tubule segments (see below – ‘Autofluorescence measurements
reveal mitochondria in the proximal tubule are in a more oxidised state’).
In an attempt to isolate the mitochondrial contribution to ROS production in the
tubules, I repeated the experiments in the presence of apocynin 500µM (an inhibitor
of NADPH oxidase, another major source of intracellular O2
-). The HEt fluorescence
signal was greatly reduced in the presence of apocynin (implying significant NADPH
oxidase activity at rest) and the microscope settings had to be adjusted to bring the
signal back within the working range. In the presence of apocynin there was no
longer any significant difference in the rate of signal change between PT cells (mean
fluorescence intensity increase hour
-1 42.2% ± 3.8; n=35 cells from 3 separate slices)
and DT cells (mean increase hour
-1 51.3% ± 3.6; n=31 cells from 3 separate slices,
p=0.14). However, in response to rotenone there was again a significantly greater
increase in the rate of signal change in the PT (mean rate post rotenone 703% ± 68 of
control rate) than in the DT (mean rate post rotenone 269% ± 74, p<0.001) (Figure
4.5B); consistent with a bigger relative rise in the rate of ROS production in the PT
in response to rotenone.103104
4.6 Glutathione levels are higher in the proximal tubule than distal
tubule
Steady state ROS production depends on a balance of ROS metabolism and
catabolism. GSH is a major intracellular anti-oxidant able to reduce ROS. MCB
forms a fluorescent adduct with GSH in a reaction catalyzed by GST, allowing
measurement of GSH cellular content. A steady state fluorescence signal was
reached by 50 minutes and the signal was significantly greater in the PT (mean
fluorescence intensity increase per tubule after 60 minutes +48.8% ± 2.5, n=40
tubules from 4 separate slices) than in the DT (mean increase per tubule +17.0% ±
3.6, n=26 tubules from 4 separate slices, p<0.001) (Figure 4.6). These findings are
consistent with a higher level of GSH in the PT than DT.
4.7 Autofluorescence measurements reveal that mitochondria in the
proximal tubule are in a more oxidized state
Changes in Δψm and ROS production may reflect differences in oxygen consumption
that might in turn reflect changes in the redox state of NADH and FADH2, which are
the substrates for complexes I and II of the RC, respectively. At 720nm excitation,
the autofluorescence signal emitted between 435-485nm (blue) arose predominantly
from mitochondrial NADH, while at 458nm excitation the signal emitted between
500-550nm (green) arose partly from FAD
2+. These interpretations were supported
by the typical pattern of the signal, consisting of striations of signal at the basal pole
of the cell, matching the known distribution of mitochondria in the tubule and the
signal seen with TMRM; further confirmation was provided by the characteristic
changes in signal observed in response to either RC inhibition or uncoupling (Figure
4.7A-F).
The resting NADH and FAD
2+ fluorescence signals were calibrated in relation to the
full available dynamic ranges, which were defined by inducing a maximally reduced
state with a RC inhibitor (CN), and a maximally oxidized state with a RC uncoupler
(FCCP). This allowed me to ‘calibrate’ the resting signal as a redox index. I105106107
generated single z-stack images at: (i) time zero; (ii) post 10 minutes of perfusion
with CN
- 1mM, and following a 10-minute washout period; (iii) post 10 minutes of
perfusion with FCCP 1μM.
Using this method, I found the resting mitochondrial NADH pool to be in a more
oxidized state in PT (mean value [f0-fFCCP]/[fCN-fFCCP] 0.57 ± 0.03; n=38 tubules from
5 separate slices) than in DT (mean value [f0-fFCCP]/[fCN-fFCCP] 0.76 ± 0.02; n=29
tubules from 5 separate slices, p<0.001). Furthermore, this was mirrored by the
finding of a more reduced FAD
2+ pool in the DT (mean value [f0-fCN]/[fFCCP-fCN]
0.39 ± 0.02, n=42 tubules from 4 separate slices) than in PT (mean value [f0-
fCN]/[fFCCP-fCN] 0.61 ± 0.03, n=43 tubules from 4 separate slices, p<0.001) (Figure
4.7G-H). Overall, these data suggest that mitochondria in the PT are in a more
oxidized state at rest, which might explain why a relatively greater response in ROS
production was observed in this nephron segment following inhibition (and
reduction) of complex I by rotenone.
4.8 Calcium signalling in the renal slice
As part of the overall aim to investigate differences in aspects of mitochondrial
function in different tubule types, it was also intended to explore the effects of MD
on Ca
2+ signalling in different nephron segments; as a possible mechanism of how
MD may lead to impaired PT transport. In order to visualise changes in intracellular
Ca
2+, slices were loaded with the fluorescent Ca
2+ indicator Rhod-2 and excited at
900nm. Dye loading appeared to be predominantly in the mitochondria (Figure
4.8A), as the images resembled those of TMRM and NADH. Extracellular ATP is a
physiological agonist that is known to initiate Ca
2+ signals in the PT, via activation of
purinergic receptors (Yamada et al., 1996). In slices loaded with Rhod-2 an
oscillating Ca
2+ signal was elicited in PT cells in response to perfusion with a
solution containing ATP 100µM (Figure 4.8B).
Unfortunately, due to difficulties in routinely achieving satisfactory dye loading with
Rhod-2, it was not possible to create a reliable and reproducible assay of
physiological Ca
2+ signalling in the PT, which could then be used to explore the108109
effects of MD and make comparisons to the DT. Other Ca
2+-sensitive dyes (Fluo-4
and Fura-2) were also tried as part of this work, as were agents that inhibit potential
dye efflux pumps in the cell membrane (probenecid and sulfinpyrazone); however,
none of these measures were effective.
4.9 Discussion
Multi-photon imaging of the kidney in vivo or in vitro is a powerful and relatively
new approach to understanding basic renal physiology (Molitoris & Sandoval, 2005;
Sipos et al., 2007). Imaging of live, intact kidney slices is a useful technique to
access all major nephron segments within the cortex and medulla (which is not
possible in vivo), as well as to investigate mitochondrial function in what is a highly
aerobic and heterogeneous tissue. Using this approach I have identified differences in
Δψm, ROS production, GSH levels and NADH/FAD
2+ redox state between the PT
and DT, at rest and in response to toxic stimuli.
4.9.1 Differences in mitochondrial membrane potential between proximal and distal
tubules
I have observed a large and consistent difference in TMRM signal between the PT
and  DT, suggesting  a difference in resting Δψm. Furthermore, the TMRM signal
appeared to vary between different sub-sections of the PT: it was larger in
convoluted compared with straight segments, though not as large in either sub-
segment when compared with the DT. I have tried to exclude a differential role of
dye extrusion by transporters in the PT and DT, since I did not observe any changes
in signal with cimetidine, an inhibitor of organic cation transport. Moreover,
although verapamil (an inhibitor of the MDR) enhanced loading of TMRM, it did so
in both PT and DT, and it did not affect the striking difference in signal between PT
and DT; strongly suggesting a real difference in Δψm. Another possible confounding
factor affecting TMRM measurements would be a difference in ΔpH between the PT 
and DT mitochondria. PMF is ultimately responsible for driving ATP synthase
activity and it consists of the sum of both Δψm and ΔpH; it is therefore theoretically 
possible that PMF could be equal between PT and DT mitochondria if ΔpH was 110
much greater in the PT. However, experiments using nigericin (an agent that
converts  ΔpH  to  Δψm [by exchanging H
+ for K
+ across the inner mitochondrial
membrane], so Δψm effectively then equals the PMF) in isolated tubules have shown
that  ΔpH  makes  very  little  contribution  to  the  total  PMF  in  PT  mitochondria 
(Feldkamp et al., 2009). This further supports the notion that variations in TMRM
signal between tubule types reflect genuine differences in PMF.
Another possible confounding factor affecting mitochondrial TMRM uptake is any
difference in cell membrane potential between the PT and DT. The concentration of
TMRM in the cytosol ([TMRM]in), is determined by the cell membrane potential and
the extracellular TMRM concentration ([TMRM]out), according to the Nernst
equation:
Cell membrane potential = -61 x log10([TMRM]in/[TMRM]out)
Given a typical cell membrane potential of -60mV, it can be seen that
[TMRM]in/[TMRM]out will equal ~10, but variations in membrane potential between
different cell types will change this value, and therefore the concentration of TMRM
to which mitochondria are exposed ([TMRM]in). I did not attempt to make
measurements of cell membrane potential in this project; however, published data
indicate that there are no major differences between cells of PT and DT (Koeppen et
al., 1983).
Experiments were performed at room temperature, due to excessive movement of
tissue at 37ºC, which made it impossible to maintain the original focal plane in timed
series experiments. This is a potentially confounding factor, as lowering temperature
alters the permeability of cell membranes (Whittam & Willis, 1963), and the activity
of ion transporters such as the Na
+/K
+-ATPase (Willis & Ma, 1969). Accordingly,
previous studies with renal cortical slices have shown that rates of ion transport and
oxygen consumption are lower at 25ºC than at 37ºC (Whittam & Willis, 1963).
Importantly, the effects of altering temperature may be more pronounced on some
cellular processes than others; for example, in kidney cortical slices, Na
+/K
+-ATPase
activity appears to be more sensitive to a reduction in temperature than K
+ transport
and Na
+-sensitive respiration, especially in non-hibernating animals such as the rat111
(although these effects were most pronounced at values below normal room
temperature) (Willis & Ma, 1969).
Interestingly, differences in PT and DT signal have recently been reported in vivo
during an investigation of the excretion of a fluorescent substrate for organic cation
transport in the kidney (Horbelt et al., 2007). Additionally, a study of Δψm in live
kidney slices using confocal imaging of tissue loaded with tetramethyl rhodamine
ethyl ester (TMRE) showed heterogeneity in signal among different cell types
(Plotnikov et al., 2007); but the investigators did not comment on the nature of these
differences.
4.9.2 Differences between proximal and distal tubules in response to chemical
anoxia
That mitochondrial function differs between the PT and DT is also suggested by
differences in their respective responses to chemical anoxia (a model of in vivo
ischaemia). It was demonstrated previously in isolated tubules that mitochondria
depolarize rapidly in the PT in response to hypoxia (Feldkamp et al., 2005b), and this
deficit is maintained even after reoxygenation (Weinberg et al., 2000). I found that in
contrast to the PT, Δψm is surprisingly well maintained during anoxia in the DT; it is
maintained at a plateau value for over 60 minutes, which is attributable to a reverse
in activity of the ATP synthase (ATPase activity). This may be due to increased
capacity for glycolytic ATP production. Alternatively, it may relate in part to
differences in the expression level of the mitochondrial regulatory protein IF1 (see
later – ‘Variation in mitochondrial function along the nephron’).
4.9.3 Reactive oxygen species production in renal tubules
ROS are thought to have wide-ranging physiological and patho-physiological effects
in the kidney. I observed an increased basal rate of ROS production per cell in PT
compared  with  DT.  Given  the  higher  resting  Δψm, it might be expected that
mitochondrial ROS production would be greater in the DT; however, it is important
to stress that I measured total cellular ROS production and this was not adjusted for112
intracellular mitochondrial mass. Although the density of mitochondria in DT is
generally a little higher than in PT, the ratio of mitochondrial volume to nuclear
volume is much greater in the PT, because the cells are larger (Pfaller & Rittinger,
1980); therefore, it is likely that basal ROS production per mitochondrion is lower in
the PT.
HEt is predominantly oxidized by O2
-, and regional differences in the origins of O2
-
production (e.g., mitochondrial versus NADPH oxidase) in the kidney have been
reported using tissue homogenates (Zou et al., 2001); however, I observed
differences in ROS production between different cell types within the same region of
the kidney. The expression of different NADPH subunits varies among different
tubule types (Gill & Wilcox, 2006), and this may therefore be an explanation for
differences in basal O2
- production. Indeed, in the presence of an NADPH oxidase
inhibitor (apocynin) I did not observe significant differences in basal ROS
production between PT and DT.
Although non-mitochondrial sources may contribute significantly to basal rates of
ROS production in the renal tubular cells, the striking rise in ROS production
observed following rotenone was likely to represent increased mitochondrial
generation, given the known actions of rotenone on complex I of the RC (Hirst et al.,
2008). The fact that a much greater rise in ROS production occurred in the PT than
the DT following rotenone exposure could be explained, at least in part, by a greater
mitochondrial mass, per cell, in the PT. However, using an established calibration
method (Duchen et al., 2003), I have also shown that mitochondria in the PT are
more oxidised at rest. Inhibition of complex I of the RC by rotenone is more likely to
produce a greater change in the rate of ROS production in mitochondria that are in a
more oxidized state, than in a more reduced state (Kushnareva et al., 2002). The
finding of a large increase in ROS production in the PT in response to inhibition of
complex I could be of relevance in understanding the pathogenesis of some forms of
FS, as evidence suggests that the activity of this complex is specifically impaired in
cystine loaded renal tubules (a model of cystinosis) (Foreman et al., 1995). Clearly, it
would be interesting to investigate rates of ROS production in this and other models
of FS.113
ROS have been extensively implicated in the pathogenesis of ischaemic AKI and
ATN (for review see (Nath & Norby, 2000). Studies using mitochondria isolated
from the cortex of rat kidneys revealed approximately 1.5 and 4 fold increases in
ROS production in mitochondria derived from ischaemic and ischaemia-reperfused
organs, respectively (Gonzalez-Flecha & Boveris, 1995). Furthermore, giving rats
exogenous SOD appeared to be protective in a model of ischaemic AKI (Baker et al.,
1985). However, it should be noted that others have disputed the protective effects of
anti-oxidants in ischaemic AKI (Gamelin & Zager, 1988), and anti-oxidants have yet
to be proven to be beneficial in human AKI. Nevertheless, learning more about ROS
production in the kidney in more detail is likely to improve our understanding of
renal diseases (including those related to MD), and could lead to novel therapeutic
strategies in the future. More recently it has been appreciated that ROS are also likely
to have physiological roles in the kidney. For example, there is evidence that O2
- can
stimulate NaCl reabsorption in the TaLH by increasing Na-K-2Cl co-transport
(Juncos & Garvin, 2005), and O2
- may also act as a mediator of tubulo-glomerular
feedback at the macula densa (Liu et al., 2007).
Elucidation of the mitochondrial contribution to ROS generation within renal tubular
cells would be enhanced by fluorescent dyes that are specifically targeted to the
mitochondria, such as mitosox; however, preliminary experiments using this dye in
the rat kidney slice model revealed that the loading was generally poor, with a weak
fluorescent signal that was insufficient to make meaningful measurements.
4.9.4 Glutathione in renal tubules
Using MCB, I found that levels of the anti-oxidant GSH were significantly higher in
the PT than DT, which is consistent with previously published biochemical data
(Brehe et al., 1976). MCB is metabolized by GST and subtypes of this enzyme may
vary along the rat nephron; the class α subtypes are selectively expressed in the PT
and the class μ and class π subtypes in the DT (Rozell et al., 1993). Differences in
GST subtype expression among tubular segments could affect the rate of increase in
fluorescence observed with MCB; however, I was unable to explore this further as114
there are no selective inhibitors of the different GST subtypes. I therefore only used
measurements of MCB fluorescence after a steady state signal was achieved, which
reflects the total amount of GSH within cells, rather than the rate of GSH and MCB
metabolism by GST.
4.9.5 Calcium dyes do not load effectively in the kidney slice model
The reasons for poor Ca
2+ dye loading in the kidney slices are unclear, but may
include extrusion of dyes from the renal cells via organic anion transporters (OATs).
This is a well recognised phenomenon in various cell lines, where inhibitors of
OATs, such as probenecid, can improve loading (Di et al., 1990). However, I did not
find any significant improvement in dye loading in the slices with probenecid.
Extracellular esterases may cleave AM-ester dyes before they can enter cells and
thus prevent loading (although another AM-ester dye [calcein] did load well into
kidney slices). As new technologies in Ca
2+ imaging become available, for example,
transgenic animals expressing Ca
2+ sensitive molecules (Tallini et al., 2006), I may
be able to re-explore this in the future.115
Chapter 5 – Results: Subclinical renal tubular disease in
patients with mitochondrial cytopathy
5.1 Demographics and clinical features
Twenty-two adult patients with mitochondrial cytopathy were recruited to the study.
Demographics and clinical features including phenotype and underlying mutations
are depicted in Table 5.1. The median age at recruitment was 41 years (range 18-68),
and the median time since diagnosis was 20 years (range 3-53). A range of
phenotypes were observed, with the most prevalent being Kearns-Sayre syndrome
(and other myopathies) and progressive external ophthalmoplegia (PEO). Generally,
the phenotypes reflected the types of mitochondrial cytopathy where survival into
adulthood is observed, although no patients with the relatively common MELAS
syndrome were recruited, and 2 patients with Leigh syndrome (often fatal in
childhood/adolescence) were included. The presence of a pathological mutation
affecting either mtDNA or nDNA was confirmed in all patients, with the exception
of one who was included in the study on the basis of a typical phenotype of
mitochondrial disease and clear biochemical evidence of decreased RC function. A
range of underlying pathological genetic mutations from either blood or muscle were
observed, the most common being mtDNA point mutations (n=13), followed by
mtDNA deletions (typically associated with Kearns-Sayre and PEO) (n=5), and
nDNA  (polγ)  mutations (n=3). The most common point mtDNA mutation was
A3243G in the TL1 gene.
A total of 10 patients had abnormal features on muscle histology (defined as the
presence of one or more of: ragged red fibres, COX negative fibres, increased SDH
staining and abnormal EM). RC function tests were performed on muscle tissue in 5
patients using standard spectrophotometric techniques (Department of Biochemistry,
Institute of Neurology, UCL, UK); 4 patients had RC complex activities within
normal limits, whilst 1 had clear decreases in the activity of complexes I and IV. The
median serum creatinine was 65µmmol/l (range 35-100, normal<120).116117
In terms of potentially confounding factors on renal function, median blood pressure
was 120 mmHg systolic (range 90-155) and 70 mmHg diastolic (40-100), and a total
of 3 patients had elevated blood pressure (>140/90). Diabetes had previously been
diagnosed in 4 patients, and 4 patients were taking drugs that might affect renal
function.
5.2 The prevalence of subclinical proteinuria is high in adult patients
with mitochondrial cytopathy
The excretion of URBP/C, UNAG/C and UA/C by adult patients with mitochondrial
disease is depicted according to clinical phenotype (Figure 5.1) and underlying
genotype (Figure 5.2). Median URBP/C was 13.8µg/mmol (range 1.8-658.1,
normal<18), median UNAG/C was 38.0µmol/hour/mmol (range 9.7-199.4, normal<28)
and median UA/C was 1.07mg/mmol (range 0.1-39.72, normal<2.5 [urinary albumin
levels that were below the level of detection of the assay were assigned the value of
0.1]).
In total, 7/22 patients (32%) had elevated URBP/C values above the normal range,
across a range of phenotypes (1/2 MERFF, 1/3 PEO, 2/2 PEO and myopathy, 1/5
Kearns-Sayre, 1/1 occipital blindness, ataxia and myoclonus and 1/1 biochemical
defect). The highest value (658.1µg/mmol) was found in the patient with impaired
RC function; this was considerably greater than the next highest value
(120.0µg/mmol) observed in the other patients.
With regards to UNAG/C, a total of 15/22 patients (68%) had an elevated value above
the normal range. However, UNAG/C can be increased in diabetes and 4/22 of the
patients were diabetic (all of whom had an elevated UNAG/C). Amongst the non-
diabetic patients 11/18 (61%) had a UNAG/C above the normal range (1/1 A3243G
carrier, 1 mitochondrial myopathy, neuropathy and deafness [biochemical defect],
3/4 Kearns-Sayre, 2/2 MERFF, 1/1 occipital blindness, ataxia and myoclonus, 1/2
PEO, 1/2 PEO and myopathy and 1/1 SANDO). Overall, 16/22 patients (73%) had
evidence of a proximal tubular disorder (defined as elevated URBP/C and/or UNAG/C),
including 12/18 (67%) of the non-diabetics.118119120
The proportion of patients with elevated UA/C (a marker of glomerular pathology)
was 5/22 (23%). However, like UNAG/C, UA/C can also be increased in diabetic
patients, and the highest UA/C value observed in this study (39.72mg/mmol) was in a
diabetic patient. Amongst the non-diabetic patients, 4/18 (22%) had a UA/C value
above the normal range (1/1 mitochondrial myopathy, neuropathy and deafness, 1/1
Leber’s optic atrophy, 1/1 MERFF and 1/1 occipital blindness, ataxia and
myoclonus).
Unfortunately, due to the wide variety of phenotypes included in the study, and the
relatively small number of patients within each group, I was unable to draw
statistically significant conclusions about differences in either mean or median
urinary values between phenotypes or genotypes.
5.3 Discussion
5.3.1 Subclinical proteinuria in adult patients with mitochondrial cytopathy
In this study I have demonstrated that the prevalence of subclinical renal proximal
tubular disease is high in adult patients with mitochondrial cytopathy. Although a
degree of albuminuria was also observed in the study participants, the prevalence
was not as high as that of tubular dysfunction. This is of interest, as the literature to
date had described predominantly cases of glomerular disease (FSGS) in adults with
mitochondrial cytopathy, whilst children were reported to typically present with renal
tubular disease (FS) (Hall et al., 2008); as discussed earlier (chapter 1.4.6 –
‘Differences between adults and children’), the reasons for these apparent differences
are unclear.
To the best of my knowledge, this study is the first to systematically investigate renal
phenotype in adults with mitochondrial disease, using sensitive markers of both PT
and glomerular dysfunction. This might explain why I have found a different pattern
of disease to that described in the literature to date, which has relied on isolated case
reports of patients who have developed overt kidney disease detected by
conventional clinical tests (such as serum creatinine and dipstick proteinuria). These121
cases probably represent the more severe end of the spectrum, and it is likely from
my results that there is a significant burden of undiagnosed subclinical renal tubular
disease in adults with mitochondrial cytopathy. The true situation is further
confounded by the difficulties that exist in reliably diagnosing mitochondrial disease,
which mean that there are probably cases of unexplained kidney disease in the adult
nephrology population that are not recognized to be due to MD.
Cases of PT dysfunction are often not detected in clinical practice until full-blown FS
occurs, as screening tests for more subtle PT abnormalities (e.g. urinary LMWPs) are
not yet widely available. In adult nephrology, in general, cases of FS are rare (with
the exception of the recent concerns over TDF); hence, awareness of the possibility
of underlying renal tubular dysfunction in adult patients with mitochondrial
cytopathy is probably relatively low.
Unfortunately, I was not able to recruit sufficient numbers of patients to be able to
draw any clear statistical conclusions about any associations between mitochondrial
cytopathy phenotype, or underlying genetic mutation, and patterns of renal disease,
and my findings are thus solely descriptive. There have been suggestions of possible
associations between mtDNA deletion and PT dysfunction in children with
mitochondrial disease (Martin-Hernandez et al., 2005), but again the numbers
involved were small and firm conclusions could not be reached. There does appear to
be an emerging literature linking defective CoQ10 synthesis and nephrotic syndrome
(glomerular disease) (Diomedi-Camassei et al., 2007; Lopez et al., 2006); the
reasons for this remain unclear, but interestingly there is evidence for mitochondrial
dysfunction in a hereditary form of nephrotic syndrome (congenital nephrotic
syndrome of the Finnish type) (Holthofer et al., 1999).
5.3.2 Difficulties of performing clinical studies related to mitochondrial cytopathy
Recruitment of adult patients with mitochondrial cytopathy is challenging, due to the
relative rarity of the disease and the difficulty of establishing an exact genetic
diagnosis in patients who have a clinical phenotype highly suggestive of
mitochondrial disease. Although the entire mtDNA genome has been sequenced,122
many nDNA genes affecting mitochondrial function remain to be discovered.
However, with increasing awareness of the disease, and more convenient and readily
available diagnostic techniques, the number of patients diagnosed with mitochondrial
disease is likely to increase in the near future, potentially allowing more subjects to
be recruited to renal studies such as this one. Furthermore, future studies on
mitochondrial cytopathy may be enhanced by the recent decision by the NHS in the
UK to nationally commission mitochondrial medicine services at three closely linked
centres in London, Newcastle and Oxford (www.ncg.nhs.uk/ncg_services.htm).
5.3.3 Potential confounding factors
There are some potentially confounding factors in my study. Firstly, patients with
mitochondrial cytopathy are susceptible to developing diabetes mellitus and/or the
metabolic syndrome, and these may clearly then have effects on the kidney
independently of the direct toxic effects of MD. Secondly, some patients were taking
other therapies (e.g. NSAIDs, ACE inhibitors) that may have effects on renal
function. Thirdly, due to the phenomenon of heteroplasmy, it is likely that the
mtDNA mutant load varied between different patients, which may have a bearing on
the resulting degree of renal dysfunction. At present, the only mechanism to measure
the mtDNA mutant load in a solid organ is via a tissue biopsy, which involves
significant risks and could not be justified for this sort of observational study.
However, the technique of isolating renal epithelial cells from urine and measuring
mtDNA mutant load in these is now being developed, and early studies suggest that
the results correlate well with the mutant load in muscle in patients with
mitochondrial disease (McDonnell et al., 2004).
In addition to human studies such as mine, improved understanding of the effects of
MD on the kidney will clearly be enhanced by the development of realistic animal
models of mitochondrial cytopathy. To date this has proved problematic (as
discussed in chapter 1.4.3), but newer models are currently in development that will
hopefully address these historical problems and significantly enhance the field of
mitochondrial research.123
Chapter 6 – Results: Subclinical renal tubular disease in
HIV infected patients
6.1 Demographics, HIV and treatment history
Patients recruited to the study were divided into 3 study groups: (1) anti-retroviral
naïve (ARTN), (2) on ART and exposed to Tenofovir (TDF), and (3) on ART but
with no history of TDF exposure (non-TDF). Table 6.1 contains the baseline
demographics, ART history and laboratory blood tests, along with data on the
prevalence of hypertension and potentially nephrotoxic non-HIV therapy in each
group. The 3 groups were well matched for sex and ethnicity. As expected, the
patients in the ARTN group were younger, and had higher plasma HIV RNA levels
compared with the 2 treatment groups. Of the patients on ART, 94% (44/47 TDF,
31/33 non-TDF) had plasma HIV RNA levels <50 copies/ml. Only 1 patient had a
HIV RNA level >400 copies/ml at the time of the study. There was no significant
difference in CD4 count (p>0.2) among the study groups. The non-TDF group had
received ART for a longer median time than the TDF group, although both groups
had been treated with a similar median total number of ART drugs.
6.2 eGFR and serum phosphate
The median eGFR in all 3 groups was normal (>90ml/min/1.73m
2), and there were
no significant differences among the groups (p>0.9). Only 1 patient in the study (in
the TDF group) had an eGFR <60ml/min/1.73m
2. Median serum HPO4
2- was lower
in the TDF group (0.94 mmol/l [range 0.46-1.43]) than either the ARTN (0.99mmol/l
[0.78-1.18]) or non-TDF (1.04 mmol/l [0.58-1.36]) groups (Figure 6.1); however,
these differences were not statistically significant (p>0.2). The proportion of patients
with HPO4
2- values below the normal range (<0.8 mmol/l) was greater in the TDF
group (11/43 [25.6%]) than either the ARTN (1/17 [5.9%]) or non-TDF (3/32
[9.4%]) groups; however, these differences were not statistically significant (p>0.2).124125126
6.3 Prevalence of sub-clinical proteinuria is high in HIV patients,
especially in those exposed to Tenofovir
Urinary markers in HIV patients are depicted in Table 6.2.
ARTN
(n=19)
TDF
(n=47)
non-TDF
(n=33) p
URBP/C
(μg/mmol)
10.4
(2.4-448.5)
24.2
(3.0-1972.4)
12.6
(3.5-693.4)
ARTN v TDF <0.03
ARTN v non-TDF >0.9
TDF v non-TDF <0.08
UNAG/C
(µmol/hr/mmol)
24.7
(6.4-325.0)
44.6
(15.9-1226.2)
46.0
(1.4-958.9)
ARTN v TDF <0.01
ARTN v non-TDF <0.04
TDF v non-TDF >0.9
UA/C
(mg/mmol)
0.8
(0-27.8)
1.0
(0-20.8)
1.2
(0.3-29.6)
ARTN v TDF >0.9
ARTN v non-TDF >0.9
TDF v non-TDF >0.9
UP/C
(mg/mmol)
10.5
(0-38.0)
14.0
(6.0-64.0)
11.0
(0-51.0)
ARTN v TDF <0.07
ARTN v non-TDF >0.9
TDF v non-TDF <0.04
Table 6.2. Urinary markers in HIV patients. Values given are the median (and
range), and are expressed as a ratio to urinary creatinine. ARTN=anti-retroviral
naïve, TDF=exposed to Tenofovir, non-TDF=no exposure to Tenofovir.
URBP/Cwas significantly different among the study groups (p<0.02) and was higher in
the TDF group than in the ARTN group (p<0.03), and there was also a trend towards
it being higher than in the non-TDF group (p<0.08) (Figure 6.2A). Within the TDF
group there was no significant difference in URBP/C between patients taking a
protease inhibitor (29.0 µg/mmol creatinine [4.0-1972.4], n=22) and those who were
not (23.1 µg/mmol creatinine [3.0-1028.3], n=25; p>0.5). Furthermore, there was no
significant correlation between length of time on TDF and URBP/C (rs=0.04, p>0.6).
UNAG/C was also significantly different among the groups (p<0.01), and was higher in
both TDF (p<0.01) and non-TDF (p<0.04) patients than in the ARTN group.
However, there was no significant difference in UNAG/C between the TDF and127128
non-TDF groups (p>0.9) (Figure 6.2B). Furthermore, there was no significant
correlation between length of time on ART and UNAG/C (rs=0.11, p>0.2).
There were no significant differences among the study groups in UA/C (p>0.8)
(Figure 6.3A). However, there were differences in UP/C (p<0.02), with a trend
towards a higher value in the TDF group than in the ARTN group (p<0.07) (Figure
6.3B). UP/C was significantly higher in the TDF group than the non-TDF group
(p<0.04). There was no significant difference in UP/C between the non-TDF and
ARTN groups (p>0.9). Overall, these results indicate that patients exposed to TDF
have increased proteinuria.
6.4 Neither urine albumin/creatinine nor protein/creatinine ratio is
sufficiently sensitive to detect all cases of subclinical nephropathy
The strongest correlation between urinary markers was found between URBP/C and
UNAG/C, followed by (in descending order of association): UNAG/C and UA/C, URBP/C
and UA/C, URBP/C and UP/C, UNAG/C and UP/C, and UA/C and UP/C (Table 6.3). Scatter
plots comparing UA/C (the recommended screening tool of NICE, UK) with URBP/C,
UNAG/C and UP/C are depicted (Figure 6.4) for each of the three study groups.
URBP/C UNAG/C UA/C UP/C
URBP/C - 0.60
(p<0.01)
0.53
(p<0.01)
0.33
(p<0.01)
UNAG/C 0.60
(p<0.01)
- 0.56
(p<0.01)
0.26
(p<0.02)
UA/C 0.53
(p<0.01)
0.56
(p<0.01)
- 0.20
(p<0.06)
UP/C 0.33
(p<0.01)
0.26
(p<0.02)
0.20
(p<0.06)
-
Table 6.3. Correlation among urinary markers. Values given are the Spearman
coefficients (range -1 to +1) and relevant p values.
Although there appeared to be some degree of correlation among urinary markers,
the level of agreement between tests in detecting abnormal proteinuria (defined as129130131
above the normal range) was generally low (Table 6.4); this suggests that they were
measuring different aspects of renal dysfunction in HIV patients.
URBP/C UNAG/C UA/C UP/C
URBP/C - 0.33 0.30 0.16
UNAG/C 0.33 - 0.25 0.11
UA/C 0.30 0.25 - 0.19
UP/C 0.16 0.11 0.19 -
Table 6.4. Agreement among urinary markers in detecting abnormal
proteinuria. Values given are the measures of agreement (κ [range 0 to 1]).
To evaluate the sensitivity of either UP/C or UA/C in detecting subclinical
nephropathy, I compared the proportions of patients in each group with elevated
values (above the normal upper limit) of UP/C or UA/C, to the proportion with
evidence of proximal tubular dysfunction (defined as elevated URBP/C and/or UNAG/C)
(Figure 6.5). The proportion of patients in each group with proximal tubular
dysfunction was considerably higher than the proportions with either elevated UA/C
or UP/C (ARTN: 10/19 [52.6%] versus 6/19 [31.6%] versus 4/16 [25.0%]; TDF:
38/47 [80.9%] versus 14/47 [29.8%] versus 24/46 [52.2%]; non-TDF: 27/33 [81.8%]
versus 13/33 [39.4%] versus 9/30 [30.0%]). This implies that either UP/C or UA/C
testing alone cannot reliably detect patients with ART-associated renal tubular
dysfunction.132133
6.5 Discussion
6.5.1 Subclinical proteinuria in HIV patients
I have performed a cross-sectional study to investigate the nature and prevalence of
subclinical nephropathy in HIV patients without overt renal disease. My results show
that the prevalence of proximal tubular dysfunction (elevated URBP/C and/or UNAG/C)
is high in both ART-naïve patients and those on ART. Patients exposed to TDF have
increased URBP/C and UP/C compared to ART-naïve patients and those taking other
forms of ART.
Rates of tubular proteinuria were found to be high in HIV patients in a previous
study (Kabanda et al., 1996); however, no significant differences were found among
different treatment groups. Subsequently, cross-sectional studies have demonstrated
an association between TDF exposure and increased urinary excretion of beta-2-
microglobulin in both children (Papaleo et al., 2007) and adults (Gatanaga et al.,
2006). Furthermore, a small longitudinal study reported that excretion of urinary
beta-2-microglobulin increased significantly in patients following the
commencement of TDF therapy (Kinai & Hanabusa, 2005). Although widely used as
a marker of proximal tubular dysfunction, urinary beta-2-microglobulin has
drawbacks as a screening tool because of its pH dependence and enzymatic
breakdown (Davey & Gosling, 1982); RBP is thought to be a more reliable low
molecular weight protein to measure (Bernard & Lauwerys, 1981).
In my study, patients on ART (whether or not it included TDF) had significantly
higher UNAG/Ccompared with ART-naïve patients; however, there were no significant
differences in UA/C (a marker of glomerular disease). This suggests that there is a
background level of proximal tubular damage in patients taking ART, which is not
specific for TDF. However, I have found that patients taking TDF have higher URBP/C
than other HIV patients (whether or not they are on ART), which could be explained
by a more specific inhibitory effect of TDF on proximal tubular uptake and/or
transport of LMWPs. This is consistent with the association of this drug with FS in
some case reports, and could also account for the increase in UP/C observed in
patients taking TDF.134
The finding that URBP/C values in my study were not normally distributed, and did not
correlate with length of time on treatment, suggests that TDF toxicity in the kidney
may be an ‘all or none’ phenomenon. This may, in turn, relate to underlying
pharmacogenomic factors; for example, it has recently been shown that ABCC2 (the
gene which encodes MRP2, an efflux pathway for TDF) haplotypes are associated
with PT dysfunction in TDF patients (Izzedine et al., 2006). The significance of
tubular proteinuria in predicting development of chronic kidney disease is currently
unknown; although it has been suggested that increased delivery of LMWPs to distal
parts of the nephron might have pathophysiological consequences (Kastner et al.,
2009; Norden et al., 2001).
6.5.2 Appropriate screening tests for renal tubular disease
The level of agreement between the different urinary tests in my study in detecting
abnormal proteinuria was generally low, and considerable numbers of patients with
evidence of tubular dysfunction did not have a raised UA/C or UP/C. Furthermore, the
correlation between tubular markers and UP/C was also weak (although patients
taking TDF did have significantly elevated UP/C). Therefore, screening for increased
urinary excretion of tubular proteins (such as URBP/C and UNAG/C) is likely to be a
more appropriate strategy for monitoring patients taking TDF than more
conventional clinical tests for nephropathy (i.e. UP/C or UA/C). This will need to be
assessed in prospective longitudinal studies, in order to identify those patients who
are at increased risk of TDF-associated renal toxicity. Unfortunately, testing for
urinary LMWP excretion is not widely available on a clinical basis in the UK;
however, this may change in the future. In the meantime, other less sensitive but
more readily available markers of PT function (such as fractional excretion of
phosphate and urine dipstick for glycosuria) could be utilised for monitoring patients
on ART.
6.5.3 Serum phosphate in HIV patients
Renal HPO4
2- wasting is one of the features of FS. I did not observe significant
differences in median serum HPO4
2- among the study groups. However, there was a135
non-significant increase in the proportion of patients with hypophosphataemia in the
TDF group. This should be explored further in larger studies, as it is an important
long-term consideration in patients taking TDF (where concern has tended to focus
more on the development and progression of renal dysfunction per se, rather than the
metabolic consequences of urinary LMWP and inorganic solute wasting). Patients
taking ART have been shown previously to have reduced bone density compared to
controls (Tebas et al., 2000). The reasons for this are unclear, but may relate to
increased osteoclastogenesis due to ART, mediated either via direct effects of the
drugs or via changes in the levels of circulating cytokines that can act on osteoclasts
(for review see (Pan et al., 2006)). Renal fractional excretion of HPO4
2- was not
measured in this study, so I am unable to comment further on the mechanism of the
effect of TDF on serum HPO4
2-.
6.5.4 Study limitations and confounding factors
I do think there have been any major confounding factors in my study, as the
different study groups were well matched and patients with diabetes or who were
infected with Hepatitis B or C were excluded. The incidence of hypertension and use
of potentially nephrotoxic non-HIV therapy was low in all groups. Although the non-
TDF group had received ART for a longer median time than the TDF group, I do not
think this weakens the findings. Indeed, it is quite possible that even bigger
differences in relative toxicity would have been observed between the two treatment
groups had they been more closely matched for duration of therapy.
My study was cross-sectional rather than longitudinal, and as such only associations
between TDF exposure and renal tubular dysfunction can be demonstrated, and
causality cannot be established. Furthermore, questions cannot be answered on
progression of kidney disease in patients on TDF, or recovery following
discontinuation. Prospective randomized controlled trials will be required to address
these.136
Chapter 7 - General discussion
7.1 The relationship between mitochondrial function and low
molecular weight protein endocytosis in the proximal tubule
RC inhibition caused only small reductions in FA endocytosis and cytosolic ATP
levels in OK cells, whereas much larger decreases were observed in both in response
to blockade of glycolysis.
Evidence in the literature (from both renal and non-renal cell lines) suggests that a
change in cytosolic ATP levels can have a significant effect on receptor mediated
endocytosis at the cell membrane. The endocytosis and recycling of transferrin and
its associated receptor in the MDCK renal cell line (which has properties more of the
DT than PT) was found to be dependent on ATP levels (Podbilewicz & Mellman,
1990). Furthermore, uptake of radiolabelled transferrin in both K562 and Hela cells
has been shown to be inhibited by ATP depletion, which was induced by exposing
the cells to N2, in the presence of 2-DG (Schmid & Carter, 1990). In the Cos7 cell
line, the chloride channel CIC-2 was upregulated at the cell membrane by cellular
ATP depletion, due to decreased endocytosis of the channel, possibly via a dynamin
dependent process (Dhani et al., 2008). The endocytosis of β-adrenergic receptors in
response to catecholamines was also found to be ATP dependent (Liao & Perkins,
1993).
A variety of processes involved in the mechanism of endocytosis have been shown to
be ATP dependent. For example, the exchange of free and bound clathrin in clathrin-
coated pits requires ATP (Wu et al., 2001). An intact actin cytoskeleton is important
for endocytosis (Gekle et al., 1997), and actin polymerisation is ATP dependent
(ATP bound to monomeric [G] actin undergoes hydrolysis when polymeric [F] actin
is formed (Korn et al., 1987). The trafficking of endocytotic vesicles within cells
along microtubules by the motor proteins kinesin and dynein is dependent on ATP
(Oda et al., 1995), and disruption of microtubule polymerisation has been reported to
inhibit endocytosis of transferrin in a non-renal cell line (Jin & Snider, 1993).
Microtubules may have a key role in receptor-ligand dissociation in endocytotic137
vesicles in hepatocytes, again in an ATP dependent process (Goltz et al., 1992).
Furthermore, receptor recycling requires dissociation from ligands within the
internalised vesicles; this process is enhanced by acidification of these endosomes,
via an ATP dependent proton pump (Gluck et al., 1996), and disruption of
acidification leads to impaired protein endocytosis (Clague et al., 1994).
A previous study on the effects of ATP depletion on fluid phase endocytosis (using
the markers Lucifer Yellow and Horse-radish peroxidase [HSP], rather than dextran)
reported that whilst CN decreased uptake, IAA had mixed effects, causing a decrease
in HSP uptake but, surprisingly, an increase in Lucifer Yellow uptake (Kempson et
al., 1991). The authors speculated this may have been due to a non-endocytotic effect
on Lucifer yellow uptake by IAA. I was unable to test the effects of IAA on
endocytosis in OK cells, as I found it to be extremely toxic to the cells. Ifosfamide is
a chemotherapeutic agent reported to cause FS (with in vitro evidence that its
metabolites may inhibit mitochondrial RC function in a PT-derived cell line
(Mohrmann et al., 1993)); it was found to cause a decrease in cytosolic ATP in live
renal cortical slices, which was associated with inhibition of uptake of HSP (Yaseen
et al., 2008).
In contrast to the above, other investigators have reported that ATP depletion does
not affect receptor mediated endocytosis in intact cells (Larkin et al., 1985), or that it
may disrupt receptor recycling, but does not inhibit a single round of endocytosis
(Clarke & Weigel, 1985). The differences observed between various studies in this
field can perhaps be explained by a number of potentially confounding factors.
Firstly, a variety of different cell models from different origins have been used, and
endocytotic pathways and machinery may vary considerably between them (similar
points could be made for the range of different ligands used). Secondly, as discussed
previously, cell cultures can vary in their relative dependence on different ATP
generating methods (aerobic versus anaerobic). Lastly, agents used to block either
RC function or glycolysis could have important confounding effects of other aspects
of cell function, affecting variables such as ROS production and Ca
2+ signalling.
Exploring the relationship between cytosolic ATP and endocytosis further in OK
cells will require a method to manipulate the former and then investigate the effect138
on the latter, in a manner that does not lead to rapid cell death. Previous work in this
area has been performed using disrupted cells where the concentration of ATP is
much more easily controlled than in an intact functioning cell. Perhaps one approach
would be to decrease cytosolic ATP rapidly with an agent like IAA, then add ATP in
known concentrations to the culture medium; however, it is unclear how much ATP
would be taken up by the cells, and extracellular ATP mediated signalling via
purinergic receptors in the cell membrane would be a major potential confounding
factor (experiments in another renal-derived cell line [WKPT] have revealed that
extracellular ATP can have an inhibitory effect on LMWP uptake (Carvou et al.,
2007)). A possible solution to this problem might involve using caged ATP, which is
not biologically active until a photosensitive bond has been broken; therefore, it can
be introduced across cellular membranes and then activated within cells using a flash
of ultraviolet light (McCray et al., 1980).
To get around the problem of OK cells being relatively anaerobic, two strategies
could be employed. The first is to try and make the OK cells switch to a greater
dependence on aerobic metabolism. Various methods are available to try and achieve
this, such as shaking culture flasks to increase aeration and lowering the culture
medium glucose concentration to reduce the drive towards glycolysis (Griner &
Schnellmann, 1994), but it is unclear how successful they generally are. An
alternative approach would be to switch to primary tissue, but primary cultures of PT
cells generally lose their phenotype within a few passages. Renal slices have been
used to investigate amino acid (Rosenberg et al., 1961) and HSP (Yaseen et al.,
2008) uptake in the PT, but they lack the normal architecture of the intact kidney and
do not provide a model whereby LMWP endocytosis can be studied selectively at the
apical PT membrane. Direct visualisation of LMWP endocytosis in the PT is now
possible in vivo using multi-photon imaging (Molitoris & Sandoval, 2005); however,
there are significant technological difficulties with this approach.
7.2 Variation in mitochondrial function along the nephron
Previous studies have shown that certain topographical patterns of injury are
observed in the renal tubule, in diseases where MD is implicated in the pathogenesis.139
For example, MD is thought to be central to the cellular injury that occurs following
ischaemia-reperfusion (which is a major cause of AKI), and ischaemia-reperfusion in
the isolated perfused kidney causes necrosis predominantly in the S3 portion of the
PT (straight PT) (Shanley et al., 1986c). Exposure to RC inhibitors in the same
preparation causes maximal structural damage in the S1 segment of the convoluted
PT (Shanley et al., 1986a). This discrepancy may be partly explained by a relatively
greater anaerobic capacity in the S3 segment, rendering it less vulnerable to RC
inhibition (although still more vulnerable than DT). Furthermore, the importance of
oxygen gradients in vivo must be considered. The S3 segment is situated in a
relatively hypoxic environment in the inner cortex and outer medulla, and is thus
more sensitive to changes in oxygen supply than the S1 segment, which is situated in
the comparatively well oxygenated outer cortex. Accordingly, PT damage in hypoxic
isolated perfused kidneys has been shown to be dependent on distance from arterial
blood supply (i.e. less damage is observed in peri-arterial tubules (Shanley et al.,
1986b)).
Infusion of inhibitors of either the RC or the citric acid cycle into the isolated
perfused kidney caused decreases in GRF, Na
+ reabsorption, ATP and oxygen
consumption (QO2) (Brezis et al., 1985). RC inhibition caused a greater depletion of
ATP in the cortex; whilst blockade of anaerobic glycolysis (with 2-DG) had the
opposite effect (i.e. it depleted ATP to a greater extent in the medulla). This
observation probably reflects the known gradient in aerobic dependence, which
decreases from the cortex down to the medulla (Lee & Peter, 1969). Morphological
changes were observed in the brush border of the PT following RC inhibition in the
isolated perfused kidney, and the extent of these changes correlated with ATP levels.
This provides another possible explanation for the impairment of LMWP uptake
observed in patients with MD, as it is likely that effective endocytosis will be
impeded by structural abnormalities in the apical membrane. It also highlights the
important role that ATP may play in the mechanism. This was further supported by
the fact that structural damage in the PT, due to citric acid cycle inhibitors, could be
overcome by succinate, which bypasses the metabolic block and allows electrons to
feed into the RC at complex II, consequently leading to restoration of ATP synthesis
by mitochondria. Interestingly, very little structural damage was observed in the DT
following infusion of RC inhibitors; although abnormalities were observed following140
the addition of 2-DG. This is consistent with the notion that DT cells are protected
from RC inhibitor induced damage by their ability to generate ATP via anaerobic
metabolism.
Extensive damage in the DT has been reported in isolated perfused kidney models of
hypoxia (rather than anoxia) (Brezis et al., 1984a), and experiments involving
isolated PT and DT cells suggested that the latter were more vulnerable to the effects
of brief periods of oxygen deprivation (Lash & Tokarz, 1990). The reasons for this
are unclear, but might include generation of ROS in the presence of a low oxygen
tension; the DT appears to have a high Δψm, and also a high density of mitochondria,
both factors that could potentially lead to significant ROS formation during
pathological states. Indeed, my measurements using HEt in kidney slices suggested
that ROS production per mitochondrion was likely to be higher in the DT than PT,
although I did not investigate the effects of hypoxia on this. Ouabain (an inhibitor of
the Na
+/K
+-ATPase) is protective against CN induced cell toxicity in the DT,
presumably because it helps to preserve cytosolic levels of ATP during metabolic
inhibition (Brezis et al., 1984b). It has also been reported to protective in the PT, but
to a lesser extent (Brezis et al., 1985).
A greater capacity to generate ATP anaerobically may not be the only explanation
for the difference in response of Δψm to RC inhibitors observed between DT and PT.
Recently, new insights have been gained into a potentially important regulator of the
mitochondrial ATP synthase, the nuclear-encoded mitochondrial protein IF1. This
protein is thought to interact with and inhibit the enzyme, predominantly when the
latter is acting in ‘reverse mode’ as an ATPase (i.e. breaking down ATP and
maintaining  Δψm) (Green & Grover, 2000). This occurs when RC activity is
impaired, and the mitochondria become net consumers of ATP. IF1 therefore has the
effect of preserving ATP levels,  at  the  expense  of  Δψm, during times of RC
compromise (such as in ischaemia). In cell culture models, IF1 overexpression
appears protective against necrotic cell death when the RC is inhibited (Campanella
et al., 2008). Using immuno-staining of fixed kidney slices, it was recently
demonstrated that the ratio of IF1 to its target molecule (the ATP5b subunit) is
higher in PT than DT (Hall et al., 2009), which might explain why Δψm depolarizes
more rapidly in the PT during RC blockade. In addition to the known effects of IF1141
in regulating ‘reverse’ ATP synthase (ATPase) activity, some recent evidence has
also emerged to support a role for IF1 in modulating ‘forward’ activity. For example,
it has been suggested that IF1 may promote dimerisation of ATP synthase molecules
(Garcia et al., 2006), and this might in turn increase the efficiency of the synthase
(Strauss et al., 2008). Increased proton flux through the ATP synthase due to greater
efficiency will cause a lowering of Δψm (Campanella et al., 2008); this could explain
the lower resting Δψm observed in PT. However, if this were the case, it would be
expected that oligomycin (which blocks the ATP synthase) would eliminate
differences between the PT and DT, but oligomycin had no significant effect on Δψm
in my experiments.
My findings in this project, along with the established literature, support the concept
that mitochondrial function (and the response to inhibition of RC function) varies
along the nephron. The question then arises, what might the teleological reasons be
for such differences? The answer probably relates to the function of the different
nephron segments. In the cortex, the role of the PT is to reabsorb vast amounts of
water and solutes, via ATP-dependent transport mechanisms. The most efficient way
to generate this ATP is by aerobic metabolism, and the PT (like other aerobic tissues
such as the heart) is highly adapted to perform oxidative phosphorylation, principally
using substrates that result in the maximum number of ATP molecules per molecule
of fuel (e.g. fatty acids). The PT has also adapted to use a range of metabolic fuels
that can be reclaimed from the renal filtrate, such as lactate, amino acids and even
citric acid cycle intermediates, at the expense of losing the cellular machinery
required to perform anaerobic glycolysis (Wirthensohn & Guder, 1986); thus,
rendering itself vulnerable to any degree of RC compromise.
It is, therefore, not surprising that AKI and shut-down of kidney function is
commonly observed clinically in response to significant circulatory disturbances
(such as sepsis and hypotension). The mechanisms that lead to oliguria in AKI
remain to be fully elucidated, but what is striking is that in the face of significant
organ dysfunction, histological damage is rarely observed (Brun & Munck, 1957).
This has lead to the hypothesis that oliguria represents a protective ‘shutting-down’
of renal function (termed ‘acute renal success’ (Thurau & Boylan, 1976)), to
minimise necrosis in tubules that have very little inherent resistance to RC142
compromise. This concept could explain why historical interventions to improve
tubular flow and urine output, such as vasodilators and diuretics, do not have
beneficial effects on outcome. As a further protective mechanism against ischaemic
insults, renal tubules appear to have significant regenerative capacity. The
mechanisms that underlie this remain unclear (Bussolati et al., 2008); but the fact is
that many patients with severe AKI do recover kidney function in the weeks after the
initial insult. The main clinical problems are the significant morbidity and mortality
that occurs within those crucial few weeks of oligo-anuria.
The function of the DT in the Loop of Henle (TALH) is to concentrate the urine. Due
to the counter-current mechanism that maintains osmotic gradients in the medulla,
the blood flow to the medulla is necessarily sluggish, and consequently the TALH
resides in a relatively hypoxic environment. It is therefore not surprising that it has
evolved significant glycolytic capacity, and appears more resistant to RC
compromise.
Thus, established differences in relative dependence on aerobic and anaerobic
metabolism, between the PT and DT, relate to differences in function and the
surrounding milieu. However, what is harder to explain (at least at present) is why
there may be intrinsic differences in mitochondrial function (e.g. ΔΨm), as described
in this study. Given that these findings are novel, and essentially unprecedented by
similar investigations in the kidney, or any other organ, any putative explanation at
this stage is necessarily speculative. Δψm can be affected by a number of factors in
intact cells such as substrate supply, proton leak across the mitochondrial inner
membrane, and the ATP/ADP ratio (Nicholls, 2004). In the PT, a more oxidized state
and lower Δψm could be explained by a greater work load and more ATP hydrolysis
to support the large amount of solute transport that occurs in this nephron segment.
Therefore, I was surprised that differences in Δψm were not corrected by inhibition of
the mitochondrial ATPase with oligomycin, especially since I knew that oligomycin
was working in the slice preparation from its profound effect on the DT in response
to anoxia. However, it is unclear to what extent solute transport does occur in kidney
slices in vitro. Indeed, if little transport is occurring under these conditions, then the
intramitochondrial ATP/ADP ratio could be high. ATP can allosterically inhibit RC143
complex IV activity in eukaryotic cells (Follmann et al., 1998), and it has been
suggested that this may provide a feedback mechanism; acting as a ‘brake’ on RC
activity in the presence of a high ATP/ADP ratio, which will limit the size of Δψm
and hence prevent excessive ROS production (Kadenbach & Arnold, 1999; Lee et
al., 2001). In this setting, oligomycin would have relatively little effect on Δψm.
My data showed that mitochondrial RC substrates in the PT are in a more oxidised
state at rest, with a lower ΔΨm; a scenario that would minimise ROS production in
cells that have a high mitochondrial mass. The importance of this was illustrated by
the dramatic rise in ROS production observed after a more reduced state at complex I
induced by rotenone. One could speculate that ΔΨm is kept relatively low in the PT
by a degree of uncoupling between RC activity and ATP generation; it will,
therefore, be of interest to explore the expression patterns of novel UCPs along the
nephron. In  contrast,  it is  perhaps  more  difficult  to  explain  why  ΔΨm should be
significantly higher in the DT in the resting state. These cells also have a high
density of mitochondria, and significant ROS production would be expected with a
high ΔΨm in the DT. ΔΨm is central to mitochondrial function, with effects on such
crucial cellular processes as ATP generation, Ca
2+ uptake and protein import. I can
only speculate that other mitochondrial functions within the DT, which require a
relatively  higher  ΔΨm, supersede in importance the increased risk of ROS
production; clearly, this hypothesis will have to be explored further in future studies.
The observations made in this study have to be evaluated within the constraints of
the kidney slice model. The slicing technique does result in some degree of trauma to
the kidney, and natural osmotic gradients that exist in certain regions, such as the
inner medulla, are lost. As metabolism is thought to be closely coupled to transport,
and it is unclear to what extent transport is occurring in the slice preparation, some
caution needs to be exercised in extrapolating my findings to the in vivo situation.
However, kidney slices have been used historically for transport studies (Hong et al.,
1983; Rosenberg et al., 1961; Yaseen et al., 2008), confirming that some solute
uptake does take place, and lending validity to the model.144
Future in vivo studies will naturally be required to confirm or refute my findings in
slices, which may include imaging mitochondrial function in whole intact kidneys.
To do this, these studies will have to overcome the technical difficulties of applying
imaging methods to the in vivo setting (e.g. achieving adequate dye loading).
Possible alternative approaches to fluorescence microscopy for studying renal
metabolism in vivo include functional MRI imaging (Bianchi et al., 2007) and
urinary metabonomics (Vilasi et al., 2007) (which essentially provides a readout of
metabolic activity in the intact kidney).
7.3 Renal dysfunction in adult patients with mitochondrial
cytopathy or HIV
My studies have revealed that patients with either mitochondrial cytopathy or HIV
have high rates of subclinical proximal tubular disease. Proteinuria (Kannel et al.,
1984) and chronic kidney disease (Foley et al., 1998) are both significant risk factors
for the development of cardiovascular disease, the leading cause of death in the
western world. Given that patients with mitochondrial cytopathy and HIV are prone
to developing the metabolic syndrome, another important cardiovascular risk factor,
the finding of renal disease in these patients may be of significance when considering
their long-term health. This becomes increasingly important as the life expectancy of
patients with HIV continues to rise, due to more potent therapy. Indeed, we may well
be witnessing a shift in the epidemiology of renal disease attributed to HIV, from
conditions related to the direct toxic effects of the virus (e.g. HIVAN and immune
complex mediated nephritis) to tubular disorders caused by drug toxicity (such as FS
due to TDF) (Wyatt & Klotman, 2006; Roling et al., 2006). My study provided
evidence that, even in patients not exposed to TDF, there was a background level of
PT toxicity likely to be due to ART.
Whether or not patients with subclinical tubular proteinuria are likely to progress to
develop overt kidney disease, or even end-stage renal failure, is currently unknown;
longitudinal follow-up studies over a significant period of time will obviously be
required to answer this question. However, it has been postulated that the existence
of abnormally high concentrations of bioactive peptides (e.g. insulin and parathyroid145
hormone) in distal parts of the nephron, due to impaired PT uptake, could have a
toxic effect of tubular cells (Norden et al., 2001). This has been supported by
experimental evidence suggesting that proteinuria in rodents may have downstream
effects on ENaC activity in the collecting duct (Kastner et al., 2009), and thus on the
function of the distal nephron. Arguing against this hypothesis is the existence of
hereditary forms of FS that produce marked tubular proteinuria, but do not progress
to any significant deterioration in renal function over a number of years (Tolaymat et
al., 1992).
Diagnosis of kidney disease in clinical practice has traditionally relied on fairly crude
markers of renal function, such as serum creatinine and urine dipstick (for albumin).
Not only are these relatively insensitive tests that will miss more subtle
abnormalities, they are also primarily markers of glomerular disease and are not
specifically designed to screen for PT dysfunction. It is, therefore, likely that they
will miss the burden of tubular disease detected using more sensitive markers in
studies such as mine. In recognition of this, interest is growing in the development of
more sensitive urinary biomarkers of kidney disease, which may detect subtle kidney
injury at an earlier stage than traditional tests. This may be an advantage in acute
conditions, where an early diagnosis and intervention may change the outcome;
whereas, previously, waiting for a significant rise in creatinine to occur may have led
to the establishment of irreversible disease. For example, the usage of urinary
neutrophil gelatinase associated lipocalin (NGAL) (Mishra et al., 2003) and kidney
injury molecule (KIM) (Liangos et al., 2007) have attracted much interest in recent
years as potential early diagnostic tests for AKI. Furthermore, by testing a range of
biomarkers, some qualitative information may be gleaned about the pattern of
disease taking place within a kidney as well as the severity. Analysis of the urinary
proteome (which involves the rapid measurement of the levels of a number of
different proteins) has shown that it appears to differ between different classes of
lupus nephritis (Oates et al., 2005). This requires further validation, but the potential
of this technology is clear; that clinical nephrology may move on from biopsy based
diagnosis (and all the inherent risks to the patient that entails), to non-invasive
techniques involving detailed screening of urine. Urine proteomic screening is likely
to eventually become a routine tool in evaluating the potential nephrotoxcity of146
newly developed medicines, which could help to prevent the kind of unexpected
problems encountered with drugs such as TDF.
Another advantage of analysing an entire proteome is that it includes peptides that
may be decreased in the urine of FS patients, due to impaired synthesis or release by
damaged PT, as well as the traditional markers of abnormal PT uptake that are
usually increased in the urine (such as RBP) (Drube et al., 2009). As LMWPs are
thought to be taken up by the PT via a common pathway (the megalin/cubulin
system), it was assumed that the proteome of FS patients would be similar, no matter
what the underlying aetiology. However, recent studies have provided evidence that
the urinary proteome does actually vary according to the cause of PT dysfunction
(Vilasi et al., 2007). It is, therefore, possible that future urine proteomic screening of
TDF patients, and comparison to the proteomes associated with other forms of FS,
may provide clues as to the underlying mechanism of PT toxicity due to TDF.
Variation in urine proteome could also explain why some forms of FS lead to
worsening kidney disease but others don’t; perhaps progression of disease depends
on which proteins are being taken up or released by the PT, rather than the overall
amount of proteinuria.147
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MELAS Mitochondrial encephalo-myopathy with lactic acidosis and
stroke
MERFF Myoclonic epilepsy with ragged red fibres
Mg Green Magnesium green
MIDD Maternally inherited diabetes and deafness
MRP Multi-drug resistance-associated protein
mtDNA Mitochondrial DNA
NADH Nicotinamide adenine dinucleotide
NADPH oxidase Nicotinamide adenine dinucleotide phosphate oxidase
NAG N-acetyl-beta-D-glucosaminidase
nDNA Nuclear DNA
NO Nitric Oxide
NRTI Nucleoside reverse transcriptase inhibitor
O2
- Superoxide
OK Opossum kidney cell
PAN Puromycin aminonucleoside nephrosis
PCT Proximal convoluted tubule
PI Protease inhibitor
PMF Proton motive force
Pol-γ DNA Polymerase Gamma
PST Proximal straight tubule
PT Proximal tubule
RBP Retinol binding protein
RC Respiratory chain
ROI Region of interest
SOD Superoxide dismutase
TALH Thick ascending limb of the loop of Henle
TDF Tenofovir149
THP Tamm Horsfall Protein
TMRM Tetramethyl rhodamine methyl ester
UA/C Urine albumin/creatinine ratio
UCP Uncoupling protein
UNAG/C Urine N-acetyl-beta-D-glucosaminidase/creatinine ratio
UP/C Urine protein/creatinine ratio
URBP/C Urine retinol binding protein/creatinine ratio150
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Appendix
Mitochondrial study - patient information sheet
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully. Please ask your
consultant in clinic if there is anything that is not clear or if you would like more
information. Take time to decide whether or not you wish to take part.
What is the purpose of the study?
All living cells in the body require energy to function properly. Mitochondria are the
components of cells that are responsible for providing this energy. Abnormalities in
mitochondria may therefore lead to cells not working properly. This study has been
designed to investigate whether or not abnormalities in mitochondria may affect the
function of cells in the kidney, and in particular their ability to reabsorb substances
normally and stop them being lost in the urine (a medical condition called “The
Renal Fanconi Syndrome”). This will be established by analysing samples of urine to
look for these substances and evidence of mild kidney damage.
Why have I been chosen?
You have been asked to take part as you are known to have abnormalities in the
function of your mitochondria, which has caused problems in other organs of your
body (such as muscle) and has lead to you being seen in this clinic. As part of the
study we would like to analyse a sample of your urine to look for evidence of mild
kidney damage which may be a result of abnormal mitochondrial function.
Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be given
this information sheet to keep and be asked to sign a consent form. You are still free
to withdraw at any time and without giving a reason. A decision to withdraw at any
time, or a decision not to take part, will not affect the standard of care you receive.
What will happen to me if I take part?
You will be asked to provide a urine specimen whilst attending the clinic. This
sample will be sent away to a laboratory for analysis. In some cases, depending on
the initial results, you may be asked for another sample of urine at a later date for
more detailed analysis. Should any abnormalities be found the consultant looking184
after you will notify you and you will be offered further tests and the opportunity to
be seen by a kidney doctor should you wish.
What are the other possible benefits and disadvantages of taking part?
The possible disadvantage is that you may be diagnosed with having a kidney
problem that you were unaware of. However, this is likely to only be mild and can be
easily treated by taking certain supplements to replace those lost in the urine, which
may have a beneficial effect on your health if you were previously deficient of these
substances.
Will my taking part in the study be kept confidential?
Your participation will be strictly confidential and only your consultant will be
aware. The researchers will not be aware of your identity and your GP will not be
sent any results.
What will happen if I don’t want to carry on with the study?
You may withdraw at any time and without giving any reason by contacting your
consultant in clinic.
What will happen to any samples I give?
Samples will be destroyed after analysis.
What will happen to the results of the research study?
You will be informed by your consultant of any abnormalities in your urine
specimen. It is intended that the results of the study when completed will be
submitted to a scientific journal for publication. No-one will be able to identify you
by reading the results as all results will be anonymous.
Who has reviewed the study?
The National Hospital for Neurology and Neurosurgery & Institute of Neurology
Joint Regional Ethics Committee.
Who is organising the research?
The research has been organised by The Department of Physiology, University
College London, in collaboration with University College London Hospitals NHS
Trust and Camden Primary Care Trust. The lead investigators are Professor RJ
Unwin and Prof MG Hanna.
Contact for further information
Prof Hanna can be contacted on the phone numbers at the top of this information
sheet.185
Thank you for taking the time to read this information sheet and for considering
taking part in this study.186
HIV study - patient information sheet
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully. Please ask your
consultant in clinic if there is anything that is not clear or if you would like more
information. Take time to decide whether or not you wish to take part.
What is the purpose of the study?
All living cells in the body require energy to function properly. Mitochondria are the
components of cells that are responsible for providing this energy. Abnormalities in
mitochondria may therefore lead to cells not working properly. Recently it has been
suggested that HIV infection and the drugs used to treat it may interfere with
mitochondria in the kidney. This may affect the function of cells in the kidney, and in
particular their ability to reabsorb substances normally and stop them being lost in
the urine (a medical condition called “The Renal Fanconi Syndrome”). The study
will investigate this possibility by analysing samples of urine to look for these
substances and evidence of mild kidney damage.
Why have I been chosen?
You have been asked to take part as you are currently attending The Mortimer
Market Clinic for monitoring or treatment of HIV infection. As part of the study we
would like to analyse a sample of your urine to look for evidence of mild kidney
damage which may be a result of abnormal mitochondrial function.
Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be given
this information sheet to keep and be asked to sign a consent form. You are still free
to withdraw at any time and without giving a reason. A decision to withdraw at any
time, or a decision not to take part, will not affect the standard of care you receive.
What will happen to me if I take part?
You will be asked to provide a urine specimen whilst attending the clinic. This
sample will be sent away to a laboratory for analysis. In some cases, depending on
the initial results, you may be asked for another sample of urine at a later date for
more detailed analysis. Should any abnormalities be found the consultant looking
after you will notify you and you will be offered further tests and the opportunity to
be seen by a kidney doctor should you wish.187
What are the other possible benefits and disadvantages of taking part?
A possible disadvantage is that you may be diagnosed with having a kidney problem
that you were unaware of. However, this is likely to only be mild and can be treated
by altering your anti-HIV medication and by taking certain supplements to replace
those lost in the urine. This may have a beneficial effect on your health if you were
previously deficient of these substances.
Will my taking part in the study be kept confidential?
Your participation will be strictly confidential and only your consultant will be
aware. The researchers will not be aware of your identity and your GP will not be
sent any results.
What will happen if I don’t want to carry on with the study?
You may withdraw at any time and without giving any reason by contacting your
consultant in clinic. This will not affect your usual medical care in any way.
What will happen to any samples I give?
Samples will be destroyed after analysis.
What will happen to the results of the research study?
You will be informed by your consultant of any abnormalities in your urine
specimen. It is intended that the results of the study when completed will be
submitted to a scientific journal for publication, and will also form part of a PhD
project. No-one will be able to identify you by reading the results as all results will
be anonymous.
Who has reviewed the study?
The National Hospital for Neurology and Neurosurgery & Institute of Neurology
Joint Regional Ethics Committee.
Who is organising the research?
The research has been organised by The Department of Physiology, University
College London, in collaboration with University College London Hospitals NHS
Trust and Camden Primary Care Trust. The lead investigator is Professor RJ Unwin.
Contact for further information
The lead investigator, Prof RJ Unwin, can be contacted on the phone numbers at the
top of this information sheet.
Thank you for taking the time to read this information sheet and for considering
taking part in this study.
You will be given a copy of this form and the consent form to keep.188
Ethics committee approval for clinical studies
Prof RJ Unwin
Professor of Nephrology
UCL
Centre for Nephrology, UCL medical
School, Hampstead Campus,
Rowland Hill St, London
NW3 2PF
Our Ref: 06L 286
Research & Development Department
1st Floor, Maple House
POSTAL ADDRESS:
Ground Floor, Rosenheim Wing
25 Grafton Way
London
WC1E 5DB
Tel: 020 7380 9579
Fax: 020 7380 9937
Email: sasha.vandayar@uclh.nhs.uk
Website: www.uclh.nhs.uk
30 August 2006
Dear Prof Unwin
Full title of study: The role of mitochondria in the renal Fanconi Syndrome.
REC reference number: 06/Q0512/62
Thank you for your letter of 11 August 2006, responding to the Committee’s request
for further information on the above research and submitting revised documentation.
The further information was considered at the meeting of the Committee held on 22
August 2006. A list of the members who were present at the meeting is attached.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for
the above research on the basis described in the application form, protocol and
supporting documentation as revised.
06/Q0512/62 Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project
Yours sincerely
Mrs Katy Judd
Chair